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Infection  with  influenza  virus  generally  produces  an  immune  response  in 
immunocompetent individuals that will  protect from further infection of the same 
strain  of  virus.  The  experiments  carried  out  in  this  study  were  designed  to 
identify correlates of protection induced  by primary experimental  influenza virus 
infection  and  to  compare  to/and  assess  Particle  Mediated  Immunotherapeutic 
Delivery  (PMID)  as  a  method  of  DNA  immunisation.  Initial  experiments 
characterised  the  protective  immune  response  observed  following  intranasal 
influenza  virus  infection  with  regard  to  the  humoral  and  cellular  responses 
generated.  It became clear that a combination of systemic and mucosal antibody 
responses  and  strong  virus-specific  CD8+   T  cell  response  in  the  lungs  were 
important in the control of viral replication.
The data on the immune responses generated following  influenza virus infection 
was  used  as  a  “gold  standard”  to  compare  the  responses  observed  following 
PMID immunisation of influenza virus nucleoprotein (NP) DNA. When PMID was 
assessed  for  its  ability  to  generate  an  immune  response,  a  mucosal  immune 
response  was  observed  in  the  D-NALT  as  well  as  a  more  general  systemic 
response.  Whilst  a  single  immunisation  induced  specific  cellular  responses,  it 
proved  inefficient at generating a  humoral  response.  Protection  studies showed 
that priming  by PMID of NP  DNA,  resulted  in  a  level  of protection that reduced 
viral replication in the lungs by 2 logs.
Investigation  into  the  phenotype  of  virus-specific  T  cells  generated  by  either 
infection  or  immunisation  showed  that  they  have  a  common 
CD44h lCD11ah lCD62L1 0  phenotype in various systemic and mucosal tissues. The 
cells  isolated  from  the  D-NALT  displayed  an  intriguing  intermediate  level  of 
CD44  expression.  In  vivo  migration  studies  showed  a  tendency  for  activated 
splenic virus-specific CD8+   T  cells  to  home  to the  D-NALT  perhaps  implying  a 
role for the  D-NALT as  a  site where  effector/memory T  cells  actively  home  as 
part of their role in immune surveillance.
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11Chapter 1  
Literature Review1.1  Influenza Virus and Vaccination
1.1.1  Influenza Virus Infection
Influenza is an acute infectious respiratory disease which,  in humans,  is caused 
by influenza virus types A and  B.  The disease  usually occurs  in  epidemic form 
with  an  abrupt  onset and  rapid  spread  over a  geographic  region.  The  virus  is 
transmitted  predominantly  in  virus  containing-droplets  generated  when  an 
infected person talks, coughs or sneezes. The virus gains access to the airways 
via  inhaled  aerosols.  Transmission  is  facilitated  by enclosed  spaces  and  close 
proximity  to  an  infected  individual.  Influenza  virus  is  a  highly  infectious  agent 
associated with a high rate of transmission.
When  influenza virus reaches the airways of a susceptible individual,  it starts to 
infect  cells  in  the  lining  of the  airways.  The  viral  infection  spreads  through  the 
epithelial  cells  of  the  airway  linings  and  causes  an  inflammation  throughout 
much  of  the  respiratory  tract.  After  an  incubation  period  of  2-3  days,  clinical 
disease  becomes  evident  and  can  vary  from  asymptomatic  or  mild  cold-like 
symptoms  to  a  severe  illness  and  death.  Patients  with  classic  “flu-like” 
symptoms experience a very abrupt onset of symptoms.  The  illness consists of 
systemic  symptoms  including  myalgia  (muscle  ache),  headache,  fever,  chills 
(shivering),  malaise  (feeling  of  illness  and  discomfort)  and  anorexia  (loss  of 
appetite).  Usually  the  headache  and  myalgia  will  predominate.  The  fever 
appears at the onset of illness and  rises rapidly to 38-40°C. The fever beings to 
reduce and the symptoms start to resolve within  3-8 days of onset. The patient 
also initially presents with localised  respiratory symptoms which consist of a dry 
cough,  blocked  nose,  nasal  discharge  and  a  sore  throat.  These  symptoms 
become more obvious as the systemic symptoms subside at around 7 days.  It is
13not  uncommon  for  patients  to  feel  unwell,  lethargic  and  depressed  for  some 
weeks after influenza virus infection.
1.1.2 Epidemiology
In the USA, influenza is responsible on average for 200,000 hospitalisations and 
approximately  36,000  deaths  annually  (Centres  for  Disease  Control  and 
Prevention,  2004a).  Influenza  virus  causes  disease  among  all  age  groups. 
Rates  of infection  are  highest among  children,  but  rates  of serious  illness  and 
death  are  highest among  persons  aged  greater than  65  years  and  persons of 
any  age  who  have  medical  conditions  that  place  them  at  increased  risk  for 
complications from  influenza e.g.  asthma or other chronic pulmonary diseases. 
Influenza  virus  causes  annual  epidemics,  and  occasional  pandemics. 
Occasionally,  a  virus  arises  which  has  mutated  to  overcome  the  pressure 
exerted  by  an  immune  population.  Such  mutant  or  drifted  variants  may 
demonstrate the ability to cause new epidemics.  However, the real threat results 
from potential gene reassortments, possibly in an intermediate host, producing a 
totally  new  virus  containing  genes  from  the  animal  reservoir  (commonly  birds 
and  pigs).  This  viral  shift can  result  in  a  pandemic  influenza  virus  strain  which 
appears completely foreign to the current immune population.
1.1.3 Influenza Virus Structure
The  causative  agent  of  influenza  is  influenza  virus  which  is  a  member  of the 
Orthomyxoviridae family.  Influenza virus is an enveloped virus with a segmented 
single-stranded  negative sense RNA genome.  Influenza viruses are divided  into 
three types A,  B and C which can be distinguished from each other by antigenic 
differences  between  their  nucleoprotein  (NP)  and  matrix  (M)  protein  antigens.
14Both  the  influenza  A and  B  viruses  are  major  human  pathogens,  however the 
influenza A virus  has greater potential to re-assort into more  pathogenic strains 
as  it  can  infect  a  number  of  host  species.  Influenza  A  virus  has  a  genome 
comprising eight segments of RNA encoding ten identified  polypeptides,  nine of 
which  are  incorporated  into  virions  (Figure  1).  Three  of  these  proteins  are 
inserted  into  the  lipid  envelope  of the  virion,  namely  haemagglutinin  (HA)  and 
neuraminidase  (NA)  which  are  involved  in  cell  entry  and  exit  respectively,  and 
the matrix protein M2, an ion channel protein involved  in uncoating of the virion. 
Underlying  the  membrane  is  the  matrix,  or  M1  protein,  the  most  abundant 
protein  of the virion, which associates with the  ribonucleoprotein  (RNP) core of 
the  virus  for  nuclear  export  of viral  RNA.  Also  associated  with  RNPs  and  M1 
protein is the RNA polymerase (comprising the basic polymerases PB1/PB2 and 
acidic polymerase PA subunits) and single stranded  RNA binding  protein  NP or 
nucleoprotein. The primary function of NP is to encapsulate the virus genome for 
the  purposes  of RNA transcription,  replication  and  packaging.  Influenza A virus 
RNA  segment  5  encodes  NP  which  has  been  found  to  be  relatively  well 
conserved  throughout the  influenza type A strains with  a  maximum  amino  acid 
difference  of  11%  (Shu  et  al.,  1993).  This  makes  it an  ideal  target for vaccine 
candidates  as  it  should  be  possible  to  protect  against  many  influenza  viruses 
using one vaccine.
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Figure 1: An illustration of the structure of an influenza A virion.  Nine proteins are 
encoded  in the genome,  3 of which  are found  in the  membrane,  haemagglutinin 
(HA),  neuraminidase  (NA)  and  the  matrix  protein  (M2).  The  matrix  protein  M1 
underlies  the  lipid  bilayer  but  also  interacts  with  ribonucleoproteins  (RNPs). 
Within  the  envelope  are  eight  segments  of  the  single  stranded  RNA  genome 
contained in the form of an RNP. Associated with RNPs is the RNA transcriptase 
complex (comprising  PB1,  PB2 and  PA) and  nucleocapsid  protein (NP).  Each of 
the  RNA segments can  be  seen with  the  proteins they encode where  NS1  and 
NS2 are non-structural  proteins.  NS1  is  a  post-translational  regulator with  many 
functions and NS2 associates with M1  and has a role in nuclear export of RNPs
161.1.4 Influenza Virus Replication
Viruses are  inert particles that are absolutely dependent on  infection  of a  living 
host cell for their replication.  Influenza virus particles have spikes of HA on their 
surface which can mediate attachment to host cells via specific receptors (sialic 
acid).  The  virus  enters  the  cells  and  uncoats,  removing  the  protein  coat  to 
release  the  nucleic  acid.  Transcription  and  translation  of  the  viral  proteins 
utilises the  host cell  machinery and  new viral  particles assemble.  The  progeny 
viral particles bud from the host cell. This budding  process uses the surface NA 
to prevent progeny virus from reattaching to the same cell.
1.1.5 The Immunopathoqeneis of Influenza Virus Infection
Human influenza A viruses tend to multiply only in the respiratory mucosa, this is 
due  to  the  requirement  of  cleavage  of  the  HA  of  the  virus  for  it  to  become 
infectious.  Trypsin-like  enzymes  produced  from  clara  cells  found  only  in  the 
respiratory epithelial  perform this cleavage and  thus  restrict virus growth to the 
respiratory  tract  (Kido  et  al.,  1999).  Infection  generally  begins  in  the  upper 
respiratory  tract  and  spreads  to  surface  epithelium  of the  lung  where  disease 
becomes evident.
CD8+   cytotoxic  T  cells  are  believed  to  play  a  pivotal  role  in  the  clearance  of 
experimental influenza virus infection in mice. While neutralising antibody is also 
generated  later  in  the  response,  it  does  not  have  a  role  in  clearing  primary 
infection  unless the viral  load  is  high  (Eichelberger et al.,  1991a,  Epstein  et al., 
1998,  Graham  &  Braciale,  1997).  Studies  using  class-1-deficient  mice  (/?2 
microglobulin'7 ')  which  lack  CD8+   T  cells,  have  shown  that  infection  with 
influenza  virus  A/PR/8/34  leads  to  increased  viral  replication  and  eventual 
morbidity,  indicating  that CD8+  T cells  are  essential for viral  clearance  (Bender
17et al.,  1992).  CD8+  T cells are first detected  in the lung around seven days post 
infection  and  their number peaks  around  ten  days  post  infection,  and  optimum 
expansion of the CD8+  T cell subset is dependent on CD4+  T cells (Eichelberger 
et al.,  1991a, Flynn et al.,  1998, Riberdy et al., 2000). The accumulation of CD8+  
T  cells  in  the  lungs  results  in  the  clearance  of  the  virus  by  Fas  or  perforin 
mediated  mechanisms (Topham et al.,  1997).  Following viral clearance, there is 
contraction  of the  CD8+   T cell  response  which  is  independent of the  level  and 
duration of antigen presentation (Badovinac et al., 2002). The mediastinal lymph 
node  plays  a  critical  role  in  generating  T  cells  responses  in  the  lung,  but 
substantial  responses  are  also  detected  in  the  spleen,  correlating  with  the 
distribution  of antigen-presenting  cells displaying  influenza virus antigens there 
(Flynn et al.,  1998, Usherwood et al.,  1999b).
Investigations  into  the  role  of  CD4+   T  cells  following  influenza  virus  infection 
initially  led  to  the  conclusion  that they were  not  required  for the  elimination  of 
virus,  as  CD4-depleted  mice  could  effectively  clear  influenza  virus  A/PR/8/34 
(Mozdzanowska et al., 2000).  A role of CD4 cells in response to influenza virus 
infection became more apparent when B and helper T cells were absent.  B cell- 
deficient mice treated with anti-CD4 depleting antibodies cannot clear influenza 
A/PR/8/34  virus  and  show  a  high  mortality  (Mozdzanowska  et  al.,  2000).  This 
data suggests that CD8+  T cells alone cannot clear virus infection and  indicates 
a  role for  CD4+   T  cells  in  maintenance  of a  cytotoxic T  cell  response.  CD4+   T 
cells alone can not effectively clear influenza virus A/PR/8/34 and it is suggested 
that  their  main  role  is  the  to  provide  help  for  antibody  production 
(Mozdzanowska et al.,  1997, Topham & Doherty,  1998).
Antibody  may  play  a  minor  role  in  primary  infection,  but what  is  clear  is  that 
neutralising  antibody  is  essential  in  protecting  individuals from further influenza
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al.,  2004).  In  particular it is the  IgA isotype of virus  specific antibody that plays 
an  important role  in  protection from  influenza virus  infection  and  other mucosal 
pathogens (mechanisms reviewed further in section  1.2.6)
1.1.6  Influenza Virus Mouse Model
Transmission  of  human  influenza  virus  to  laboratory  animals  was  originally 
demonstrated  in ferrets which  were  inoculated  with  respiratory secretions from 
influenza  patients and  as a  result developed febrile  respiratory illnesses, which 
were transmissible among cagemates.  It was also observed that mice inoculated 
under anaesthesia with  nasal turbinate material from  infected ferrets developed 
pneumonia  (Maher  &  DeStefano,  2004).  These  findings  led  to  the  use  of 
experimental animals as assay systems for virus infectivity and ultimately to their 
use as models for assessment of novel antiviral compounds and vaccines.  Mice 
are  an  ideal  animal  model to study pathogenesis and  the  immune  response to 
influenza  viruses.  They  offer  the  advantages  of  reproducible  responses  to 
infection (especially with inbred strains), small size and easy maintenance.
Influenza  virus  infection  of  mice  is  not  associated  with  a  febrile  response,  in 
contrast  to  humans  or  the  ferret  model  of  influenza.  The  mouse  model  can 
represent a severe viral pneumonitis, in which host responses may contribute to 
the pathogenesis of the disease. This study has focused on the C57BL/6 mouse 
model which is the best characterised model for influenza A virus infection (Allan 
et al.,  1990,  Eichelberger et al.,  1991a,  Eichelberger et al.,  1991b).  Influenza A 
viruses multiply only in the respiratory mucosa; the initial cycles of growth occur 
in  the  upper  respiratory  tract,  and  the  infection  later  spreads  to  the  surface 
epithelium of the lung. Viruses are generally eliminated within  10 days of primary
19infection,  In  parallel  with  the  development  of  CD8+   cytotoxic  T  lymphocytes 
(Allan et al.,  1990).
1.1.7  Influenza Vaccination -  Room for Improvement?
1.1.7.1  Introduction
Current human  influenza vaccines contain  haemagglutinin as their main or only 
viral  antigen.  They  have  been  traditionally  produced  from  viruses  grown  in 
embryonated  hen  eggs,  although  more  recent vaccine  stocks  have  also  used 
viruses grown  in tissue culture. These vaccines have contributed to a reduction 
of the burden imposed on the population by annual influenza epidemics.
Influenza virus haemagglutinin and neuraminidase are large glycoproteins easily 
accessible  on  the  viral  membrane.  Both  are  highly  immunogenic  and  are 
obvious  choices  as  vaccine  antigens.  As  a  result  of  these  proteins  being  so 
immunogenic,  an  infected  population  can  become  rapidly  protected  from 
reinfection  which  generates  an  immunological  pressure  that  can  lead  to  virus 
mutation and the problems of antigenic drift and/or shift.
The  efficacy of the  current vaccines  depends  primarily on  the  antigenic match 
between  circulating viruses with the strains used for vaccination, as well as the 
subject’s  age  and  immune  status.  Current  vaccines  prevent  illness  in 
approximately 70-80% of healthy individuals under the age of 65. This number is 
far lower in the elderly reducing to 30-40% (Palese & Garcia-Sastre, 2002). The 
ability of current vaccines  at  preventing  death  is estimated  to  be  around  80%, 
even in the higher risk elderly population (Patriarca et al.,  1985).
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whole,  split and subunit formulations, which are administered  intramuscularly or 
subcutaneously or b) cold-adapted,  live attenuated vaccine which is intranasally 
administered.  The  inactivated  vaccine  produces  significantly  higher  serum 
antibody responses whereas the cold  adapted  vaccine  induces  higher levels of 
nasal  IgA (Abramson,  1999, Treanor et al.,  1999). The two vaccines have been 
shown  to  have  similar  efficacy  in  preventing  laboratory-confirmed  influenza 
(Treanor et al.,  1999). The cold adapted vaccine was shown to be 85% effective 
and the inactivated vaccine was 71% effective.  Live cold-adapted vaccines are a 
promising  approach  to  immunisation  but the  response  in  the elderly is  modest. 
However  in  combination  with  the  inactivated  virus,  it  provides  increased 
protection from influenza virus infection (Treanor & Betts,  1998).
On  October  5th   2004,  Chiron  Corporation  released  a  press  statement 
announcing  that  their  licence  to  manufacture  Fluvirin®  influenza  virus  vaccine 
was  suspended  at  its  Liverpool  facility.  This  was  as  a  result  of  concerns  of 
bacterial  contamination  and  failure  of  Chiron  to  comply  with  UK  Good 
Manufacturing  Practices. As a result this will prevent release of their vaccine for 
the  2004-2005  season.  Fluvirin®  is  reported  to  comprise  up  to  20%  of  the 
influenza vaccine market in the  UK (Chiron, 2004).  Chiron also supply Fluvirin® 
to the  USA where  it takes  up approximately 50%  of the  market share (Centres 
for Disease Control and Prevention, 2004b). As a result health committees have 
changed  their guidelines  for recommending  who  is  to  be  vaccinated  and  have 
requested that healthy individuals aged 2-64 are not vaccinated this year.
211.1.1.2 The Future
The future  of influenza  vaccine  design  has focused  for some  time  now on  the 
development  of  a  cold-adapted  virus  vaccine  (Abramson,  1999,  Wareing  & 
Tannock,  2001).  Virus  is grown  in  cells or embryonated  hen  eggs  and  adapted 
to  growth  at  25°C.  The  resulting  strains  are  temperature  sensitive  with 
attenuated pathogenicity and are therefore suitable for use as live vaccines. The 
growth  of virus for vaccine  use  in tissue  culture has  also  become  preferable to 
the  use  of  embryonated  hen  eggs  as  a  proportion  of  the  population  has 
developed sensitivity to proteins from the eggs.
Efforts have also been made to genetically engineer live viruses to have  unique 
properties  that  lead  to  attenuation  (Parkin  et  al.,  1997).  With  the  advances  in 
reverse  genetics  it  has  also  been  possible  to  rescue  influenza  virus  vaccine 
candidates from cells transfected with plasmids (Neumann et al.,  1999).
As  a  result  of  the  continuing  antigenic  drift  of  the  virus  it  is  necessary  to 
reformulate  the  vaccine  almost  every  year.  A  universal  influenza  vaccine  still 
remains the goal of many researchers.  Some viral  proteins are more conserved 
than others, and several studies have investigated the use of such proteins. The 
conserved  areas of the virus tend to be poorly immunogenic,  and  are therefore 
less likely to induce a protective response.  Several studies have focused on the 
M2  matrix  protein  and  have  shown  promising  protection  using  a  murine  viral 
challenge model (Fiers et al., 2004).
221.2 The Mucosal Immune system
1.2.1  Introduction
The  mucosal  surfaces  of  the  body  are  characterised  as  being  thin  and 
permeable  barriers  to  the  interior of the  body  and  are  involved  in  a  variety  of 
physiological activities e.g. gas exchange in the lungs and food absorption in the 
gut. The necessity for permeability of the surface lining of these sites creates an 
understandable  susceptibility to  infection  and  it  is  therefore  not  surprising  that 
the majority of infectious agents invade the human body at these sites.
The  mucosal  surfaces  are  similar to  the  skin  in  that they  act  as  a  barrier and 
define  a  boundary.  However  unlike  the  skin,  the  mucosa  of  the  gut  and 
respiratory tract must absorb substances resulting in an inherent susceptibility to 
infection  by  invading  microbes. The  immune  system  has  evolved  a  specialised 
capacity to  distinguish  between  food  antigens  and  pathogenic  microbes which 
avoids  the  potentially  harmful  induction  of  a  strong  immune  response  to  food 
while  retaining  the  ability  to  detect  and  kill  pathogenic  microbes  gaining  entry 
through  the  gut.  The  mechanism  by  which  the  immune  system  is  able  to 
distinguish between a variety of self and non-self antigens is called tolerance.
1.2.2 Organisation of the Mucosal Immune System
The  immune  system  is  divided  into  two  compartments.  First  is  the  systemic 
immune  system,  comprising  bone  marrow,  the  spleen  and  lymph  nodes.  The 
second  compartment consists of the  lymphoid  tissues associated with  mucosal 
surfaces, or mucosal associated lymphoid tissue (MALT), and external secretory 
glands  and  is  known  as  the  mucosal  immune  system.  Mucosal  surfaces  are 
associated  with  the  gastrointestinal,  genitourinary  and  respiratory  tracts.  The
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immunocompetent  cells  such  as  B  and  T  lymphocytes.  These  cells  are 
organised  into the MALT and are the main components of the mucosal  immune 
system.  Each  compartment  of  the  immune  system  is  associated  with  both 
humoral  and  cell  mediated  responses,  however,  the  nature  of  the  immune 
response induced in each compartment is different.
Mammals  and  birds  have  evolved  distinct  respiratory  and  gastrointestinal 
lymphoid  compartments that can  participate  in the defence of associated  distal 
mucosa.  Respiratory  lymphoid  structures  include  the  bronchial  associated 
lymphoid  tissue  (BALT),  nasal  associated  lymphoid  tissue  (NALT),  lung 
parenchyma and alveolar cells in the respiratory tract.  Gastrointestinal lymphoid 
structures  constitute  the  gut  associated  lymphoid  tissue  or  GALT  which 
comprises  the  lamina  propria  (LP),  Peyer’s  patches  (PP)  and  possible  solitary 
lymphoid nodules (SLN) in the intestine (Kraehenbuhl & Neutra,  1992).
1.2.3  The Nasal Associated Lymphoid Tissue
The  upper  respiratory  tract  is  an  important  site  for  defence  against  invading 
pathogens  as  it  is  the first site  of contact of inhaled  antigens with  the  immune 
system  (Kuper  et  al.,  1992).  The  NALT  in  the  mouse  comprises  a  pair  of 
organised lymphoid aggregates (organised, or O-NALT) located on the posterior 
side of the palate at the entrance to the nasopharyngeal duct, this is illustrated in 
Figure  2.  It  also  includes  the  less  organised,  diffuse  lymphoid  tissue  lining  the 
nasal  passages  known  as  the  diffuse  or  D-NALT  (Asanuma  et al.,  1997).  The 
nasal  tissues  appear  to  be  functionally  equivalent  to  the  Waldeyer’s  ring  of 
tonsils and  adenoids in the human and are most likely to be responsible for the 
immune response generated following intra-nasal immunisation in the mouse
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Figure  2:  Shows a) the  human  nasal  associated  lymphoid  tissue also  known  as 
the  Waldeyer’s  Ring,  comprising  the  adenoid  and  various  tonsils  b)  shows  the 
two organised lymphoid structures of the murine organised or O-NALT located on 
the posterior side of the palate indicated with arrows and c) the diffuse or D-NALT 
comprising  the cells  lining the  nasal cavity (NC). The O-NALT can  also  be  seen 
towards the bottom of this figure indicated by arrows.
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25(Tamura et al.,  1998). The O-NALT has been shown to be an inductive site,  like 
the  Peyer’s  patch  in  the  small  intestine.  By  contrast,  the  D-NALT  appears  to 
function as an effector site comparable to the lamina propria in the gut (Heritage 
et al.,  1997, Wu et al.,  1997, Zuercher et al., 2002).  Recent studies have shown 
the  murine  D-NALT  to  be  a  site  of  long  term  viral-specific  humoral  immunity 
(Liang et al., 2001) and also a site of persistence of influenza virus specific CD8+  
T cells following primary influenza infection (Wiley et al., 2001).
1.2.4  M Cells
Sampling  of  luminal  antigen  occurs  at  specialised  local  inductive  sites  in  the 
organised  MALT that appear as single or aggregated mucosal lymphoid follicles 
in  the  NALT,  bronchi  and  intestines.  In  order  for  antigens  to  elicit  mucosal 
immune  responses,  they  must  be  transported  across  the  epithelial  barrier  at 
these  sites  prior  to  contact  with  antigen  presenting  cells  (APCs).  This  is 
accomplished  by  virtue  of  a  specialised  epithelium  over  mucosal  lymphoid 
follicles  called  the  follicle  associated  epithelium  (FAE).  The  FAE  contains  M 
cells,  a  unique  epithelial  cell  type  specialised  for transport of macromolecules, 
particles and microbes (Kuper et al.,  1992, Neutra et al.,  1996).
M  cells  are  well  suited  for  efficient  endocytosis  and  transcytosis.  They  lack  a 
rigid  brush  border cytoskeleton and their apical surfaces have  broad  membrane 
microdomains  which  can  mediate  endocytosis.  The  M  cell  basolateral 
membrane is deeply invaginated to form a large intraepithelial pocket containing 
T  and  B  lymphocytes  and  macrophages  (Neutra  et  al.,  1996).  This  structural 
specialisation brings the basolateral surface to within a few microns of the apical 
surface  and  greatly shortens the distance that transcytotic vesicles  must travel 
to cross the epithelial  barrier.  After being  transported through  M  cells,  antigens
26are  processed  by  macrophages  and  dendritic  cells  and  presented  to  T  and  B 
lymphocytes present within and below the epithelium.
1.2.5  The Common Mucosal Immune System
In general, mucosal associated lymphoid tissues can be divided into two distinct 
compartments,  namely the inductive and effector sites.  Inductive sites are areas 
where  naive  B  and  T  lymphocytes  are  clonally  selected  and  expand  upon 
antigen  contact.  The  second  compartment  comprises  effector  sites  where 
activated B and T lymphocytes relocate after antigen priming in inductive sites to 
express their effector functions.  Previous animal model studies have shown that 
the  inductive  sites  present in  certain  locations,  such  as  GALT  (PP) or in  some 
specific  BALT,  function  as  primary  sources  of  precursor  cells  which  migrate 
through  the  lymphatics  and  blood  and  ultimately  populate  remote  mucosal 
tissues  (Phillips-Quagliata  &  Lamm,  1988).  More  recent  studies  suggest  that 
such  inductive  sites  are  not  necessarily  restricted  to  PP.  Additional  sites  have 
been  identified  in  the  nasal  mucosa,  the  palative  tonsils  and  other  organised 
lymphoid tissues of Waldeyer’s ring in the nasopharynx (Kuper et al.,  1992).
An  important  consideration  for  vaccine  development  is  the  fact  that 
immunisations  at  certain  inductive  sites  may  give  rise  to  a  humoral  immune 
response  at  multiple  effector  sites  by virtue  of the  so-called  common  mucosal 
immune  system  (CMIS).  An  early  study  on  the  CMIS  demonstrated  that 
following the transfer of Ig-committed B cells from various lymph nodes, the cells 
demonstrated  a  tendency  to  home  to  certain  areas  of  the  mucosal  immune 
system  (McDermott  &  Bienenstock,  1979).  Evidence  from  other  studies  has 
indicated  that  stimulation  of the  mucosal  immune  system  at  one  mucosal  site 
can lead to secretory IgA (slgA) production in the local, as well as distal mucosal
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resulted  in  the  production  of IgA secreting  B  cells  in  the  intestine,  bronchi  and 
the  genitourinary  tract  (Nugent  et  al.,  1998).  Other  examples  include  those 
reported  by Dupuy et al.  (1999) and by Gallichan & Rosenthal  (1998) who have 
shown  intranasal  immunisation  (HPV  and  HSV  vaccines  respectively)  induced 
secretory  and  serum  derived  humoral  responses  in  the  female  mouse  genital 
tract.
The concept of the common mucosal immune system is best established for the 
components  of the  GALT.  PP  are  inductive  sites  and  have  been  described  as 
the  major  locations for antigen  specific  B  cell  activation  (Craig  &  Cebra,  1971) 
and  generation  of IgA memory  B cells  (Lebman et al.,  1987)  as well  as for the 
induction  of  antigen  specific  cytotoxic  T  lymphocytes  or  CTL  (London  et  al.,
1987). Generally, these primed B and T cells relocate from PP, undergo terminal 
differentiation and eventually home to the lamina propria and the intra epithelial 
lymphocyte  compartment  of  the  gut  (McDermott  &  Bienenstock,  1979).  By 
contrast,  little  is  known  about the  anatomic  location  and  functional  potential  of 
inductive and effector sites in the respiratory tract.
Zuercher  et al.  (2002)  analysed  the  induction  of reovirus  specific  humoral  and 
cellular  immune  responses  in  the  upper  respiratory  tract  (URT)  of mice.  They 
found  a  number  of  functional  similarities  between  the  MALT  of  the  URT  and 
gastrointestinal  tracts.  Both  sites  contain  organised  secondary  lymphoid  tissue 
lined  by epithelium,  possibly enabling  them  to effectively absorb  antigen.  Also, 
following  reovirus  infection,  both  sites  result  in  germinal  centre  reactions 
involving the expansion of specific IgA and lgG2a B cells. Both sites also contain 
a  similar  draining  lymph  node  that  may  serve  to  amplify  the  responses 
generated in the PP and  NALT respectively. The authors also report detection of
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compared to lymph nodes that drain the NALT, clearly shows that the NALT is a 
potent inductive site for specific CTL responses upon intranasal infection.
1.2.6  Antibodies and the Mucosal Immune System
The predominance of IgA over other immunoglobulin isotypes is a characteristic 
of most mucosal secretions and  it is now well established that levels of IgA are 
much higher in mucosal secretions than in blood. IgA is present in most mucosal 
secretions  in  higher  concentrations  than  any  other  immunoglobulin  isotypes, 
with the exception of the male and female genitourinary tracts where  IgG is the 
prominent isotype (Mestecky et al.,  1999).
Production  of  IgA  is  especially  prominent  in  the  intestinal  tract  because  of  its 
length,  surface area and  level of exposure to microbial  antigens.  The existence 
of  a  specific  receptor-mediated  transport  mechanism  through  the  epithelium 
means  that  most  of  the  IgA  produced  is  secreted  locally  (Mostov,  1994).  A 
receptor termed the  polymeric immunoglobulin  receptor (plgR)  binds molecules 
of immunoglobulin (Ig) that are composed of more than a single basic 4-chain Ig 
subunit.  Such  polymeric  immunoglobulins  include  most  of  the  locally 
synthesised IgA (dimers) and all of the IgM (pentamers).
The plgR is synthesised by enterocytes and other mucosal epithelial cells and is 
expressed  on  their  basolateral  plasma  membrane,  where  it  can  bind  locally 
produced  IgA  and  IgM  antibodies.  The  resulting  plgR-immunoglobulin 
complexes  undergo endocytosis and vesicular transport to the apical surface of 
the  enterocytes,  where  plgR  is  proteolytically  cleaved  at  a  site  between  the 
external  and  intramembranous  domains.  This  results  in  the  release of  IgA,  still
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into the mucosal secretions (Lamm,  1998).
Recent  studies  have  shown  that  some  mucosal  secretions  in  humans  also 
contain IgG, where it functions together with secretory IgA (slgA) in host defence 
(Robert-Guroff, 2000).  Clinical studies have also shown that  IgG concentrations 
predominate  over  slgA  in  the  lumen  of the  lower  respiratory  tract  and  female 
genital  tracts  (Kitz et al.,  2000,  Merrill  et al.,  1985).  Spiekermann  et al.  (2002) 
reported the expression of FcRn, a neonatal MHC class  l-related  Fc receptor, in 
bronchial  epithelial  cells  of  the  adult  human,  non-human  primates  and  the 
mouse. Their data defines a function of FcRn at mucosal surfaces and explains 
how IgG can cross epithelial barriers by receptor mediated transcytosis and can 
also  be  reabsorbed  by  epithelial  cell  surface  expression  of  FcRn  to  transport 
luminal  IgG-bound antigen for processing in the LP or systemically.
It  is  recognised that  IgA,  and  more recently  IgG,  present in  intestinal  and  other 
mucosal  secretions,  provide  a  first  line  of  immunological  defence  against 
microbial  pathogens  by  helping  to  prevent  them  from  adhering  to  and 
penetrating the mucosal epithelium (Lamm,  1997, Robert-Guroff, 2000).  IgA has 
also  been  shown  to  be  able  to  mediate  effective  resistance  to  microbial 
challenge in mice (Mazanec et al.,  1987, Michetti et al.,  1992). The production of 
Sendai  and  influenza  virus was  specifically inhibited  by the antibody  (Mazanec 
et  al.,  1995)  and  systemic  administration  to  mice  of  an  IgA-class  monoclonal 
antibody,  with  specificity  for  rotavirus  inner  capsid  protein,  is  able  to  inhibit 
intestinal epithelial infections (Burns et al.,  1996).
Evidence  has emerged  in  support of a  role for IgA in  protection  inside mucosal 
epithelial  cells.  This  possibly  arises  from  the  obligatory  plgR-mediated
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supporting this idea was carried out in two chambered culture vessels containing 
polarised  monolayers  of epithelial  cells that expressed  plgR on  the  basolateral 
surface.  The  cells  were  infected  from  the  apical  surface  with  a  virus  and  IgA- 
class  monoclonal  antibody against viral envelope  protein  was  added  below the 
basolateral  surface,  from  which  it  could  be  endocytosed  via  the  plgR  and 
transcytosed.  Under  these  conditions,  the  production  of  Sendai  and  influenza 
virus  was  specifically  inhibited  by  IgA  (Mazanec  et  al.,  1992,  Mazanec  et  al., 
1995).
1.2.7  The Mucosal Immune System and its Cellular Repertoire
In  addition  to  the  organised  lymphoid  tissue,  in  which  induction  of  immune 
responses occur within the mucosal  immune system,  small foci of lymphocytes 
and  plasma  cells are  scattered  widely throughout the  lamina  propria  of the  gut 
wall. These represent the effector cells of the gut mucosal immune system.
The T lymphocytes of the gut can be divided into a number of groups. There are 
the conventional a£TCR (T cell receptor) CD4 and CD8 cells,  but there are also 
those  with  more  unusual  surface  phenotypes  such  as,  k<*TCR  and  o/?TCR, 
CD8aa lymphocytes. The receptors of this second class of T cells do not bind to 
normal MHC:peptide complexes but instead bind to a number of different ligands 
including MHC class  1b molecules (Steele et al., 2000).
Although  yd T cells are well  represented in peripheral  blood and in afferent and 
efferent lymph, they are rarely found  in  lymph  node parenchyma,  spleen, PP or 
thymus  (Bucy  et  al.,  1988,  Hein  &  Mackay,  1991).  yd T  cells  are  localised  in 
tissues  (Hein  &  Mackay,  1991)  and  are  disproportionately  abundant  in  the
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interspersed  between  enterocytes  (Goodman  &  Lefrancois,  1988).  Analysis  of 
the  respiratory  epithelium  has  shown  no  significant  levels  of  y6  T  cells  or 
a/?TCR, CD8aa lymphocytes (Liang, 2001).
The  lymph  nodes and T cell areas of the spleen are the only known anatomical 
structures in which great diversity of antigen can be presented and the resulting 
clonal  expansion  and  differentiation  of  lymphocytes  supported.  Therefore,  the 
relative absence of y6 T cells from these areas is consistent with the hypothesis 
that  y6  T  cells  do  not  routinely  rely  on  professional  antigen  presenting  cells 
(APCs)  for antigen  recognition.  Instead  they  may  recognise  antigen  directly  in 
tissues,  sometimes  using  extremely  limited  TCR  y6  diversity  (Janeway  et  al.,
1988). Janeway et al. also propose that in addition to recognition of a diversity of 
microbial antigens y6 T cells can also respond to unique “stress antigens” which 
are markers of cell infection or transformation.
y6  T  cells  have  also  been  implicated  in  autoantibody  production  and 
development  (Peng  et  al.,  1998).  They  may  also  be  beneficial  during 
transplantation  (Gorczynski  et  al.,  1996).  These  authors  reported  that  down- 
regulation  of  aft  T  cells  correlated  with  the  prolongation  of  allogenic  graft 
survival,  which  is thought to  be  mediated  by the  y6 T cell  suppression  of IL-12 
and  IFNy production  by mesenteric lymph  node TH1   cells.  Finally  y6 cells  have 
been implicated in regulation of T cell leukaemias (Penninger et al.,  1995).
1.2.8  Effector Mechanisms Against Mucosal Infection
The mucosal immune system is structurally and functionally divided into sites for 
antigen  uptake  and  processing  or  inductive  sites,  and  effector  sites  engaging
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characterised  example  of  inductive  and  effector  sites  in  the  mucosal  immune 
system is that of the Peyer’s patch and  lamina propria of the gut (Brandtzaeg et 
al.,  1999, Hein,  1999).
The major mucosal effector mechanisms to respiratory virus infection have been 
described  in  section  1.1.5  but  in  addition  to  respiratory  mucosal  effector 
mechanisms  there  are  also  mechanisms which  are  unique  to the  gut  mucosa. 
Like  the  respiratory  mucosa,  the  GALT  is  characterised  by  the  presence  of 
specialised  M cells within the  FAE  (as discussed  in section  1.2.4). The GALT is 
also characterised by the presence of intraepithelial T cells with unusual surface 
phenotypes  for  example  the  ytfTCR  or  the  CD8aa  molecule  (as  discussed  in 
section  1.2.7).  Intraepithelial  lymphocytes  (lELs)  are  distinct  from  systemic  T 
cells with their unusual surface phenotype and can be divided  into 2 categories: 
type a  lELs with the conventional a/?TCR which recognise antigen presented by 
MHC,  and  type  b  lELs  which  include  y<TTCR T  cells  and  are  not  restricted  by 
conventional  MHC.  Type  b  lELs  are  cytolytic  and  secrete  cytokines  and 
chemokines  (Barrett  et  al.,  1992,  Taguchi  et  al.,  1991),  they  have  also  been 
shown to protect from infection by defending the integrity of the epithelial barrier 
to  infection  by  promoting  epithelial  wound  healing,  maturation  and  general 
homeostasis  of the gut (Boismenu  &  Havran,  1994,  Komano et al.,  1995).  The 
gut  is  also  specialised  in  that  IgA  is  the  predominant  immunoglobulin  isotype 
produced. This has already been reviewed in section  1.2.6.
331.3 The Mucosal Immune System and Vaccination
1.3.1  Introduction
The respiratory tract is the first site of attack by many major pathogens including 
influenza  virus.  Effective  generation  of  immune  responses  at  the  respiratory 
mucosa and  regional lymphoid tissues is likely to be of great importance for the 
prevention  of  infectious  diseases.  However,  the  majority  of  vaccines  currently 
used to induce protection from infectious respiratory diseases work by activating 
the  systemic  immune  system.  Although  the  cells  of  the  immune  system  may 
circulate between mucosal and non-mucosal tissues after activation, vaccination 
focused  on  the  direct  activation  of the  mucosal  immune  system  may  improve 
overall efficacy.
Numerous  studies  have  indicated  that  induction  of systemic  immunity  through 
parenteral  immunisation  can  effectively  protect against  systemic  infections  but 
usually  fails  to  specifically  protect  the  mucosa  surfaces  (Mestecky,  1987). 
Induction  of  mucosal  immunity  at  the  site  of  infections  on  the  other  hand, 
provides  the  main  protection  against  mucosal  infection  (Mestecky  &  McGhee, 
1992).  The  mucosal  immune  system  differs  in  several  other  ways  from  the 
systemic  immune  system.  Mucosal  immunisation  frequently  results  in  the 
stimulation  of  both  mucosal  and  systemic  immune  responses,  while  systemic 
immunisation  typically  only  induces  systemic  responses  without  activating  the 
mucosal immune system.
Mucosal surfaces such as the gastrointestinal,  respiratory and genital tracts, are 
the  principal  sites  of  entry  and  colonisation  for  many  pathogens.  In  order  to 
effectively  protect  these  surfaces,  the  mucosal  immune  system  needs  to  be 
properly  activated  through  direct mucosal  immunisation  (Chen,  2000).  Mucosal
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There  is  an  obvious  advantage  of  having  an  orally  or  nasally  administered 
vaccine  over  the  use  of  a  conventional  needle  and  syringe  to  administer  a 
vaccine.  Mucosal  delivery  may  enhance  vaccine  efficacy  by  inducing  both 
mucosal  and  systemic immunity simultaneously  but  it also  has  the  potential  to 
increase vaccine safety and minimise vaccine adverse effects by avoiding direct 
contact  between  potentially  toxic  vaccine  components  and  the  systemic 
circulation.  It  may  also  reduce  the  need  for  trained  personnel  required  for 
administration.  Finally,  it allows  for easy administration  of multivalent vaccines 
(Lee et al., 2000).
1.3.2  Approaches to Developing Mucosal Vaccines
The various barriers of the mucosal immune system prevent efficient absorption 
of  mucosally  delivered  vaccines.  The  barriers  include  mechanical  barriers  like 
mucus  that  clears  antigens  from  the  respiratory  system  and  enzyme 
degradation. Mucosal immunisation also has to overcome the acquired barrier of 
tolerance,  whereby the  immune  system  can  have  reduced  capacity to  develop 
an  immune  response  upon  re-exposure  to  or  immunisation  with  the  same 
antigen.  Oral  tolerance  is  an  important  natural  mechanism  by which  we  avoid 
developing allergic reactions to ingested foods and to certain other antigens.
There  are various  approaches  to developing  mucosal  vaccines  including  using 
live microbes as vectors for delivery or encapsulation of the vaccine to protect it 
from  the  environment  that  it  enters.  Recombinant  viral  and  bacterial  vectors 
have  been  created  to  serve  as  a  vehicle  to  transport  and  express  foreign 
antigen.  These  vectors  are  attenuated  through  mutation  while  retaining  the 
ability  to  invade  and  populate  a  mucosal  surface.  There  is  also  the  possibility
35that several different antigens can be expressed from one live vector,  potentially 
achieving  protection  against  a  number of diseases  with  a  single  immunisation 
(Lee  et  al.,  2000).  Recombinant  adenoviruses  that  express  Simian 
immunodeficiency  virus  (SIV)  envelope  proteins  have  been  cloned  and 
administered  via  either  intranasal  or  oral  routes  to  Rhesus  macaques.  These 
viral  vectors  have  induced  strong  humoral,  cellular  and  mucosal  responses  in 
these primates (Buge et al.,  1997). Adenoviruses have also been engineered to 
express  bovine  herpes  simplex  virus  glycoproteins  and  have  been  shown  to 
stimulate  high  levels  of glycoprotein  D  specific  IgA (Papp  et al.,  1999).  Finally, 
Salmonella  has  also  been  investigated  for  suitability  for  use  as  a  live  vector 
(Nayak  et  al.,  1998).  Nayak  et  al.  demonstrated  that  expression  of 
pneumococcal  surface  protein  A  in  Salmonella  resulted  in  resistance  to  S. 
pneumoniae in mice with stimulation of systemic and  mucosal  humoral immune 
responses demonstrated.
Current  efforts  in  developing  mucosal  vaccines  are  directed  towards  finding 
more efficient means of delivering antigens to the mucosal  immune system that 
bypass the phenomenon of tolerance. There is also great emphasis on research 
focusing  on  the  discovery  of  effective,  safe  mucosal  adjuvants  that  generate 
stronger mucosal immune responses.
1.4  DNA Vaccination
1.4.1  Introduction
DNA immunisation arose from the discovery that injections of pure plasmid DNA 
encoding  B-galactosidase,  luciferase  or  chloramphenicol  acetyltransferase 
resulted  in  long  term  reporter  gene  expression  in  transfected  muscle  fibres
36(Wolff et al.,  1990).  It was  subsequently shown  that  if the  plasmid  encoded  an 
antigenic  protein,  it  was  possible  to  induce  immune  responses  against  the 
expressed  protein  (Tang  et  al.,  1992).  Tang  et al.  described  the  production  of 
antibodies  against  human  growth  hormone  induced  by gene  gun  immunisation 
of DNA coated  gold  microparticles.  Gene gun  plasmid  delivery was also shown 
to  elicit  cell  mediated  immunity  leading  to  cross  strain  protection  against 
influenza  virus  infection  (Ulmer  et  al.,  1993b).  Antibody  responses  and/or 
protection  were  also  shown  to  be  induced  by  DNA vaccination  against several 
other  viral  antigens,  including  HIV  (Wang  et  al.,  1993),  a  lethal  influenza 
challenge (Robinson et al.,  1993) and rabies virus (Xiang et al.,  1994).
An advantage for expressing antigen in the host rather than having to administer 
antigen  (such as inactivated virus,  recombinant proteins or peptides) is that the 
potential  for  losing  antigenicity  during  any  inactivation  process  is  avoided. 
Expressing  the  antigen  in  the  host  also  allows  synthesis  of  proteins  with  a 
conformation  and  post translational  modifications that are  likely to  be similar to 
or  identical  to  the  native  antigen.  Finally,  intracellular  antigen  processing  and 
presentation by MHC I can lead to the induction of CTL responses.
1.4.2  Immune Responses Induced by DNA Vaccines
DNA  vaccines  have  been  shown  to  induce  high-titre  serum  antibodies  to  a 
variety  of  different  antigens  including  viral,  bacterial,  eukaryotic  and  tumour- 
associated  proteins.  For  example,  DNA  constructs  encoding  viral  proteins 
including  influenza  virus  haemagglutinin  (HA)  can  induce  a  long-term  humoral 
response  in  vivo (Fynan  et al.,  1993,  Ulmer et al.,  1994).  HA contains a signal 
sequence that allows  transport to the  cell  surface via  a  secretory pathway,  but 
other  proteins  not destined  for secretion  such  as  influenza  virus  NP  have  also
37been  shown  to  have  the  capacity  to  induce  long-lived  humoral  responses  in 
mice, with antibody responses persisting from six months to two years (Ulmer et 
al.,  1993a, Yankauckas et al.,  1993).
The ability of DNA vaccines to induce cytotoxic T-cell (CTL) responses was first 
demonstrated  using  influenza  virus  NP  (Ulmer et al.,  1993a).  This  antigen  is a 
conserved,  internal  protein  of  the  virus  and  a  target  for  cross-reacting  CTL 
(Wraith  et  al.,  1987).  Intramuscular  injection  of a  plasmid  coding  for  influenza 
virus  NP  was  found  to  induce  CTL  in  mice  and  furthermore  these  mice  were 
observed to be protected from a cross strain,  lethal challenge of influenza virus 
(Ulmer et al.,  1994, Ulmer et al.,  1993a).
The  precise  mechanisms  by which  CTL are  induced following  DNA vaccination 
are  still  unclear.  However,  there  are  three  proposed  mechanisms  by  which  a 
CTL response may be induced.  Firstly, and least convincingly,  it is possible that 
myocytes are directly transfected after intramuscular injection.  However, the low 
level  of expression of MHC  I  and the lack of detectable  levels of co-stimulatory 
molecules  by muscle  cells suggests they may not be  capable of functioning  as 
professional  APCs.  The  second  idea  is  that  of  direct  priming,  where  APCs 
resident near the site of immunisation  become directly transfected with  plasmid 
DNA,  which  can  in turn  present peptide via the  MHC class  I  pathway to elicit a 
CTL  response.  Finally,  and  most  convincingly,  is  the  cross  presentation 
hypothesis  where  it  is  proposed  that  antigen  is  transferred  from  transfected 
monocytes to professional APCs (Corr et al.,  1999, Ulmer et al.,  1996). This idea 
of  cross-presentation  is  supported  by  a  study  which  investigated  responses 
elicited  by  intramuscular  injection  of  DNA  encoding  either  secreted  or 
cytoplasmic  forms  of  an  antigen.  The  secreted  form  of the  antigen  proved  to 
generate  stronger  CTL  responses  and  supports  the  facilitation  of  cross­
38presentation  of  the  antigen  from  non-professional  APCs  (Boyle  et  al.,  1997). 
Recent  data  has  also  shown  evidence  that  cross  priming  is  the  predominant 
mechanism  for  inducing  CD8+   T  cell  responses  following  gene  gun  DNA 
immunisation (Cho et al., 2001). This study reported that professional APCs are 
capable of taking  up exogenous antigen from  DNA transfected  non-APCs  such 
as monocytes and keratinocytes.
DNA vaccination  has  been  shown  to  generate  a  variety  of immune  responses 
depending on the delivery technique (Oran & Robinson, 2003, Oran & Robinson, 
2004).  Studies  using  DNA  vaccines  expressing  influenza  virus  HA  in  either  a 
membrane  bound,  or  secreted  form,  compared  delivery  by  intramuscular 
injection  and  gene gun  immunisation.  Typical  strong  Th1  type  responses were 
observed  following  intramuscular  immunisation  of  DNA  encoding  membrane 
bound  HA.  The  strongest type  2  responses were  observed  following  gene gun 
immunisation with the secretory form of HA.  Further investigation following viral 
challenge  revealed  that  regardless  of the  T-helper/T-cytotoxic status,  Tc1  type 
cells  underwent more efficient expansion,  and only Tc1  cells were found  at the 
site  of  challenge.  It  was  concluded  that  the  type  of  memory  T  cell  response 
induced  by  DNA vaccination,  be  it Th1/Th2 or Tc1/Tc2,  does  not influence the 
response at the site of an infection.
DNA vaccines  have other advantages over traditional whole  microbial vaccines 
and  subunit vaccines.  One advantage  is they do not require the use of purified 
proteins,  which  can  be  difficult  and  expensive  to  produce  and  store  in  large 
quantities,  or  viral  vectors  which  may  be  associated  with  safety  issues.  More 
importantly,  vaccines that  use  inactivated  microbes or their components do  not 
provide endogenously synthesised proteins and generally act as poor agents for 
eliciting  CTL  responses,  which  are  considered  to  be  important  for  controlling
39most  infections.  DNA-mediated  expression  of the  immunising  proteins  in  host 
cells  results  in  the  presentation  of  normally  processed  protein  to  the  immune 
system  which  is  important  for  inducing  immune  responses  against  the  native 
forms of proteins (Webster et al.,  1994).
1.4.3  DNA Delivery Methods
The  immune  response  can  be  dramatically  altered  depending  on  the  delivery 
route  of  DNA  immunisation  chosen.  In  the  past,  the  most  common  route  of 
immunisation  has  been  direct  intramuscular  injection.  Of  the  original  DNA 
immunisation  studies,  this  was  the  method  of  choice  and,  as  previously 
described,  has  proven  to  be  a  good  method  of  inducing  both  humoral  and 
cellular immune responses.  More recently, other methods of DNA delivery have 
been  investigated with gene gun,  epidermal  powder immunisation and  biojector 
being  three  examples.  The  biojector  is  a  needle  free  device  for  delivering 
substances intramuscularly or subcutaneously.
A  recent  study compared  the  CD8+   T cell  responses  generated  following  DNA 
delivery by syringe, gene gun, and biojector (Trimble et al., 2003).  It was shown 
that  DNA vaccine administered  via gene gun  generated  the greatest frequency 
of  antigen  specific  CD8+   T  cells  compared  to  the  other  methods.  Gene  gun 
administration  also  proved  to be favourable because the dose of DNA required 
to  generate  the  response  was  much  lower  than  for  the  other  methods.  It  is 
thought that the  superior response  observed  using  the  gene  gun  is  due  to the 
ability of this route of administration to generate professional APCs that express 
the  antigen  as  a  result  of  a  low  number  of  APCs  being  directly  transfected. 
Intradermal  immunisation  via  the  gene  gun  can  directly  target  antigen  to
40Langerhans cells, which are immature DCs, but nevertheless professional APCs 
(Condon et al.,  1996).
Another  method  of  DNA  delivery  recently  investigated  is  the  encapsulation  of 
DNA  in  lipids  to  protect  the  nucleic  acid  from  degradation  following  mucosal 
immunisation.  Intranasal  immunisation  of  DNA-lipid  complexes  expressing  a 
model  antigen  was  found  to  result  in  an  increase  in  production  of  antigen 
specific  IgA  in  murine  vaginal  and  rectal  tracts,  while  an  antigen  specific  CTL 
response  was  observed  in  the  spleen,  genital  and  cervical  lymph  nodes 
(Klavinskis  et  al.,  1999).  These  results  show  potential  for  application  to 
immunisation against any pathogen invading at a mucosal site.
1.4.4  Particle Mediated Immunotherapeutic Delivery (PMID)
The  gene  gun  is  a  ballistic  device  designed  to  propel  DNA  coated  gold 
microparticles into the epidermis or other tissues.  PMID of DNA to the epidermis 
has  resulted  in  immunity to  pathogens that  invade  mucosal  surfaces,  including 
influenza  virus  and  rotavirus  (Chen  et  al.,  1997,  Ulmer  et  al.,  1993a, 
Yankauckas  et  al.,  1993),  and  it  is  possible  that  epidermal  inoculation  is  as 
effective at inducing  immunity at distal  mucosal sites as that obtained  by direct 
mucosal  immunisation.  Protection from  rotavirus  infection  elicited  by gene  gun 
delivery to perianal tissue was recently compared to that elicited by conventional 
epidermal  gene  gun  immunisation  (on  the  abdomen)  (Chen  et  al.,  1999).  The 
protection obtained by mucosal immunisation was higher than that for the same 
amount  of  DNA  administered  by  epidermal  immunisation.  This  result  is 
consistent  with  the  hypothesis  that  direct  mucosal  immunisation  is  a  more 
effective means of generating protective immunity against mucosal pathogens.
411.4.5 Enhancing the Immune Response to DNA
Bacterial  plasmid  DNA  contains  immunostimulatory  sequences  (ISS)  which 
exhibit  adjuvant  properties.  The  immunostimulatory  properties  were  first 
identified  by a  study focusing  on  why vaccination  with  Bacille  Calmette-Guerin 
(BCG)  reduced  tumour  growth  (Tokunaga  et  al.,  1999).  Further  research 
mapped  the  stimulating  sequence  of  BCG  and  subsequently  extended  these 
observations  to  other  bacterial  DNA.  The  stimulatory  potential  of  prokaryotic 
DNA  was  later  found  to  relate  to  the  presence  of  unmethylated  CpG  motifs 
(Krieg  et  al.,  1995)  and  since  then  CpG  motifs  on  bacterial  DNA  have  been 
shown  to  have  adjuvant  properties  (Roman  et  al.,  1997).  CpG  motifs  have 
subsequently  been  shown  to directly activate  macrophages  and  dendritic cells 
(Sparwasser et al.,  1998,  Sparwasser et al.,  1997)  and  recognition  of bacterial 
CpG  has  been demonstrated to be mediated  by a Toll  Like Receptor 9 (TLR9). 
This  was  confirmed  by  a  report  that  TLR9  deficient  mice  did  not  respond  to 
immunostimulatory CpG-DNA (Hemmi et al., 2000).
Several studies have investigated whether immune responses can be enhanced 
if  cellular  uptake  of  DNA  following  needle  injection  is  a  limiting  factor. 
Electroporation has been used as a technique to enhance the cellular uptake of 
DNA  (Widera  et  al.,  2000).  The  authors  demonstrated  that  electroporation 
results  in  increased  delivery  of  DNA  to  cells  with  subsequent  increased 
expression  of antigen  and  superior humoral  immune  responses against weakly 
immunogenic antigens.
Research  has  also  focused  on  co-administration  of  plasmids  expressing 
cytokines  which  are  known  to  emphasise  certain  components  of  immune 
defence  that  correlate  with  protection.  One  such  example  combined  mucosal
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combination  of an  HIV  DNA vaccine  candidate with  plasmids  expressing  IL-12 
and  GM-CSF was  shown  to  induce  a  strong  CTL  response  to the  HIV antigen 
both  systemically and  more  importantly  at  mucosal  sites  (Okada  et  al.,  1997). 
Other more  recent examples  have  shown  protection  against  HSV following  co­
administration of plasmids expressing IL-12 and IL-18 (Lee et al., 2003), and the 
generation  of  stronger  memory  responses  following  vaccination  and  co­
administration of a plasmid expressing IL-12 (Chattergoon et al., 2004).
Another approach to enhance the immune responses elicited  by DNA has been 
to deliver the DNA mucosally and directly to M cells (Wu et al., 2001). This study 
focused  on  the  coupling  of  DNA  to  reovirus  protein  sigma  1,  which  when 
coupled  to  polylysine  could  directly  bind  to the  apical  surface  of M  cells  in  the 
NALT.  Intranasal  immunisation  with  this  complex  resulted  in  antigen-specific 
serum IgG and long-lived mucosal IgA as well as a substantial CTL response.
1.4.6  DNA Vaccines and Influenza
Influenza DNA vaccines have been extensively studied and constructs encoding 
the  surface  glycoproteins,  HA  and  NA,  internal  proteins  NP  and  M1  and  non 
structural  protein  NS1  have  all  been  assessed  for  their  ability  to  generate 
protective immune responses (Chen et al.,  1998, Robinson et al.,  1997, Ulmer et 
al.,  1993a).  Immunisation with plasmid DNA encoding influenza HA is capable of 
inducing  cell-mediated  and  humoral  immunity and  protecting  against intranasal 
challenge  with  influenza  virus  (Ulmer  et  al.,  1994,  Webster  et  al.,  1994). 
Furthermore,  induction of CTLs and protection against virus challenge has been 
demonstrated  with  plasmid  DNA  encoding  influenza  virus  NP  (Ulmer  et  al., 
1993b).  These  studies  have  primarily  been  carried  out  by  introducing  DNA  by
43intramuscular  injection,  and  research  into  gene  gun  immunisation  has  been 
limited and less productive (Chen et al., 2000).
1.5  Lymphocyte Trafficking
1.5.1  Introduction
In  1964,  Gowans  and  Knight demonstrated  that  circulating  naive  lymphocytes 
enter  secondary  lymphoid  tissue  via  high  endothelial  venules  (HEV)  before 
subsequently  returning  to  the  circulation  through  efferent  lymph  (Gowans  & 
Knight,  1964).  Further research showed how memory T lymphocytes selectively 
recirculate  back through tissues from which they originated  (Cahill et al.,  1977) 
and together these early studies began to contribute to the hypothesis of tissue 
specific  lymphocyte  recirculation.  The  benefits  of  recirculation  are  two-fold; 
firstly,  antigen  specific lymphocytes  have  the chance  to  come  into contact with 
specific  antigen  regardless  of  where  the  antigen  is  in  the  body.  Secondly,  it 
ensures that  particular subsets of lymphocytes are delivered  to where they are 
required the most.
Recirculation  begins  with  leukocytes  interacting  transiently  and  reversibly  with 
vascular  endothelium  through  adhesion  receptors  in  a  process  called  rolling. 
This  is  the  first  step  in  a  multistep  model  of  leukocyte  recruitment  (Butcher, 
1991, Springer,  1994). As a leukocyte rolls along the surface of the endothelium 
it  is  allowed  to  sample  the  surface  for  activating  factors.  Activation  allows  a 
firmer  adhesion  between  the  leukocyte  and  the  endothelium  before  the 
leukocyte  is  slowed  down  completely  due  to  high  affinity  interactions.  At  this 
stage  leukocytes  can  receive  further  signals  to  trigger  their  transmigration 
through junctions between cells in the endothelial layer. Once they have entered
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inflammation.  At  this  point  they  can  exert  their  effect  before  either  dying  or 
leaving  a  tissue  and  returning  to  the  circulation  via  the  efferent  lymph  and 
thoracic duct.
1.5.2  Chemokines
Chemokines  are  a  group  of  small,  structurally  related  molecules  that  regulate 
cell  trafficking  of various types of leukocytes through  interactions with  a  subset 
of seven-transmembrane,  G  protein-coupled  receptors.  Chemokines have been 
subdivided  into 2 major groups on the basis of the arrangement of their two N- 
terminal  cysteine  residues,  CXC  and  CC,  depending  on  whether  the  first  two 
cysteine  residues  have  an  amino acid  between  them  (CXC)  or are adjacent to 
each other (CC).
Chemokines  can  be  divided  into  two  effector  categories:  homeostatic  and 
inflammatory.  Homeostatic  chemokines  are  expressed  in  certain  tissues, 
suggesting  a  specific  function  involved  in  cell  migration.  The  inflammatory 
chemokines,  however,  are strongly induced  by inflammatory or immune stimuli 
and  participate in the development of immune/inflammatory reactions.  Recently, 
chemokines  have  been  shown  to  exert  pivotal  roles  in  the  development  and 
function  of the  immune  system.  Two  studies  have  shown  crucial  roles  for the 
chemokines  CXCL12  and  CCL3  in  B  cell  and  T  cell  development  (Kelner  & 
Zlotnik,  1995, Nagasawa etal.,  1996).
451.5.3 The Multistep Model of Leukocyte Recruitment
All  leukocytes  are  believed  to  extravasate  through  a  series  of  steps  that  are 
considered  to  be  similar regardless  of the type  of leukocyte  involved  (Butcher, 
1991).  The  multistep  model  can  be  seen  in  Figure  3.  The  initial,  reversible 
interaction  is  mediated  by  the  interaction  of  selectins  with  their  glycoprotein 
ligands. The selectin family comprises three members which fall into two groups: 
The first is L-selectin (CD62L) which is expressed on many leukocytes including 
naive  T  cells.  The  second  group  includes  E-selectin  (CD62E)  and  P-selectin 
(CD62P)  both  of which  are  expressed  by  activated  endothelium.  All  selectins 
bind  sialomucins  that  present  oligosaccharides  related  to  sialyl-Lewisx.  L- 
selectin  recognises  sulphated  sialyl-Lewisx-like  sugars  called  peripheral-node 
addressin  (PNAd)  (Vestweber  &  Blanks,  1999).  Selectin-mediated  bonds  are 
very  weak  and  the  pressure  exerted  by  blood  flow  can  easily  dissociate 
upstream  bonds, while  new bonds form  downstream. This selectin-glycoprotein 
interaction  causes  the  leukocyte  to  roll  across  the  surface  of the  endothelium 
and  results  in  the  loose  tethering  of the  leukocyte allowing  it to  interact further 
with the endothelium.
The  second  step  occurs  as  the  leukocyte  is  rolling  across  the  surface  of the 
endothelium, where  it can  become activated  by chemokines which are  involved 
in  the  stimulation  of  leukocyte  movement.  In  response  to  chemokines,  rolling 
leukocytes  subsequently  rearrange  their  cytoskeletons  and  change  in  shape 
from  spherical  to  a  more  flattened  shape  which  allows  integrins  on  the  cell 
surface to engage with their ligands on the endothelial cells and further slow the 
movement of the leukocyte. The most common integrins involved in this second 
stage of adhesion are leukocyte function-associated antigen type  1   (LFA-1; also 
referred  to  as  CD11aCD18  and  a\jt2   integrin)  and  the  two  a4  integrins,
46(also know as very late antigen-4 or VLA-4) and a4 /?7  (also known as  LPAM-1). 
The  a4  integrins  have  also  been  shown  to  play a  part  in  the  rolling  step  of the 
model  (Berlin  et  al.,  1995).  Leukocytes  demonstrate  high  affinity  binding  to 
endothelial  cells  when  the  interaction  is  mediated  by  integrins.  Integrins 
recognise  specific  ligands  on  the  endothelial  cell  surface.  The  ligands  include 
intracellular  adhesion  molecules  ICAM-1  /  ICAM-2  (which  bind  LFA-1)  and 
vascular  cell  adhesion  molecule  (VCAM-1)  as  well  as  mucosal  addressin  cell 
adhesion  molecule  (MAdCAM-1)  which  function  as  the  ligands  for  the  a4  
integrins.  Leukocytes  now exhibit firm  adherence,  they no  longer exhibit  rolling 
and appear fixed. Studies on blood lymphocytes have shown that they only stop 
if their p2 integrins (e.g.  LFA-1) are triggered into a high affinity conformation by 
signalling through  G  protein  coupled  receptors  (Bargatze et al.,  1995, Warnock 
et  al.,  1998).  More  recently,  studies  on  the  migration  of T  lymphocytes  have 
shown  that the  chemokine  CCL21  (also  known  as  SLC-secondary  lymphocyte 
chemoattractant and thymus-derived  chemotactic agent TCA-4) triggers  LFA-1- 
mediated  arrest  of  rolling  T  lymphocytes  (Campbell  et  al.,  1998b,  Stein  et  al., 
2000,  Warnock  et  al.,  1998).  Chemokines  have  been  shown  to  be  capable  of 
mediating  this arrest process on  peripheral  blood  lymphocytes and  lymph  node 
cells (Campbell et al.,  1998b).
The final step in the model is the transmigration of leukocytes through the vessel 
wall between the endothelial cell junctions and into the tissue. Once through the 
endothelial  layer,  leukocytes  can  migrate  along  gradients  of  chemoattractants 
towards a site of inflammation.
4748Figure 3: An illustration of the  multistep  model of leukocyte  migration taken from 
von  Andrian,  U.  H.  &  Mackay,  C.  R.  (2000).  T-cell  function  and  migration.  Two 
sides of the same coin. N Engl J Med 343,  1020-34. Graduated arrows at the top 
of the figure demonstrate the flow of blood  in the vessel and  how the velocity of 
blood  is fastest at the centre of the vessel  and  approaches zero at the epithelial 
surface.  Leukocytes interact transiently and  reversibly with vascular endothelium 
through  adhesion  receptors  in  a  process  called  rolling.  Tethering  and  rolling  is 
facilitated by selectins and the a4 integrins.  As a leukocyte rolls along the surface 
of  the  endothelium  it  is  allowed  to  sample  the  surface  for  activating  factors. 
Activation  occurs  via  interactions  with  chemoattractants  bound  to  seven 
transmembrane  domain  receptors  on  the  endothelial  cells.  Activation  allows  a 
firmer  adhesion  between  the  leukocyte  and  the  endothelium  via  02  and  a4 
integrins  before  the  leukocyte  is  slowed  down  completely  due  to  high  affinity 
interactions.  At this  stage  leukocytes  can  receive  further signals  to  trigger their 
transmigration through junctions between cells in the endothelial layer.Tethering Rolling Activation Arrest
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491.5.3.1  T Lymphocytes and the Multistep Model
Naive T lymphocytes gain access to the lymph nodes through HEVs. Expression 
of L-selectin  on  the  lymphocyte  is essential  for  binding  to  PNAd  and  the  initial 
contact  to  the  HEV  (Arbones  et  al.,  1994).  Furthermore,  successful 
extravasation  of  a  T  lymphocyte  at  this  stage  involves  activation  through  the 
chemokine  CCL21  (Gunn  et  al.,  1999)  binding  to  its  ligand  the  chemokine 
receptor  CCR7  on  the  lymphocyte  (Campbell  et  al.,  1998a,  Yoshida  et  al.,
1998).  Finally,  naive  T  lymphocytes  express  the  p2  integrin  LFA-1  which 
interacts  with  ICAM-1/2  on  the  endothelial  cell  surface  to  promote  firm 
adherence to stop the rolling before diapedesis can occur.  L-selectin and CCR7 
are  unnecessary  for  migration  to  inflammatory  sites,  and  are  therefore 
downregulated following activation of the T lymphocyte.  Meanwhile activation  is 
associated  with  an  increased  expression  of  the  integrins  LFA-1  and  VLA-4 
(Mobley & Dailey,  1992).
Different effector subsets of T lymphocytes are also grouped  according to their 
expression of different chemokine receptors. Type 2 CD4+  effector cells primarily 
express  CCR3  and  CCR4,  whereas  type  1   cells  phenotypically  express  high 
levels  of  CCR5  and  CXCR3  (Zlotnik  &  Yoshie,  2000).  CD8+   effector  T 
lymphocytes  have  not  been  extensively  characterised  with  regard  to  their 
chemokine  receptor  expression,  but  it  would  appear  that  they  have  a  similar 
pattern to CD4+  effector T cells in that chemokine receptor expression correlates 
with the cytokine profile, type 1   or type 2 (Cerwenka et al.,  1999b).
501.5.3.2 Integrins versus Selectins
It  has  been  shown  that  both  integrins  and  selectins  play  important  roles  in 
cellular  trafficking.  However,  integrins  have  been  shown  to  play  a  more 
important role when the  leukocytes are activated  CD8+  effector lymphocytes. A 
study was recently carried out to investigate the functional impact of blocking the 
effects of certain integrins and selectins on the migration of effector CD8+  T cells 
to  sites  of  viral  replication  (Bartholdy  et  al.,  2000).  This  investigation  blocked 
either; two of the major selectins (E and  P-selectin), or one selectin (P) and one 
integrin (ICAM-1) or finally two integrins (ICAM-1  and VCAM-2). Results showed 
that failure  to  interact with  endothelial  selectins  is  of  little functional  relevance; 
however,  integrins  are  crucial for a virus-induced  T cell  mediated  inflammatory 
response.
1.5.4  Migration of Effector T Lymphocytes
Naive T lymphocytes express high levels of L-selectin,  low levels of LFA-1  and 
are  CCR7  positive,  all  of which  aid  the  extravasation  of these  cells at HEVs to 
enter  lymph  nodes  (Warnock  et  al.,  1998,  Weninger  et  al.,  2001).  Upon 
activation,  these  naive  lymphocytes  down-regulate  these  lymph  node  homing 
molecules  and  enhance  expression  of  molecules  involved  in  the  migration  to 
non-lymphoid  tissues  such  as  the  skin  and  intestinal  mucosa.  For example,  a 
subset of circulating  memory CD4+  and  CD8+  T lymphocytes express  E and  P- 
selectin  ligands in addition to the chemokine receptor CCR4.  Expression of this 
combination  of surface  antigens  is  a  phenotype  known  to  be  characteristic  of 
skin  homing  lymphocytes  (Campbell  et  al.,  1999,  Tietz  et  al.,  1998,  Xie  et al.,
1999).  By contrast, expression of  integrin is thought to be a characteristic of 
gut homing cells (Kuklin et al., 2000). While expression of these combinations of 
molecules partially correlates with the migration patterns of the cells, there does
51appear to be a  level of promiscuity in the  use of certain  homing  molecules.  For 
example, a population of CD4+  T cells have been shown to utilise P-selectin and 
P-selectin glycoprotein ligand to migrate to the intestine (Haddad et al., 2003).
CCR7 has been shown to divide human memory T lymphocytes into two distinct 
subsets:  CCR7'  memory  cells  which  express  receptors  for  migration  into 
inflamed  tissues  and  show  immediate  effector function,  while  CCR7+   memory 
cells  express  lymph  node  homing  molecules  and  lack  immediate  effector 
function.  These  cells  were  termed  effector  (T Em)  and  central  memory  (T Cm) 
(Sallusto et al.,  1999) and have more recently been described in mice (Bjorkdahl 
et al.,  2003).  A recent study,  in  a  murine  model,  carried  out an  investigation  in 
the  trafficking  of  effector  memory  CD8+   cells  in  lymphoid  and  non-lymphoid 
tissues following viral or bacterial infection (Masopust et al., 2001).  It was shown 
that  antigen  specific  memory  cells  preferentially  migrated  to  non-lymphoid 
tissues and that this migration was independent of the infectious agent used and 
the route used to administer the pathogen. A complementary study by the same 
group investigated the migration patterns of activated primary and memory CD8+  
cells.  It was  shown  that activated  CD8+  T  lymphocytes  migrated  extensively to 
all  non-lymphoid  tissues  irrespective of the site of the  initial  antigen  encounter. 
Also,  using  an  adoptive  transfer  system,  migration  of  these  non-lymphoid 
populations was demonstrated to be  promiscuous with a  preference for homing 
to the tissue of origin. These results suggest that subsets of memory cells exist 
in  each  tissue  and  exhibit  a  tendency  towards  homing  to  their  original  site  of 
activation (Masopust et al., 2004).
521.5.4.1  Chemokines and Tissue Specific Homing
Chemokines  have  been  shown  to  be  important  in  the  role  of cell  arrest  in  the 
multistep  model  of  lymphocyte  homing  (Campbell  et  al.,  1998b).  Lymphocyte 
expression  of  adhesion  molecule  and  chemokine  receptors  directs  their 
migration  from  the  blood  into tissues.  Chemokines function  at  several  steps  in 
these  homing  pathways  mediating  firm  arrest  of  lymphocytes  rolling  along 
vascular  endothelium,  promoting  diapedesis,  and  segregating  lymphocytes 
within  tissues  into  functional  microenvironments.  The  best  characterised 
example  of  these  chemokine  functions  are  CCL21  and  CCL19  which  are 
involved  in  homing  to  secondary  lymphoid  tissues  and  mediate  entry  of naive 
lymphocytes  before  segregation  into distinct T and  B  cells  areas  (Muller et al., 
2002).
Other chemokines  trigger only  certain  specialised  subpopulations.  An  example 
is CCL20 which triggers adhesion of CD4+ memory T cells but  has no effect on
naive  T  cells  (Campbell  et  al.,  1998b).  Another  example  is  CCL17  which  is
expressed  on  skin  endothelium,  and  functions  in  conjunction  with  CCR4 
expression  on  skin-homing  lymphocytes.  CCL17  helps to  mediate  skin  specific 
homing  (Campbell  et al.,  1998a).  This  finding  has  brought about the  idea  that 
triggering  of  adhesion  of  cells  to  the  endothelial  layer  may  serve  as  a 
checkpoint, allowing only certain subsets of cells to enter a particular tissue.
Due  to  its  restricted  expression  in  the  intestine,  CCL25  has  attracted 
considerable  attention  as  a  potential  intestinal-specific  homing  chemokine 
(Kunkel et al., 2000,  Uehara et al., 2002).  Neutralisation of CCL25 in vivo with a 
blocking  antibody,  has  directly shown  that  CCL25  and  its  receptor  CCR9
function  in  the  recruitment  of effector lymphocytes  to  the  small  intestinal
53epithelium following their activation in the GALT (Svensson et al., 2002). CCL25 
has  also  been  shown  to  play  an  essential  role  in  the  intestinal  homing  of  IgA 
antibody  secreting  cells  by  mediating  their  extravasation  into  intestinal  lamina 
propria  (Hieshima  et  al.,  2004).  A  closely  related  chemokine  CCL28  has  also 
been  implicated  in  mucosal  tissue-specific  homing  due  to  its  expression  by 
epithelial  cells  in  several  mucosal  tissues  including  the  trachea,  lung,  colon, 
mesenteric lymph nodes, salivary gland, and  mammary gland  (Pan et al., 2000, 
Wang et al., 2000).
1.5.4.2  Homing and Adhesion in the Respiratory Compartment
There has been little research carried out to investigate respiratory lymphocytes 
with  regard to their trafficking  patterns and  homing  receptors.  Studies in animal 
models suggest that there is a distinct pattern of recirculation for respiratory tract 
T  lymphocytes.  In  the  mouse  NALT,  T  cell  binding  has  been  shown  to  be  L- 
selectin/PNAd  mediated  and  not  as  a  result  of  o^/MAdCAM-l interactions, 
suggesting  a  closer  link  of  these  cells  to  peripheral  lymph  than  to  gut  lymph 
(Csencsits et al.,  1999).  By contrast, in sheep, lung lymphocytes appear to have 
their own distinct migration profile due to their low expression of both  L-selectin 
and of the a4 j37 integrin (Abitorabi et al.,  1996).
More recently in a study focused on the homing of lymphocytes to the bronchial 
associated  lymphoid  tissue  (BALT),  it  was  noted  that  homing  to  this  area  is 
mediated  by  collaboration  between  L-selectin/PNAd,  o^A/CAM -l  and  LFA- 
1/ICAM  interactions. This is the first report of unique  high  level of a $ iA/CAM-1 
interaction  in  a  secondary  lymphoid  tissue  (Xu  et  al.,  2003).  This  study  also 
showed that anti-or4 and anti-VCAM-1  monoclonal antibodies were able to inhibit 
around  40%  of  total  lymphocyte  homing  to  the  BALT,  but  more  specifically
54blocked  70%  of  the  homing  of  a  memory  T  cell  rich  T  lymphocyte  pool 
suggesting  that aV?i  and  VCAM-1  are  involved  in  the  recruitment of memory T 
cells to the BALT.
The mechanism of lymphocyte homing to the lungs is not fully understood.  In a 
model  of  murine  pulmonary  inflammation,  ICAM-1  has  been  implicated  in 
lymphocyte  recruitment to the  lungs  (Chin  et al.,  1998).  L-selectin  and  ICAM-1 
have also been shown to play an important role in the migration of lymphocytes 
to the lungs in the murine asthma model  (Keramidaris et al.,  2001).  Bacterial or 
viral  infection has been shown to generate effector and  memory CD8+  cells that 
migrate  preferentially  to  the  non-lymphoid  tissues  including  the  lungs, 
suggesting these cells either continuously circulate through peripheral tissues or 
reside in them  permanently (Masopust et al.,  2001).  However,  there have been 
no  reports  specifically aimed  at investigating the trafficking  of cytotoxic CD8+  T 
cells into the lungs. One recent study did show,  by utilising monoclonal antibody 
blocking,  that  LFA-1  is  essential  in  the  retention  of  activated  CD8+   T 
lymphocytes in the murine lung (Thatte et al., 2003).
In  the  murine  influenza  virus  model,  it  has  been  demonstrated that the  integrin 
arfi  (VLA-1) is responsible for retaining protective memory CD8+  T lymphocytes 
in the lung via attachment to the extracellular matrix.  However recruitment is not 
VLA-1  dependent (Ray et al., 2004).  It was observed that lung VLA-1  expressing 
CD8+   lymphocytes  were  resistant  to  the  apoptosis  that  follows  recovery  from 
influenza  virus  infection,  and  it  is  proposed  that  in  vivo  this  resistance  is 
conveyed through VLA-1  binding to its ligand type I or type IV collagen.  It would 
appear that this  resistance  may allow the  establishment and  maintenance of a 
resident  protective  memory  population  and  this  finding  is  supported  by  the 
Masopust  et al.  (2001)  study  that  demonstrated  evidence  of  resident  memory
55cells  and  the  preferential  relocation  of  memory  cells  induced  back  into  non­
lymphoid tissues including the lung.
1.6.1  Aims of this investigation
Whilst the current influenza vaccines provide protection and are associated with 
an  excellent  safety  record  and  are  well  tolerated  (Beyer  et  al.,  2002)  there 
remains  room for improvement.  The  influenza  virus  is  continuously undergoing 
antigenic  change  driven  by  pressures  to  evade  the  acquired  immunity  of the 
population.  Any  antigenic  shift  exhibited  by  the  circulating  virus  strains  puts 
pressure on  the  manufacture of protective vaccine stocks.  The circulating virus 
strains  have  to  be  constantly  monitored  so  that  accurate  predictions  can  be 
made as to what vaccine strains are  required.  The vaccine  must aim to protect 
against any new virus strains which appear virtually on an annual basis. The real 
threat  is  that  of  a  pandemic,  where  highly  pathogenic  influenza  virus  strains 
pass  from  animal  reservoirs  to  humans  and  cause  fatal  disease.  If  the  next 
influenza  pandemic  was  to  strike  tomorrow,  inactivated  vaccines  could  offer 
immediate  prophylaxis,  however  their  supply  is  limited  and  the  production  of 
more  vaccine  is  time  consuming  and  obviously  dependent  on  a  supply  of 
embryonated  hens  eggs.  On  an  annual  basis,  it  is  estimated  that 6  months  is 
required  to  organise  sufficient  eggs  for  vaccine  manufacture  (Gerdil,  2003). 
Taking  this  into  consideration,  vaccines  based  on  conserved  viral  proteins  are 
ideal  candidates  for  a  new  influenza  vaccine  as  they  are  highly  conserved 
between  different  strains  of  virus  and  one  vaccine  should  be  efficient  at 
controlling most influenza virus strains.
Investigations  have  been  carried  out  using  the  internal  conserved  NP  and  M 
proteins and vaccinations with these have elicited protective immune responses
56in  mice.  Some of these data were  based  on the  protection  generated following 
DNA immunisation which has been reported by several groups. This included an 
investigation into PMID of DNA as a method of immunisation.  Ballistic gene gun 
immunisation  has  been  shown  to  generate  strong  humoral  and  cellular 
responses  but  the  analysis  of  this  response  has  often  been  limited  to  the 
systemic immune system. As influenza virus infects via a mucosal  route,  it is of 
interest to assess  the  ability of PMID  immunisation  of  DNA to  elicit a  mucosal 
immune response. The work presented was aimed at characterising the immune 
responses  elicited  by  DNA  immunisation  administered  to  naive  mice  by  the 
PMID  route.  These  results  would  be  compared  to  the  protective  immune 
responses generated  in  a  murine  model  of influenza virus  infection.  It is  hoped 
that  this  detailed  characterisation  of  both  viral  and  vaccine  induced  immune 
responses  will  provide  an  insight  as  to  whether  PMID  delivery  of  DNA  can 
induce  immune  responses  that  may  be  required  by  a  new  generation  of 
vaccines.
This study will initially characterise the immune response generated by influenza 
virus  infection with  regard to humoral and  cellular immune responses. With this 
information,  studies will  continue analysing  the  immune  response generated  by 
PMID delivery of a  plasmid  coding for influenza virus  NP.  Comparison  of these 
data  should  indicate  desirable  characteristics  required  of an  influenza  vaccine 
and  assess  PMID  as  a  vaccine  delivery  method  for  a  respiratory  pathogen. 
Finally  studies  will  characterise  the  antiviral  cellular  response  induced  by  both 
infection  and  vaccination  with  regard  to  the  homing  characteristics  of effector 
CD8+   T  cells.  This  analysis  should  assess  how  good  PMID  of  NP  DNA  is  at 
generating  a  response  similar  to  that  of experimental  infection  and  predict  its 
effectiveness as a vaccine.
571.6.2 Hypothesis to be Tested
It is hypothesised that virus-specific B and T lymphocytes will traffic extensively 
throughout  the  body  by  virtue  of  the  CMIS  following  activation  by  either 
intranasal  influenza  virus  infection  or  PMID  of  influenza  virus  NP  DNA, 
regardless  of  their  initial  site  of  activation.  This  analysis  will  determine  the 
efficacy  of  PMID  of  NP  DNA  at  stimulating  a  broad  anti-influenza  immune 
response  in  terms  of the  strength  and  distribution  of virus-specific  cells  when 
compared  with  influenza  virus  infection  which  normally  produces  sterilising 
immunity.  The  IEF  technique  was  developed,  in  conjunction  with  fragment 
cultures, to aid  in the  identification of the production of anti-influenza antibodies 
by ASCs  in  various  compartments.  Influenza  virus-specific cytokine  ELISPOTs 
and flow cytometry analysis of tetramer positive anti-viral cells was developed to 
allow  identification  of  the  location  of  virus  specific  CD8+   T  cells  following 
infection  and  immunisation  and  to  elucidate  their  phenotype  and  homing 
patterns.  Together  these  analyses  will  aid  in  the  determination  of  the  clonal 
distribution of virus-specific ASCs and whether virus-specific T cells identified in 
different  compartments  of the  immune  system  have  similar  homing  properties 
regardless of their method of activation.
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Materials and Methods2.1  Mice
Adult,  6-8 week old, female  C57BL/6  mice  (H-2b) were  obtained  from  Charles  River 
Laboratories  UK  and  were  maintained  in  specific  pathogen  free  conditions  at  the 
Institute for Animal Health,  Compton,  UK or at GSK,  Stevenage,  UK. The mice were 
allowed to acclimatise for at least seven days before the start of a study. The animals 
were housed in groups of up to 10 and checked daily throughout each experiment.
2.2 Virus
Influenza virus A/PR/8/34 (H1N1) was purchased from Charles River SPAFAS (North 
Franklin,  CT).  This  was  provided  as  a  preparation  of  allantoic  fluid  obtained  from 
specific pathogen free chicken embryos infected with  influenza virus A/PR/8/34. The 
influenza virus was used to infect mice intranasally with a sub-lethal concentration of 
500 EID50 (50% egg infectious doses) in 30//I of PBS.
2.3 Isolation of Immune Cells
At  certain  time  points  post  infection,  mice  were  sacrificed  for collection  of  various 
tissues  of the  mucosal  and  systemic  immune  system.  Briefly,  the  following  tissues 
were collected from each animal and placed in Hanks’ balanced salt solution (HBSS; 
GIBCO  Biomedical  research  laboratories,  Grand  Island,  N.Y.):  spleen,  lungs,  gut, 
hind  legs  (for  bone  marrow),  mediastinal  lymph  node  (MedLN),  mesenteric  lymph 
nodes  (MesLN)  and  head  (for  NALT,  which  was  not  placed  in  HBSS).  Each  tissue 
was  treated  slightly  differently  to  prepare  it  for  incubation  as  fragment  cultures  (to 
investigate  secreted  immunoglobulins)  or  to  isolate  the  lymphocytes,  as  described 
below:
60Lymph nodes
Fat  was  dissected  away  from  the  lymph  nodes.  Prior  to  incubation  as  fragment 
cultures each  lymph  node was sliced  in  half, and  both  pieces were placed  in  1  ml of 
RPMI  1640  medium  (GIBCO)  supplemented  with  10%  foetal  calf  serum,  penicillin 
and  streptomycin  to  final  concentrations  of  100IU  and  100jig/ml  respectively,  and 
amphotericin  at  a  final  concentration  of 0.25//g/ml  (hereafter  referred  to  as  RPMI). 
Cells were isolated from lymph nodes for immune assays by placing in 5ml RPMI and 
rubbing  each  node  between the frosted  ends  of sterile glass  slides to disaggregate 
the  cells.  The  resulting  cell  suspension  was  harvested  by  centrifugation.  Cell 
suspensions  were  washed  twice  using  PBS  and  the  cells  were  counted  (using 
Trypan  Blue  exclusion  and  a  haemocytometer  or  using  an  automated  Guava 
counter).
Spleen and lung
Spleen  and  lung tissues were cut into  1-2mm fragments and  placed  in  1ml of RPMI 
medium prior to fragment culture.  Cells for immune assays were isolated by placing 
in  10ml  RPMI  and  rubbing spleen  or lung tissue between the frosted ends of sterile 
glass slides to disaggregate the cells. The resulting cell suspensions were harvested 
by centrifugation  and  any contaminating  erythrocytes  were  lysed  by  incubating  the 
samples for 1  minute with red blood cell lysing buffer (Sigma,  UK). Cell suspensions 
were  washed  twice  using  PBS  and  the  cells  were  counted  (using  Trypan  Blue 
exclusion and a haemocytometer or using an automated Guava counter).
Bone marrow
Tissue  was  dissected  away  from  the  hind  legs  to  expose  the  femur  which  was 
divided into 3 sections, each of which was placed in  1ml of RPMI.  Bone marrow was 
only used in fragment culture analysis.
61O-NALT
The  O-NALT was  isolated  by the  method  described  Asanuma  et al  (1997).  Briefly, 
the head of the mouse was collected and fur removed from the entire head. The eyes 
and loose tissues behind the eyes were removed  before the lower jaw was removed 
to  expose  the  palate.  Using  a  scalpel,  a transverse  cut was  made  behind  the  eye 
sockets  and  the  back  portion  of  the  head  and  remnants  of  brain  tissue  were 
discarded.  The  tip  of the  nose  containing  the foreteeth  was  removed,  as  were  the 
cheekbones and the cheek muscles. The O-NALT was identified and  isolated  under 
a dissection  microscope.  It was visualised  as two small  longitudinal  lymphoid  strips 
located on the posterior side of the palate. The whole palate was removed under the 
dissection microscope and the O-NALT was peeled off the palate using fine forceps. 
Cell  suspensions  were  made  by  rubbing  the  O-NALT  between  the frosted  ends  of 
sterile glass slides to disaggregate the cells.
D-NALT
Heads  were  prepared  as  for  the  O-NALT  and  after  removing  the  palate,  the  teeth 
were cut away. The remaining nose part consists of the nasal bones, nasal turbinates 
and  the  septum.  This  nose  part was cut  into very small  pieces and transferred  into 
DMEM/10%FCS  containing  4mg/ml  collagenase A  (Roche  Molecular  Biochemicals, 
UK).  This suspension was incubated with gentle rocking at 37°C for 30 minutes. The 
digested  mixture  was  strained  through  a  70jjm  cell  strainer  and  centrifuged  at 
1400rpm for 5 minutes. It was then resuspended in 5 ml DMEM/10% FCS.
A Percoll (Amersham Pharmacia, UK) density gradient was prepared by layering 2ml 
40%  Percoll  over  2ml  75%  Percoll.  The  5ml  D-NALT  suspension  was  carefully 
layered  onto  the  gradient  before  centrifugation  at  2000rpm  for 20  minutes  at  room 
temperature (RT).  D-NALT lymphocytes were removed from the interface of the 40% 
and  75%  layers with a sterile glass  Pasteur pipette and  transferred into a new 15ml
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resuspended  in  1ml  DMEM/10%  FCS.  For  incubation  as  fragment  cultures  the  D- 
NALT was left intact and cut into three fragments,  each of which was placed  in  1   ml 
RPMI.
Peyer’s patches and Gut
Peyer’s  patches  were  removed  from  the  gut,  cut  in  half  and  placed  in  1ml  RPMI. 
Sections of approximately 5 cm from the duodenum,  ileum and colon of the gut were 
cut longitudinally to expose the mucosal surface, before several 2mm sections were 
collected.  The  gut  sections  were  washed  6  times  in  PBS  containing  0.05%  EDTA, 
0.25pg/ml  amphotericin,  penicillin  and  streptomycin  at final  concentrations  of  100IU 
and  100jug/ml  respectively  before  being  placed  in  1ml  of  RPMI  for  incubation  as 
fragment  cultures.  Only  cells  from  the  Peyer’s  patches  were  isolated  for  immune 
assays  by placing them in  10ml  RPMI  and  rubbing  each  Peyer’s patch  between the 
frosted ends of sterile glass slides to disaggregate the cells.
Serum
When  animals  were  Schedule  1   culled  whole  blood  was  collected  in  to  Serum 
Separation  tubes  (BD  Biosciences,  San  Jose,  CA).  Serum  was  separated  by 
centrifugation at 14000 rpm for 3 minutes. Serum was stored at -20°C until analysis.
2.4  Fragment Culture Method
Cultures of tissues were prepared  by an adapted technique previously described for 
culture  of  small  intestinal  lymphoid  tissue  (Khoury  et  al.,  1994).  All  the  fragment 
cultures,  prepared  as  described  above,  were  incubated  at  37°C  in  a  humidified 
environment of 95%  oxygen  5%  carbon  dioxide for 5  days  after which the fragment 
culture medium was removed and stored at -20°C for analysis.
632.5 Isoelectric Focusing Using the BioRad Criterion™  System
A  Criterion  IEF  gel  pH3-10  (BioRad  Laboratories,  Hercules,  CA) was  prepared  and 
inserted into the Criterion tank. The upper buffer chamber was filled with  1  * Cathode 
buffer  (BioRad)  and  the  reservoir  of  the  tank  was  filled  with  1*  anode  buffer 
(BioRad). Samples were mixed in a 1:1  ratio with  IEF sample loading buffer (BioRad) 
before  loading  into  the  gel  along  with  5  jul  of  undiluted  IEF  standards  pi  4.45-9.6 
(BioRad).  The samples were separated  by electrophoresis  on the  pH  3-10  gradient 
gel under the following 3 step protocol:  100V for 1  hour, 250V for 1   hour and 500V for 
30min.
Various  protein  visualisation  techniques  were  investigated  which  will  not  be 
discussed  here  since  protein  staining  following  IEF  separation  using  the 
PhastSystem proved to be far superior.
2.6 IEF Using the Amersham Biosciences PhastSvstem™
Samples were  separated  by electrophoresis  on  a  PhastGel™  IEF  3-10  (Amersham 
Biosciences,  Uppsala,  Sweden).  Briefly, the ampholytes within the gel were allowed 
to  prefocus  at  2000V  for  75Vh  to  create  a  pH  gradient,  followed  by  sample 
application at 200V for 15Vh, and focusing at 2000V for 410Vh.
Proteins were visualised using Plus One Coomassie Tablets, PhastGel™ Blue R-350 
(Amersham  Biosciences)  and  PhastGel™  Protein  Silver  Staining  Kit  (Amersham 
Biosciences)  and  the  results  were  compared  to  those  obtained  using  the  BioRad 
Criterion system.
642.7  Protein Transfer and Immunoglobulin Visualisation
Two  techniques  were  established  to  visualise  the  virus  specific  immunoglobulin 
proteins  once  they  had  been  transferred  to  HYBOND-P  PVDF  membrane 
(Amersham Biosciences) as follows:
Active Transfer
Towbin  transfer buffer was  prepared  and  chilled  to 4°C to improve heat dissipation. 
The  buffer comprised  25mM Tris,  192mM glycine,  20%  (v/v)  methanol,  pH8.3. After 
electrophoresis,  the  gel  was  equilibrated  in  transfer  buffer  for  15min,  before  a 
gel/PVDF  membrane sandwich was created  in the transfer cassette of the  Criterion 
Blotter™  (BioRad)  as  described  in  the  manufacturer’s  protocol.  Transfer  of protein 
was carried out under electrophoresis at 100V for 60min.
Following  transfer  of protein,  unbound  areas  of the  membrane  were  blocked  for  1  
hour at RT by incubating in a 5% (w/v) solution of Marvel (powdered milk) in 1x Tris- 
buffered saline  (TBS) (10*  comprising 20mM Tris,  500mM sodium chloride, pH 7.4). 
The  membrane  was  incubated  at 4°C,  under  agitation,  with  a  0.2mg/ml  solution  of 
sucrose  purified  Influenza  A/PR/8/34  (Charles  River  SPAFAS)  in  TBS/0.5%  (w/v) 
Marvel for 4 hours.  The membrane was washed 4 times in TBS/0.05%  (v/v) Tween- 
20  for  at  least  5  min/wash.  The  membrane  was  treated  with  a  3%  (v/v)  hydrogen 
peroxide solution in TBS/0.05% (v/v) Tween-20, at room temperature for 2 min under 
agitation. The membrane was washed 4 times as before, followed by incubation with 
goat  anti-influenza  A  (H1N1)-HRP  (BioDesign  International,  Saco,  Maine)  at  a 
dilution of 1  in 5000 made up in TBS/0.5%  (w/v) Marvel/0.05%  (v/v) Tween-20.  The 
membrane  was washed  4 times  as  before,  prior to visualising  the  protein  using  an 
ECL Western  blotting  detection  system  (Amersham  Biosciences)  using  the  method 
described in the manufacturer’s protocol.
65The influenza specific antibodies were also visualised using incubation with goat anti 
influenza A-biotin  (BioDesign  International) optimised to a dilution of 1   in  5000.  This 
was  followed  by  a  wash  step,  as  before,  prior to  incubation  with  streptavidin-HRP 
(DAKO,  Denmark)  at  a  dilution  of  1   in  20  000  in  TBS/0.05%  (v/v)  Tween-20.  The 
proteins were visualised using chemiluminescence as described above.
Passive Transfer
Virus  specific  immunoglobulins  were  transferred  from  the  gels  by  passive  diffusion 
onto  a  membrane  precoated  with  a  10pg/ml  solution  of  sucrose  purified  Influenza 
A/PR/8/34  (Charles  River  SPAFAS)  in  TBS/0.5%  (w/v)  Marvel.  Membranes  were 
coated  overnight  with  agitation  at  4°C,  before  blotting  was  carried  out.  Following 
transfer,  unbound areas of the membrane were blocked for 1  hour at RT using a 5% 
(w/v) solution of Marvel in  1* Tris-buffered saline (TBS) (10* comprising 20mM Tris, 
500mM  sodium  chloride,  pH  7.4).  The  membrane  was  incubated  at  RT for  1   hour, 
with  agitation,  in  a  1:1000  dilution  of  goat  anti-mouse  Ig  (H+L)-HRP  (Southern 
Biotechnology,  Birmingham, Alabama),  in  1*TBS/1%  (w/v) Marvel/0.1%  (v/v) Tween 
20.  The  membrane  was  washed  4  times,  before  immunoglobulin  was  visualised 
using an ECL Western blotting detection system (Amersham Biosciences).
2.8  Analysis of Influenza A/PR/8/34 Monoclonal Antibodies
The following  monoclonal antibodies (MAbs), with specificity for Influenza A/PR/8/34 
haemagglutinin  (HA),  were  kindly  supplied  as  hybridomas  by  Prof.  Nigel  Dimmock 
(University of Warwick):  H36-4.5-2 (lgG2a),  H37-45-5R3 (lgG3),  H37-66-1  (IgA),  H9- 
D3-4R2  (lgG3).  MAb  supernatants  were  prepared  as  previously  described 
(Vokoyama, 2000).
66The  MAbs  were  analysed  by  IEF  (BioRad  Criterion™  system  and  Amersham 
PhastSystem™)  and  Influenza  A/PR/8/34  specific  immunoblotting,  as  previously 
described.
2.9 Fragment Culture Concentration
Selected  fragment  cultures  were  concentrated  by  centrifugation  using  Vivaspin  6 
columns-106  MWCO  (VivaScience,  Sartorius  Group,  Goettongen,  Germany)  to 
investigate  the  effect  of concentrating  the  proteins  before  separating  them  by  IEF. 
The  columns  feature  twin  vertical  membranes  and  a  dead  space  to  prevent drying 
out of samples and allow collection of concentrated sample.
2.10 Quantitation of Anti-Influenza Antibodies by ELISA
In order to quantify the amount of anti-influenza antibodies, three ELISA assays were 
developed.  The  first,  a  capture  ELISA  was  used  to  create  an  isotype  specific 
standard  curve,  the second  replaced  Ig  standards with fragment cultures to directly 
quantify the amount of each Ig isotype present in a fragment culture. The third ELISA 
was virus-specific and was used to indirectly quantify the anti-influenza antibodies.
Capture ELISA
The wells of Nunc-lmmuno 96 well plates (Nalge Nunc, Rochester, NY.) were coated 
overnight at 4°C with  10Ojal of unlabelled anti-lg isotypes (lgG1,  lgG2a,  lgG2b,  lgG3, 
IgA and  IgM),  at a  concentration of 5pg/ml  in  coating  buffer (comprising  20mM Tris 
HCI pH 8.5). The plate was washed three times in  Phosphate buffered saline (PBS) 
before blocking  any unbound  regions with a solution of PBS/1 %  (w/v)  Marvel/0.05% 
(v/v)  Tween-20  for  1  hour at room  temperature.  Purified  mouse  Ig  standards  lgG1, 
lgG2a,  lgG2b,  lgG3,  IgA,  IgM  (Sigma,  Poole,  England)  were  diluted  to  a  starting
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microlitre volumes were used to coat the corresponding anti-isotype wells for 2 hours 
at  room  temperature.  The  wells  were  washed  as  before,  with  a  subsequent 
incubation with  10Opil of anti-isotype AP conjugated antibodies at RT for 2 hours. One 
final wash step was carried out as before. The development reagent was prepared by 
dissolving  one  p-nitrophenyl  phosphate  tablet  (Sigma,  UK)  in  15ml  diethanolamine 
buffer.  One hundred  microlitre volumes of development reagent were added to each 
well after the wash step and development was allowed to occur until a colour change 
was observed.  At this  point, the reaction was stopped  by the addition of 50//I of 3M 
NaOH to each well and the optical densities were measured at 405nm.
Capture ELISA for analysis of fragment culture samples
The  protocol  used  was  identical  to  that  described  above  however,  the  Ig  isotype 
standards were replaced with fragment culture samples.
Influenza Virus Specific ELISA
Sucrose purified Influenza A/PR/8/34 2mg/ml (Charles River SPAFAS) was detergent 
disrupted  in  a  10  %  (v/v)  detergent  buffer  solution  (10x  comprising,  0.05M  Tris 
pH7.5,  0.5%  Triton-X-100  and  0.6M  KCI.)  and  subsequently  diluted  to  a 
concentration  of 5/yg/ml.  One  hundred  microlitre volumes of the  detergent disrupted 
influenza virus were used to coat wells of Nunc immuno plates overnight at 4°C.  Any 
unbound  regions  were  blocked  by  incubating  200//I  of  a  solution  of  PBS/1 %  (w/v) 
Marvel/0.05%  (v/v) Tween-20 in each well for 1   hour at RT.  The wells were washed 
as  described  above.  Serial  dilutions  of fragment  culture  were  prepared  and  100//I 
volumes  were  incubated  in  appropriate  wells  for  4  hours  at  RT.  The  wells  were 
washed  as  previously  described  before  development  with  alkaline  phosphatase 
conjugated antibodies as described above.
682.11  IFNy ELISPOT -  Influenza NP Peptide Stimulation
Wells of a 96 well Multiscreen-IP plate (Millipore, Watford, UK) were coated with 50//I 
of rat anti-mouse IFNy (BD Pharmingen, San Diego, CA) diluted to a concentration of 
15/yg/ml in PBS.  Plates were incubated overnight at 4°C, or at RT for at least 4 hours. 
Plates  were  washed  twice  with  PBS  and  blocked  using  200/yl  RPMI  for 2  hours  at 
37°C.
Cells  were  collected,  isolated,  washed,  counted  and  diluted  in  RPMI  to  a  final 
concentration of either 2 or 4*106 cells/ml.  Murine recombinant IL-2 was added to the 
cells at a concentration of 10U/ml and  100/vl aliquots of cell suspension were plated 
out  in  triplicate.  NP366.374  peptide  (ASNENMETM)  was  diluted  to  a  concentration  of 
20//g/ml  in  RPMI,  and  100/vl  volumes  were  mixed  to  each  well  (giving  a  final 
concentration of 10/yg/ml).  Plates were incubated for 16-30 hours at 37°C.  (16 hours 
was  found  to  be  sufficient for  strongly  responding  cells  e.g.  lungs  and  MedLN  but 
other tissues e.g. NALT and PP required a longer incubation of 30 hours).
Plates  were  washed  4  times  with  PBS  before  incubation  with  50/yl  anti-IFNy-biotin 
(BD  Pharmingen)  at  a  1:1000  dilution  in  PBS  for  2  hours  at  RT  with  shaking  (or 
incubated  overnight  at  4°C).  The  plates  were  washed  four  times  with  PBS  before 
incubation with 50//I goat-anti-biotin-AP (Vector Labs, UK) at a 1:1000 dilution in PBS 
for 2 hours at RT with shaking (or overnight at 4°C).
Plates  were  washed  a  final  time  before  development  with  50//I  of  Bio-Rad  AP 
conjugate  substrate  prepared  according  to  the  kit  manufacturer’s  protocol.  Plates 
were  left to  develop  in  the  dark  at  RT and,  when  purple  spots  appeared  (about  10 
mins) the reaction was stopped using three washes of distilled and deionised water.
692.12 Tetramer Staining
Single  cell  suspensions  from  pooled  lymphoid  tissues  of  individual  mice  were 
prepared  and  influenza  specific  cells  were  analysed  using  phycoerythrin  (PE) 
conjugated  H-2Db  NP366-374  tetramer  (Prolmmune,  Oxford,  UK)  displaying  the 
dominant NP CD8 epitope ASNENMETM.  Before tetramer staining, cell suspensions 
were enriched for CD8+  T cells.  Briefly, cells were incubated with a  1:100 dilution of 
the following monoclonal antibodies: TIB 120 (anti-MHC II), RA3-6B2 (anti-B220) and 
GK1.5  (anti-CD4)  for  1   hour  with  rotation  at  4°C.  Cells  were  collected  by 
centrifugation  before  incubation  with  1*107  Dynabeads/ml  (Dynal  Biotech,  Norway) 
for 30min with rotation at 4°C. Cells with bound monoclonal antibody and Dynabeads 
were  removed  using  a  magnet  and  the  remaining  cells  were  washed  in  DMEM 
medium supplemented with  10% FCS.
For the tetramer staining,  1-2 *  106 cells of a suspension were washed in  PBS/0.1% 
BSA  before  being  incubated  with  one  test of the  tetramer (2//I) for one  hour in  the 
dark  at  room  temperature.  The  cells  were  washed  and  counterstained  with 
fluorescein isothiocyanate (FITC) conjugated anti- CD8 (BD Pharmingen, San Diego, 
CA)  for  30  min  in  the  dark  at  4°C.  Cells  were  washed  one  final  time,  before 
resuspension  in 300//I of the wash buffer and detection of immunofluorescence on a 
FACSCalibur using CellQuest software (BD Biosciences, San Jose, CA).
The  first  tetramer  staining  experiment  also  investigated  indirect  tetramer  staining 
following  stimulation  of  cell  suspensions  with  irradiated  influenza  virus  infected 
splenocytes.  This  was  carried  out  to  stimulate  lower  frequency  populations  to  a 
frequency detectable  by  FACS  analysis.  Briefly,  lymphocytes were  prepared from 2 
naive spleens  before being  incubated with  1ml of influenza virus A/PR/8/34 infected 
allantoic fluid  in a 37°C water bath for 2 hours. The cell/virus suspension was made
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bath.  Cells were irradiated at 3000rads before being diluted to 2*106 cells/ml.  Equal 
numbers of irradiated  stimulator cells were  incubated with  cell  suspensions from the 
various tissues  at 37°C for 7 days.  Cells were then  harvested  by centrifugation and 
stained with tetramer and analysed as before.
2.13 Virus Specific Lymphocyte Phenotvoinq
Single  cell  suspensions  were  prepared  from  pooled  lymph  nodes  (inguinal, 
mediastinal,  mesenteric),  spleen,  Peyer’s  patches,  lungs  and  D-NALT  (prepared  as 
previously described) in PBS/0.1% BSA. Cells were initially enriched for CD8+  T cells 
(as  previously  described)  before  being  stained  with  tetramer  (as  previously 
described) and  counterstained with various antibodies for 30  min  in the dark at 4°C. 
Antibodies  used  were  as  follows:  FITC  conjugated  anti-CD44,  anti-CD11a,  anti- 
CD62L,  anti-CD69  and  Cychrome-5  (Cy5)  conjugated  CD8.  PE  conjugated  aS i 
integrin was used in conjunction with, FITC conjugated anti-CD8 and allophycocyanin 
(APC)  conjugated  pentamer  (Prolmmune,  Oxford,  UK).  The  pentamer  staining 
protocol  was  the  same  as for tetramer staining,  however one  test  used  10//I  of the 
reagent.  All  antibodies were obtained from  BD  Pharmingen  (San  Diego,  CA) except 
anti-CD8-Cy5  which  was  conjugated  on  site  and  a  gift  from  Dr  Agnes  Le  Bon 
(Edward  Jenner  Institute).  Detection  of  immunofluorescence  was  carried  out  on  a 
FACSCalibur using CellQuest software (BD Biosciences, San Jose, CA).
712.14 PMID Cartridge Preparation
The  following  details  and  equations  were  required  in  the  preparation  of  DNA 
cartridges:
•  Ethanol used must be dried and stored for at least 1   week in a desiccator.
•  Roughly 35mg of gold  (2//g  particle size,  Powderject/Chiron,  Madison, Wl) is 
required to make 40 cartridges
•  The  DNA  loading  rate  (DLR)  is  2,  which  results  in  approximately  0.5  pg 
DNA/cartridge.  Amount  of  DNA  required  =  (weight  of  gold  (pg)  x  DLR)  / 
concentration of DNA (pg/ml)
•  0.05M  spermidine  (Sigma,  UK)  is  pre-aliquoted  and  stored  at  -20°C.  The 
amount of spermidine required relates to the volume of plasmid to be used.  If 
volume  of plasmid  <  10OpI,  amount of spermidine  =  10Opl.  If the  volume  of 
plasmid  is  >  10OpI,  the same volume  of spermidine  as volume of plasmid  is 
used.
•  Volume  of ethanol  PVP  required  =  amount  of gold  (pg)  /  8.75  which  is  the 
amount  of  gold  required  per  ml  of  ethanol  to  give  roughly  0.5pg  gold  per 
cartridge.
The  concentration  of  plasmid  DNA  present  was  quantified  using  GeneQuant 
(Biochrom,  UK).  This was  required to calculate the  amount of DNA required for the 
number  of  cartridges  required  (which  was  calculated  using  the  equation  shown 
above).  Gold and spermidine were sonicated together for 30 seconds, and  mixed on 
a  vortex  mixer prior to  addition  of the  DNA.  A volume  of calcium  chloride,  equal  to 
that of the  spermidine,  was added  before  immediate  mixing  on  a vortex  mixer.  The 
DNA was allowed to precipitate onto the gold for 10 min. Meanwhile, a 10mg/ml fresh 
stock of PVP (polyvinyl pyrrolidone, Sigma, UK) was prepared in dried ethanol before 
subsequent dilution to a working concentration of 0.15pg/ml in ethanol. The gold was
72centrifuged  for  a  few  seconds  at  14000  rpm.  The  gold/plasmid  pellet  was  washed 
three times with  1ml of dried ethanol, resuspending the pellet between washes.
After  the  third  wash,  the  ethanol  was  removed  and  the  pellet  resuspended.  The 
calculated  volume  of  ethanol/PVP  was  placed  in  a  glass  vial  before  180pl  of  the 
ethanol/PVP  mix was  used  to  transfer some  of the  plasmid  coated-gold.  This  step 
was repeated until all of the gold had been transferred into the ethanol/PVP mix.
The  ethanol/PVP/gold  mix  was  loaded  into  the  tube  turner  which  was  already 
preloaded  with  tefzel  tubing  (Powderject/Chiron,  Madison,  Wl).  A flow of humidified 
nitrogen  through  the  spinning  tubing  was  used  to  ensure  even  coating  of  the 
DNA/gold.  The  spin  rate  helped  to  expel  the  excess  ethanol  and  an  increased 
nitrogen flow assisted with drying the plasmid/gold coated tubing. The tubing was cut 
into  even  1.27cm  lengths  (cartridges)  using  a  BioRad  tubing  cutter.  The  cartridges 
were  stored  with  a  silica  gel  capsule  at  RT  overnight  to  allow  the  silica  gel  to 
dehydrate the cartridges further,  before longer term storage at 4°C.  Cartridges were 
freshly prepared for each experiment.
For every batch  prepared the actual amount of DNA coated  onto the cartridges was 
determined  by eluting the  DNA from two cartridges. A 50pl volume of DNase/RNase 
free  water  was  carefully  added  to  the  centre  of each  of two  cartridges  in  a  1.5ml 
Eppendorf  tube,  before  incubation  for  30  min  at  37°C.  Following  incubation,  the 
water/gold  was  spun  out  of the  cartridges  by  centrifugation  for a  few  seconds  in  a 
Microfuge  at  14000  rpm.  The  eluent was  pooled  and  quantified  on  the  GeneQuant 
and using the following equation - fjg DNA /  cartridge = GeneQuant reading (gg/ml) /  
20, and the amount of DNA in each cartridge was calculated.
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Teijin  Films,  UK)  layered  over  parafilm  on  a  perspex sheet.  The  penetration  of the 
gold  particles  was  assessed  by  densitometry  of the  parafilm  to  confirm  a  uniform 
firing  pattern  from  each  cartridge.  Mylar  is  a  polyester  film  which  is  strong  and 
puncture  resistant  and  the  Mylar/parafilm  combination  was  suggested  by 
PowderJect/Chiron  as  a  suitable  skin  substitute  for  testing  cartridge  firing/gold 
penetration for quality control purposes.
2.15 DNA Immunisation
The abdomen  of each  animal was  shaved  prior to  immunisation with two cartridges 
by PMID  at 500psi  helium gas pressure  using the  BioRad  Helios gene gun  (BioRad 
Laboratories,  Hercules, CA).  In a typical vaccination, each cartridge contained 0.5mg 
gold coated with approximately 0.5pg plasmid DNA.
For transfer studies and phenotypic analysis, mice were immunised with two doses at 
day 0 and again at day 7. This had the effect of boosting the antigen specific cellular 
response (personal communication with Dr Fiona Cook).
2.16 Virus Titration
Specific  pathogen  free  10  day  old  embryonated  hen  eggs  were  provided  by  The 
Institute for Animal Health (Compton, Berks). These were used as a medium in which 
to  propagate  influenza  infected  lung  homogenates  using  the  method  previously 
described  (Mahy,  1985).  Briefly,  lung  homogenates  were  prepared  in  1ml 
PBS/gentamicin  (50pg/ml)  using  a  tissue  homogeniser (PRO200  homogenizer with 
Multi-Gen  7  generators,  PROscientific,  Oxford,  CT).  Ten-fold  serial  dilutions  of the 
homogenised tissue were made before  100pl of each dilution was used to infect the
74allantoic  cavity  of  the  eggs  in  triplicate.  The  eggs  were  incubated  at  37°C  for  48 
hours. After incubation, embryos were killed at 4°C overnight, before 50pl aliquots of 
the infected allantoic fluid was harvested from each egg and  placed  in the wells of a 
round  bottomed  96  well  plate.  The  presence  of  influenza  virus  was  detected  by 
utilising the ability of the virus to agglutinate red  blood  cells.  Chicken  red  blood cells 
were washed 3 times in saline and diluted to a 1% working stock before the addition 
of 50pl to the aliquot of allantoic fluid. The red blood cells and allantoic fluid were left 
undisturbed for 45 min on a white surface.  If no virus was present, the red blood cells 
formed  a  small  pellet.  A  positive  result  was  observed  as  a  continuous  sheet  of 
agglutinated red blood cells.
The  highest amount of infectious  virus  in  a  lung  homogenate  may  be  estimated  by 
measuring the highest dilution that can still infect an embryonated egg. The smallest 
amount  of virus  capable  of doing  this,  on  50%  of occasions,  is  known  as  the  egg 
infections  dose  (EID50).  Virus  titre  in  EID50  was  calculated  as  previously  described 
(Mahy,  1985).
2.17  Transfer Experiments
The  homing  properties  of  naive  and  effector  CD8+   T  lymphocytes  from  C57BL/6 
Ly5.1  mice were investigated  in an adoptive transfer model.  Effector CD8+  cells were 
generated  in  the  influenza  model  by  intranasal  infection  with  500  EID50  influenza 
virus A/PR/8/34 or by PMID immunisation with two doses of 0.5/yg influenza NP DNA 
as previously described.
Total  lymphocytes  were  isolated  from  20  spleens  and  enriched  for  CD8+   T  cells 
before  CD8+   cells were  sorted  using  a  MoFlo  (DakoCytomation,  Denmark).  These 
cells had  been  labelled with  10 times the amount of antibody used for FACSCalibur
75analysis.  Briefly,  spleens  were  pooled  into  groups  of  5  and  cell  suspensions  were 
prepared before staining with a 1   in 20 dilution of FITC conjugated anti-CD8 antibody 
for  30  min  in  the  dark  at  room  temperature.  Cell  suspensions were washed  before 
being  pooled  into  one  final  group  and  resuspended  to  1*107  cells/ml.  Following 
MoFlo  isolation,  CD8+  T cells were washed  3 times  in  PBS  before  1><107 cells were 
transferred intravenously in naive C57BL/6 Ly5.2 recipients.
Two  days  following  transfer,  recipient  animals  were  culled  and  lymphocytes  were 
isolated  from  the  spleen,  liver,  lungs,  IngLN,  MedLN,  MesLN,  NALT  and  Peyer’s 
patches  before  they  were  stained  with  influenza  specific  tetramer  (as  previously 
described)  and  counterstained  with  FITC  conjugated  anti-Ly-5.1  and  peridinine 
chlorophyll  protein-cychrome 5.5  (PerCP-Cy5.5) conjugated anti-CD8. All antibodies 
were obtained from  BD  Pharmingen  (San  Diego,  CA) and  immunofluorescence was 
detected  using  a  FACSCalibur  and  CellQuest  software  (BD  Biosciences,  SanJose, 
CA.).
76Chapter 3
Characterisation of Murine Humoral and Cellular Responses to 
Intranasal  Infection with  Influenza Virus A/PR/8/34
773.1  Introduction
Infection with  live  influenza  virus can  result in  sterilizing  immunity.  Experiments 
were  designed  to  characterise  the  immune  cells  and  factors  that  contribute  to 
this  protective  response.  The  aim  of the  proposed  work  was  to  quantitate  the 
immune  responses  and  mechanisms  contributing  to  the  in  vivo  induction  of 
sterilising  immunity generated  using  a  murine  model  of influenza virus infection 
and to compare the immune responses with those elicited following vaccination.
A fragment culture technique was developed which allowed collection of specific 
antibodies  produced  by  antibody  forming  cells  (AFCs)  isolated  from  various 
areas  of  the  mucosal  and  systemic  immune  systems.  ELISAs  could  then  be 
used  to  measure  how  much  virus-specific  antibody  was  secreted  from  each 
tissue  “fragment”.  ELISPOT  assays  were  used  to  enumerate  the  virus-specific 
IFNy  secreting  CD8+   T  cells  in  the  various  tissues  which,  according  to  the 
literature  is  a  more  sensitive  method  for  detecting  the  presence  of  low  level 
populations  of  antigen  specific  CD8+   lymphocytes  (Karlsson  et  al.,  2003).  An 
attempt  was  also  made  to  measure  the  clonal  populations  of  virus-specific 
antibody produced after infection  in terms of size and  location.  Using  isoelectric 
focusing  gels,  the  separation  of serum  and  fragment culture  supernatants  into 
their respective  charges,  based  on amino acid  structure,  allows the analysis of 
clonal  populations  in  terms  of number of “bands”.  Determination  of whether or 
not the  same  bands were found  in  different tissues  could  give  an  indication  of 
the migration of clonal populations of AFCs.
Results gained from these  initial studies will give an  indication of what needs to 
be stimulated  by a vaccine candidate  in order for it to be successful  not only in
78terms  of  the  strength  of  response  but  also  in  terms  of  the  breadth  and 
anatomical location of responding cells.
3.2  Results
3.2.1  Murine Anitbodv Responses to Influenza Virus Infection are Dominated by 
Those Seen in the Mediastinal Lymph Node
At certain time points post infection, mice were sacrificed for collection of various 
tissues of the systemic and mucosal immune systems.  Cultures of these tissues 
were prepared by a technique adapted from that previously described for culture 
of small intestinal lymphoid tissue (section 2.4).
In  order  to  quantify  the  amount  of  specific  anti-influenza  virus  antibodies 
produced  by  the  fragment  cultures,  three  modifications  of  enzyme-linked 
immunosorbent assays (ELISA) were developed. The first, a capture ELISA was 
used  to  create  an  immunoglobulin  (Ig)  isotype  specific  standard  curve.  The 
second  replaced  Ig  standards  with  fragment  culture  supernatant  to  directly 
enumerate  the  quantities  of each  Ig  isotype  present  in  each  fragment  culture. 
The  third  ELISA  was  designed  to  indirectly  quantify  the  anti-influenza  virus 
antibodies present in fragment cultures.
The  data  generated  from  the  analysis  of  fragment  cultures  showed  a  high 
sensitivity with a detection limit equivalent to 1ng/ml Ig. The immune response to 
influenza  virus  was  observed  to  be  dominated  by  cells  and  tissue  fragments 
isolated  from  the  MedLN.  Immunoglobulin  production  by  fragment  cultures  at 
various times post influenza virus infection is shown in Figure 4.
79The  results  shown  in  Figure  4  demonstrate  that  influenza  virus  infection 
upregulates  total  antibody  secretion  (across  all  Ig  isotypes)  detected  in  the 
fragment  culture  supernatants.  The  graph  for  day  0  shows  a  background  Ig 
production  in  most  tissues,  but  predominantly  in  the  gut.  This  result  was 
expected  considering  the  constant  assault  of  this  area  by  antigen.  As  the 
infection  progresses  all  isotypes  were  seen  to  be  upregulated  with  responses 
peaking  around  day  10,  before  the  IgG  levels  diminish  and  IgA  production 
increases. A dominant splenic IgM response is also observed.
The results of influenza virus-specific antibody production are shown in Figure 5. 
The  initial virus-specific antibody response was  observed  in the  MedLN,  before 
being  detected  in  the  lungs  and  the  D-NALT.  IgG  isotypes  are  the  dominant 
isotype early in the virus-specific response however, as the infection is cleared a 
large increase in virus-specific IgA production is observed.
The  proportion  of virus-specific  Ig  produced  is  shown  in  Figure  6.  Most of the 
IgA produced in the MedLN is 100% virus specific as the infection is cleared with 
lower levels of viral specificity (<25%) observed for the other Ig isotypes.
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Figure 4:  Total  Ig  production  as  calculated  by  ELISA  is  seen  to  increase  in  all 
tissues  examined  following  intranasal  influenza  virus  infection.  12  female 
C57BL/6 mice were intranasally infected with 500 EID5 0  influenza A/PR/8/34 virus 
while  3  C57BL/6  mice  remained  uninfected.  Fragment  cultures  were  prepared 
from various tissues of the mucosal and systemic immune system prior to (dayO) 
and  10,  14 and 21  days  post influenza virus  infection.  Fragment cultures from  3 
individual mice per timepoint were pooled  before the amount of total  Ig within the 
samples was calculated. All tissues are seen to exhibit a dramatic increase in  Ig 
production  after  influenza  virus  infection  which  is  clearly  dominated  by  the 
response observed  in the MedLN.  This data is generated from fragment cultures 
pooled from 2 experiments.
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Figure 5: Virus-specific Ig is seen to be predominantly produced in the MedLN.  12 
female  C57BL/6  mice  were  intranasally  infected  with  500  EID50  influenza 
A/PR/8/34 virus and fragment cultures were prepared from various tissues of the 
mucosal  and  systemic  immune  systems.  Fragment  cultures  from  3  individual 
mice  per timepoint were  pooled  before the amount of virus-specific Ig within the 
samples  was  calculated  at days  10,  14  and  21  following  infection.  The  MedLN 
response  dominated  throughout  the  timecourse  with  spread  to  the  respiratory 
compartment and  spleen seen in  later timepoints.  Day 21  show a  predominance 
for  IgA  class  Ig  in  the  MedLN.  This  data  is  generated  from  fragment  cultures 
pooled from 2 experiments.
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Figure 6: As influenza virus infection is cleared, 25-50% of the IgG isotypes and 
100%  of  IgA  produced  in  the  MedLN  is  influenza  virus-specific.  12  female 
C57BL/6  mice  were  intranasally  infected  with  500  EID50  influenza  A/PR/8/34 
virus and fragment cultures were  prepared from various tissues of the  mucosal 
and systemic immune systems. The relationship between total  Ig (Figure 4) and 
influenza virus-specific Ig (Figure 5) was calculated, and shown as a percentage 
of  virus-specific  Ig  in  the  total  Ig  pool.  This  data  is  generated  from  fragment 
cultures  pooled from two experiments and the method of analysis was adapted 
from a method previously described by Khoury et al., (1994).
83Unfortunately,  the  ELISA  assays  used  to  detect  influenza  virus-specific  IgA  in 
the D-NALT or bone marrow were unable to demonstrate any responses. This is 
in  contrast  to  previous  studies  by  our  group  that  have  shown  specific  IgA 
antibody forming cells (by ELISPOT) to be long lived and numerous (Liang et al., 
2001).  This  result may  be  a  reflection  of the  sensitivity of these  populations  of 
plasma cells to the fragment culture conditions.
3.2.2  Influenza Virus Infection Induces Virus Specific CD8+  Cells Throughout the 
Mucosal Immune System
Direct  tetramer  staining  was  carried  out  on  various  mucosal  and  systemic 
tissues to locate  influenza  virus-specific populations of CD8+  T cells.  Results in 
Figure  7  show that virus  specific CD8+   T  cells  were  detected  in  all  the tissues 
examined with the exception of the PP. At 10 days post influenza virus infection 
the  dominant  response  was  observed  in  the  lungs  and  D-NALT.  In  addition 
virus-specific  CD8+   T  cells  were  surprisingly  recorded  in  the  gut  (MesLN).  In 
vitro  restimulation  with  influenza  virus  infected  irradiated  stimulators  was  also 
carried  out  on  these  cells  to  determine  if  it was  possible  to  enhance  any  low 
frequency  populations.  Cells  were  stimulated  with  equal  numbers  of irradiated 
influenza virus-infected splenocytes for 7 days prior to tetramer staining. Culture 
of  the  cell  suspensions  with  stimulators  was  unsuccessful  and  no  tetramer 
positive cells were observed  upon  FACS analysis.  IFNk ELISPOT is considered 
to  be  a  superior  technique  for  identifying  and  enumerating  low  frequency 
populations,  so all future CD8+  T cell frequency analysis focused on the use of 
ELISPOT  for  the  identification  of  influenza  virus-specific  cells  in  the  various 
tissues examined.
84The  results  in  Figure  8  show  the  virus-specific  IFNy  secreting  CD8+   T  cell 
response  to  influenza  virus  infection  over  time.  Influenza  virus  infected  mice 
were followed for up to 6 months post infection at which time memory cells were 
observed.  The  early  response was  dominated  by recruitment of large  numbers 
of virus specific CD8+  T cells to the  lungs.  The  response  in the  lung  peaked at 
day  10 after which the cells  rapidly dissipated.  The  response initially peaked  in 
the  MedLN  (Day  7),  but virus  specific  IFNk secreting  CD8+   T  cells  were  also 
detected  in  the  spleen  and  surprisingly  in  the  MesLN.  There  was  also  a 
substantial recruitment of virus-specific cells to the D-NALT and less surprisingly 
to the spleen.
3.2.3  Isoelectric Focusing of Antibodies: A Useful Tool to Investigate the 
Clonalitv of a Serum Humoral Response to Influenza Virus Infection
Isoelectric Focusing  (IEF) is an established technique for separation of proteins 
with small differences in charge (Braun et al.,  1979). The possibility of using IEF 
as  a  technique  to  separate  antibodies  generated  during  an  immune  response 
and to identify the clonality of the antibodies was investigated.
Gel  running  apparatus  from  two  different  manufacturers  were  evaluated  for 
suitability as  systems  to separate  antibodies following  influenza  virus  infection. 
The first apparatus was the  BioRad  Criterion™  System which was compared to 
the  PhastSystem™  from Amersham  Biosciences.  Both were assessed for ease 
of use and results obtained following protein staining and immunoblotting.
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Figure  7:  Direct influenza  NP tetramer and  CD8 staining  on C57BL/6 tissues  10 
days following  intranasal  influenza  virus  infection.  Virus specific CD8+   cells can 
been  seen at various frequencies in all of the tissues examined  except PP.  The 
strongest response is seen  in the lungs and  D-NALT with  3.2% and  0.6% of the 
cells  respectively  being  CD8+   NP366.374  H2-Db  tetramer.  At  this  timepoint,  a 
minimal  response  is  observed  in  the  MedLN,  which  is  below  the  level  of 
detection of the assay.
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Figure 8:  Influenza virus specific  CD8+  T cell  responses are first detected in the 
MedLN and  peak in the lung day 10 after influenza virus infection.  Five C57BL/6 
mice  per timepoint were  infected  with  500  EID50  influenza A/PR/8/34  virus  and 
the  virus-specific  CD8+  IFNy  secreting  cellular  response  was  characterised  by 
IFNk  ELISPOT  at various time  points  post  infection  in  various  tissues.  Tissues 
were  pooled from 5 mice and  cell  suspensions were plated  out in triplicate.  The 
response  seems  to  be  initiated  in  the  MedLN  and  subsequently  spreads  to  the 
lungs  and  spleen.  The  response  is  dominated  by that  observed  in  the  lungs  at 
day 10 post infection and seems to persist predominantly in the D-NALT but also 
in  the  spleen  and  MesLN  with  influenza  specific  IFNy  secreting  cells  being 
observed  in  these  tissues  at  6  months  post  infection.  Error  bars  indicate  the 
standard  deviation  between  replicates  and  this  data  is  a  representative  of  3 
experiments.
87Both  systems  demonstrated  strengths  and  weaknesses.  In  respect  of ease  of 
use  and  protein  staining  the  PhastSystem  was  superior  in  terms  of resolution. 
However,  the  Criterion  system  proved  to  be  better when  it came to  confirming 
that the protein detected in samples was antibody.
The  in-built staining tank of the  PhastSystem helped to produce excellent silver 
staining which can  be seen  in  Figure 9.  RPMI controls were run (lanes  1   and 9) 
and comparing the banding  pattern with that of the samples in the other lanes it 
can  be  seen  that  the  lower  bands  were  possibly  representative  of  calf serum 
used  to  supplement the  medium.  The  best staining  was  observed  in  lane  7  at 
both  time  points.  This  was  a  sample  of  serum  and  not  of  fragment  culture 
supernatant.  At  12 days  post influenza  virus  infection,  the  best protein  staining 
of a fragment culture  sample was  seen  in  the  lung  (lane  2),  where there are  3 
close  bands which could  represent 3 antibody forming  cell clones.  Interestingly, 
there  is  a  weak  but  broad  response  seen  in  the  D-NALT  (lane  5) where  there 
were  7  (uniformly  spaced)  bands  observed  on  the  freshly  stained  gel  (but 
perhaps  not as clear on the reproduced  image).  As the infection  is cleared and 
the  animals  recover,  the  profile of protein  staining  of the fragment cultures and 
serum  changes  (Figure  9  b).  The  protein  staining  seen  in  the  respiratory 
compartment  vanishes  and  the  clearest  separation  was  observed  in  lane  15 
where  the  spleen  fragment  culture  was  focused.  There  was  also  a  noticeable 
banding pattern observed from the colon (Iane10) but this has not reproduced as 
distinctly  in  the  scan  compared  with  the  bands  observed  in  the freshly stained 
gel.
8889Figure  9:  Fragment  cultures  of  C57BL/6  tissues  were  prepared  following 
intranasal  influenza  A/PR/8/34  virus  infection  and  separated  by  IEF  on  the 
PhastSystem  and  subsequently  silver  stained.  Lane  numbers  correspond  to 
fragment cultures taken from various tissues at either a) the peak of infection or 
b)  40  days  post  infection,  the  key  can  be  seen  below.  Lane  2  in  both  images 
shows  RPMI  medium  containing  foetal  bovine  serum  which  was  used  in  the 
fragment culture method and is thought to contribute to the large band observed 
at the bottom of the gels. At day  12 post infection  (a) the best protein staining is 
seen  in  the  serum.  There  is  also  a  concentration  of  protein  seen  in  the  lungs 
(lane  2).  By  day  40  post  infection,  no  protein  staining  is  observed  in  the 
respiratory compartment.  The  best staining  is seen  in the spleen  (lane  15),  with 
some banding also observed in the lamina propria.
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to  identify  influenza  virus-specific  immunoglobulin  bands  in  the  samples.  The 
blotting  system  supplied  with  the  PhastSystem  proved  to  be  very  inefficient at 
transfer,  so  the  BioRad  Criterion  system  was  predominantly  used.  Initial 
experiments  focused  on  active  transfer  and  visualisation  of  influenza  virus 
A/PR/8/34  HA  specific  monoclonal  antibodies  (MAb)  kindly  supplied  as 
hybridomas by Prof.  Nigel  Dimmock (University of Warwick). These hybridomas 
were  cultured  and  supernatants  were  prepared  as  previously  described 
(Yokoyama,  2000).  Figure  10a shows the  results of an active transfer following 
IEF  separation  of the  MAbs.  Two  monoclonals  in  particular  (indicated  using  *) 
showed  the  characteristic  banding  patterns  expected.  This  multiple  banding 
pattern results from microheterogeneity providing a diversity of isoelectric points. 
This result was encouraging, however, a high level of background remained and 
there was still  relatively poor resolution  in  serum samples. When the technique 
was applied to fragment culture samples, the low levels of antibody proved to be 
below the detection limit of the assay.
In  an  attempt to improve visualisation of virus-specific immunoglobulin  bands a 
method  involving  passive diffusion of the antibodies onto influenza virus coated 
membranes  was  assessed.  Figure  10b  shows  the  initial  results  obtained  from 
passive diffusion.  Immediately it can be seen to be a much cleaner blot, with no 
background,  and  no  bands  present  in  the  negative  control  (naive  serum).  Few 
bands were observed at day 15 post influenza virus infection,  but there appears 
to be a large amount of smearing within the lane.  Perhaps this is indicative of a 
more polyclonal response shortly after the peak of infection. The results from 60 
days  post  infection  show  that  there  are  several  more  distinct  bands,  perhaps 
indicative  of  greater  levels  of  antibody  production  which  could  be  an  efficient 
system for controlling subsequent infection.
91The  method  of passive  transfer was  applied  to fragment cultures  but no bands 
could  be  visualised.  The  level  of  antibody  in  the  fragment  culture  samples 
appeared to be below the level of detection of this method. Attempts were made 
to  concentrate  the  fragment  cultures  approximately  10-fold  using  Vivaspin 
columns.  However,  this  had  no  effect  on  increasing  the  sensitivity  of 
immunoglobulin visualisation.
Unfortunately, time constraints prevented further development of IEF analysis at 
this  stage.  The  technique  that was  developed  could  be  applied  to  monitor the 
clonality of a serum antibody response to influenza virus infection, and  perhaps 
be  adapted  to  any  antigen  encounter.  The  main  goal  of the  IEF  study was  to 
characterise  the  antibody  response  from  within  the  various  tissues  to  give  a 
snap  shot  of  the  AFCs  in  circulation  at  any  one  time.  It  was  hoped  that  this 
technique  would  provide  some  information  about  the  AFCs  in  specific tissues 
and  an  insight  into  the  breadth  of  clonal  response  (number  of  bands)  and 
strength of response (size of bands) and the circulation of these cells following a 
sterilising  immune  response. These could  be  important factors when assessing 
the efficacy of a vaccine candidate.
92a) b)
naive
Figure  10: a) active influenza virus-specific immunoblotting following  monoclonal 
antibody  isoelectric  focusing  using  the  BioRad  Criterion  system.  The  image 
shows the lanes where  isoelectric point (pi) makers,  naive serum (-), and serum 
from an influenza virus infected mouse (+) were focused. * indicate characteristic 
banding  patterns of MAbs.  b) native transfer of antibodies from naive serum and 
serum collected  on days  15 and 60 post influenza virus infection. At day 60 post 
infection,  several  bands  are  observed  possibly  characteristic  of  a  polyclonal 
response more efficient at controlling subsequent infection.
933.3 Discussion
Originally  it  was  thought  that  IgA  was  the  most  significant  immunoglobulin
isotype  involved  in  the  control  of  influenza  virus  replication  in  the  upper
respiratory  tract  (Renegar  &  Small,  1991a).  These  authors  reported  that
following  infection,  intranasal  treatment  with  anti-lgA,  but  not  anti-IgG  or anti-
IgM,  completely  abolished  protection  from  reinfection.  This  data  was  further
supported  by the fact that  intravenous  injection of anti-influenza  polymeric  IgA,
but  not  anti-IgG  or  IgM,  could  protect  naive  mice  against  intranasal  influenza
virus  infection  (Renegar  &  Small,  1991b).  Subsequent  studies  using  IgA
knockout  mice  proved  that  IgA  may  not  be  required  for  the  prevention  of
influenza virus  infection  (Mbawuike et al.,  1999). This controversy was recently
cleared  up  by  finding  that  only  intravenous  installation  of  polymeric  IgA  can
prevent virally induced  pathology in the upper respiratory tract.  By contrast,  IgG
can  prevent  viral  pathology  in  the  lung.  These  results  demonstrated  that  both
*
isotypes were important.  IgG can act as a backup for secretory IgA protection in 
the nose, as well as being the isotype involved in protection in the lung (Renegar 
et al., 2004).
Unfortunately  use  of  the  fragment  culture  technique  to  isolate  virus-specific 
antibodies  did  not  allow  quantification  of  anti-influenza  specific  IgA  in  the  D- 
NALT.  IgA AFCs appear to be very sensitive to the fragment culture conditions 
because this was the only isotype to remain undetected in the D-NALT. Previous 
studies  by  our  group  have  shown  that  IgA AFCs  are  the  most  numerous  and 
long  lived  cells  remaining  within  or  being  constantly  recruited  to  the  D-NALT 
(Liang et al., 2001).  Further studies within our group have shown a requirement 
for  lower  pressure  sorting  of  AFCs  by  FACS  to  ensure  continual  antibody 
secretion and lack of survival of these cells in adoptive transfers which also hints
94at  the  sensitivity  of  these  cells  to  manipulation  (Dr  S  Hou,  personal 
communication).
In  cellular  responses  to  respiratory  virus  infections  dendritic  cells  (DCs)  have 
been shown to play a role in  initiating  and driving T cell  responses to infections 
in  the  lungs  (Banchereau  &  Steinman,  1998).  Resident  lung  DCs  acquire 
antigen from the invading virus, become activated and subsequently traffic to the 
local  draining  lymph  node  (mediastinal).  It  is  here  where  the  antigen  can  be 
displayed  to  naive  T lymphocytes  resulting  in their activation,  clonal expansion 
and  subsequent  migration.  This  has  been  clearly  demonstrated  for  CD8+   T 
lymphocytes  becoming  activated  in  influenza  virus  infection  (Cerwenka  et  al., 
1999a)  and  it  is  understood  that  CD8+   cytotoxic T cells  play a  key role  in  viral 
clearance (Doherty et al.,  1997,  Swain et al.,  2004).  Neutralising antibody plays 
a  major  role  in  protection  from  re-infection  and  immune  memory,  but does  not 
contribute  significantly  in  viral  clearance  during  a  primary  infection  unless  the 
viral load is high (Eichelberger et al.,  1991a,  Epstein et al.,  1998). The ELISPOT 
data  (Figure  8) shows a strong early response  in  the  MedLN which  appears to 
have  peaked  by day 7.  This  coincides  with  a  sudden  influx of CD8+   effector T 
cells  into  the  lungs,  peaking  at  day  14  before  rapidly  tailing  off.  Such  an 
accumulation of CD8+  T cells in the lungs correlates with an expected clearance 
of the  virus  by day  10  post  infection  (Doherty et  al.,  1997).  The  T-lymphocyte 
mediated  viral  clearance  has  been  shown to involve  Fas or perforin dependent 
mechanisms (Topham et al.,  1997).
The  initial  response  seen  in  the  MedLN  was  also  observed  in  a  study  of 
activation,  differentiation  and  migration  of influenza  virus  specific  CD8+  T  cells 
during  influenza virus infection (Lawrence & Braciale, 2004). The authors report 
an initial activation of CD8+  T cells in the MedLN that is exclusive to the draining
95lymph  node and  occurs during the first three days post infection. The activated 
MedLN cells were shown to exit the draining lymph node and traffic to and seed 
the  spleen  and  peripheral  lymph  nodes.  The  most highly activated  and  divided 
cells were found to traffic to the lungs. These observations correspond with the 
observations  from  the  data  reported  here  and  provide  an  explanation  for  the 
initial  response  seen  in  the  MedLN  which  spreads  rapidly to the  lungs,  spleen 
and MesLN.
This data shows significant virus-specific effector CD8+  T cell populations in the 
spleen,  D-NALT and more surprisingly the MesLN.  In murine influenza virus and 
Sendai  virus  infection  models,  the  response  observed  in  the  spleen  has  been 
explained  by  the  distribution  of  antigen  presenting  cells  (Flynn  et  al.,  1998, 
Usherwood  et  al.,  1999b).  A  recent  study  has  also  shown  the  preferential 
migration  of effector CD8+  T cells,  induced  both  by viral and  bacterial  infection, 
to non-lymphoid  tissues (Masopust et al.,  2001) perhaps explaining the effector 
CD8+   T  cells  observed  in  the  D-NALT.  There  is  also  evidence  that  T  cell 
responses  to  influenza  do  not  require  encapsulated  lymph  nodes  and  that the 
NALT  is  sufficient  for  inducing  immune  responses  (Lund  et  al.,  2002).  The 
reported  study  used  lymphotoxin-alpha  deficient  mice which  lack  lymph  nodes 
and have a disrupted splenic architecture. These mice were observed to have a 
capacity  to  elicit  delayed  but  strong  influenza  virus-specific  CD8+   T  cell 
responses  that  were  capable  of  killing  target  cells  displaying  influenza  viral 
peptides.  The  mice  were  able  to  control  low titre  infections  of  influenza  virus. 
However,  mice  succumbed  to  a  high  dose  infection  resulting  from the delay in 
the  generation  of  effector  CD8+   responses.  This  demonstrates  that  essential 
organised  lymphoid  tissues  such  as  lymph  nodes  or  the  spleen  are  not 
absolutely  required  to  generate  effective  immunity  against  influenza  virus 
infection.
96In  contrast  to  previous  reports  regarding  the  distribution  of antigen  presenting 
cells  and  the  resultant  response  seen  in  the  spleen,  data  generated  by 
Lawrence  and  Braciale  (2004)  showed  activated  MedLN  cells  exiting  the 
draining  lymph node before trafficking to and seeding the spleen and  peripheral 
lymph  nodes.  These  observations  correspond  with  the  observations  from  the 
data  reported  here  and  provide  an  explanation for the  initial  response  seen  in 
the  MedLN which spreads rapidly to the lungs, spleen and  MesLN.  Considering 
both  data,  perhaps the  initial  response observed  in the spleen  is as a  result of 
both MedLN cells and APCs trafficking there.
Following  recovery  from  acute  infection  a  state  of  immunological  memory 
develops  which  functions  to  protect  from  reinfection.  The  data  produced 
indicates that at 6 months post infection influenza-specific CD8+  T cells persist in 
the  D-NALT,  MedLN,  MesLN  and  the  spleen.  The  populations  observed  in  the 
lymph  nodes  and  some  of the  population  in  the  spleen  are  likely to  be  central 
memory  (T Cm)  populations  due to their location,  and  the  requirement of CD62L 
expression  for  lymph  node  homing  (Gallatin  et  al.,  1983).  They  may  however 
also  be  T Em  populations  circulating  from  the  tissues.  By  contrast,  it  is  possible 
that the populations observed  in the D-NALT, and to a lesser extent the spleen, 
are  effector  memory  (T Em)  populations  (Sallusto  et  al.,  1999)  which  have  the 
ability to migrate to non-lymphoid tissues, a characteristic of TE M  cells generated 
through  viral  or  bacterial  infection  (Masopust  et  al.,  2001).  TE M   cells  are  an 
essential  and  powerful  first  line  defence,  whereas  the  T Cm  populations  provide 
reserve  defences  (Lanzavecchia  &  Sallusto,  2002).  There  is evidence that T Cm 
and T em are generated differentially during and immune response, depending on 
the  conditions  of  activation  (Manjunath  et  al.,  2001,  Weninger  et  al.,  2001). 
These authors report that murine CD8+  T cells activated in vitro can acquire the 
characteristics of either T Cm  or TEM .  By contrast,  it has also been  proposed that
97T Cm and T Em do not necessarily represent distinct populations but are in fact part 
of  a  differentiation  pathway  in  which  naive  T  cells  are  activated  into  effector 
cells,  before  differentiation  into  T Em  followed  by  the  acquisition  of  T cm 
characteristics  (Wherry  et  al.,  2003).  Wherry  et  al.  (2003)  investigated  the 
appearance  of  CD8+   TE M   and  T Cm  after  infection  of  mice  with  lymphocytic 
choriomeningitis  virus  (LCMV)  or  Listeria  monocytogenes.  The  authors  report 
that  CD8+   T em  convert to  T Cm  and  proposed  the  linear differentiation  model for 
the  generation  of  CD8+   TE M   and  TCM -  The  model  describes  TE M  being  derived 
directly from effector cells and  T Cm derived from TEM . Whether the population of 
memory  cells  observed  in  the  D-NALT  are  in  fact  TE M   cells  remains  to  be 
investigated.
To compare and support the data generated in this study, Weninger et al. (2001) 
demonstrated  that  murine  antigen  primed  CD8+   T  cells  cultured  in  vitro  with 
interleukin  (IL)-15  resemble  T Cm  cells  in  phenotype  and  function,  while  cells 
stimulated  with  IL-2  resemble  TE M   cells.  In  transfer  studies,  it was  shown  that 
naive and  T Cm,  and to a  lesser extent TE M  cells  localised to the T cells areas in 
the spleen, whereas only T Cm cells homed to the lymph nodes.
The  CD8+   T  cell  migratory  pattern  was  recently  characterised  following 
secondary challenge with influenza A virus in mice that had already been primed 
with a serologically distinct influenza A virus (Marshall et al., 2001). The authors 
report  populations  of memory CD8+  T  cells that are  phenotypically diverse and 
widely  dispersed  with  the  largest  numbers  of  influenza  virus-specific  CD8+   T 
cells detected  in the spleen at every timepoint and the response peaking at day 
10 post challenge.
98Current influenza vaccines  in  clinical  use  contain  HA as their main or only viral 
antigen. The efficacy of the current vaccines depends primarily on the antigenic 
match  between  circulating  viruses with the strains  used for vaccination, as well 
as  the  subject’s  age  and  immune  status.  Characterisation  of the  humoral  and 
cellular  response  to  influenza  virus  infection  has  produced  data  that  can  be 
compared  to  the  responses  induced  by  vaccination.  It  is  expected  that  for  a 
vaccine  to  be  efficacious  it  must  mimic  the  natural  protective  response 
generated  by influenza virus infection and that it should  produce a strong virus- 
specific response in the lungs which will contribute to the killing of virus infected 
cells and thus limit or prevent the spread of viral infection.
The work described in the next chapter will focus on the response generated by 
a DNA vaccine administered by PMID of influenza virus NP DNA coated on gold 
particles.  The  plasmid  used  encodes  a  conserved  antigen  (NP)  that  does  not 
vary between strains and is not subject to antigenic shift and drift. The study has 
also been developed to see  if a  non-mucosal  route of immunisation can  initiate 
similar  CD8+   T  cell  responses  as  experimental  infection  does,  and  more 
interestingly whether it can induce a response in the NALT, where antigen is first 
encountered, similar to the results observed in the experimental infection model.
Much  of  the  literature  published  on  IEF  is  concerned  with  IgG  detection  in 
samples  collected  from  multiple  sclerosis  (MS)  patients.  Analysis of oligoclonal 
bands  of  IgG  and  IgM  focused  from  cerebrospinal  fluid  using  IEF  gels  is  an 
established test used  in the diagnosis of MS (Andersson et al.,  1994,  Sharief et 
al.,  1990).  However, there are some older papers that discuss the focusing and 
identification of antibodies  (Braun et al.,  1979,  Keck et al.,  1973). The paper by 
Keck  et  al.  describes  a  technique  using  radiolabelled  specific  antigen  to 
visualise antibodies within whole serum.
99The most successful  IEF technique from this study concentrated on the BioRad 
Criterion  system.  Influenza  A/PR/8/34  virus-specific  MAbs  produced  the 
characteristic  banding  patterns  expected  (figure  10a),  which  confirmed  that  a 
sensitive  technique  capable  of  visualising  anti-influenza  antibodies  had  been 
developed.  However,  concerns  remained  regarding  the  detection  of 
immunoglobulin  in  the  fragment  cultures.  When  the  technique  was  applied  to 
fragment  cultures  it  proved  to  be  insufficiently  sensitive  to  detect 
immunoglobulin.  A  second  native  transfer  method  improved  resolution  (figure 
10b),  however  it  also  proved  to  lack  the  sensitivity  required  to  detect  the  low 
levels of antibody in the fragment cultures.
Various  problems  were  encountered  whilst  trying  to  set  up  the  IEF  technique. 
Difficulties ranged from poor reagents and technical support to identifying bands 
on  gels  to  be  immunoglobulin.  Various  protein  stains  were  investigated,  and 
silver staining gave the best result using the Amersham PhastSystem (Figure 9). 
When  this  system  was  used  for  western  blotting  techniques  however,  it  was 
found  to  have  a very  poor blotting  system.  The  most successful  IEF technique 
from  this  study  concentrated  on  the  BioRad  Criterion  system.  Influenza 
A/PR/8/34  virus-specific  MAbs  produced  the  characteristic  banding  patterns 
expected  (figure  10a),  which  confirmed  that  a  sensitive  technique  capable  of 
visualising  anti-influenza  antibodies  had  been  developed.  However,  concerns 
remained  regarding  the  detection  of  immunoglobulin  in  the  fragment  cultures. 
When  the  technique  was  applied  to  fragment  cultures  it  proved  to  be 
insufficiently  sensitive  to  detect  immunoglobulin.  A  second  native  transfer 
method  improved  resolution  (figure  10b),  however  it  also  proved  to  lack  the 
sensitivity required to detect the low levels of antibody in the fragment cultures.
100Low  sensitivity  led  to  the  investigation  into  concentration  of fragment  cultures 
using Vivaspin columns to concentrate fragment cultures approximately 10-fold. 
Unfortunately,  concentration  using  this  method  had  no effect on  increasing  the 
sensitivity of the technique.  If time had allowed,  it may have  been  interesting to 
try and  isolate influenza virus-specific antibodies.  It could  be possible to do this 
by using affinity column purification. Amersham Biosciences manufacture HiTrap 
Affinity columns to which  it would  be possible to couple  purified  influenza virus. 
Fragment  cultures  could  then  be  run  through  the  column,  and  influenza  virus- 
specific antibodies would  be  retained  in the  column  bound  to the purified virus. 
The virus bound antibodies could then be eluted with an alkaline solution before 
being focused on IEF gels.
Another possible alternative would be to create a virus-specific hybridoma library 
in  a similar style to the work carried out by J.E.  Crowe Jr.  (Crowe et al.,  1994). 
This study involved the immunisation of chimpanzees with recombinant vaccinia 
virus expressing  respiratory syncytial virus  (RSV)  F or G  protein.  Animals were 
then  challenged  with  RSV  and  peripheral  blood  lymphocytes  isolated.  Total 
lymphocytes  were  then  transformed  with  Epstein-Barr  virus  to  generate 
lymphoblastoid  cells  lines that secreted  anti-RSV antibodies. All  lymphoblastoid 
cells  generated  were  screened  for  anti-RSV  production  by  ELISA,  and 
supernatants were tested for viral neutralisation. To adapt this technique for this 
study,  cell  suspensions  would  have  to  be  prepared  from  all  of  the  tissues 
investigated  and  hybridoma  cell  lines  generated.  Once  anti-influenza  virus 
antibodies were  identified,  the  CDR3  regions of the  binding  site of an  antibody 
could then be determined  by sequencing and compared to the CDR3 regions of 
antibodies  produced  in  other  compartments.  This  would  identify  whether  the 
same antibody is  produced  in different areas of the body and therefore whether
101antibody secreting cells from the same clone have trafficked to different parts of 
the immune system to produce the same anti-influenza virus antibody.
IEF  has  been  shown  to  be  a  novel  method  for  the  characterisation  of  the 
clonality of a serum antibody response to influenza virus infection. This method 
has  the  potential  to  be  applied  to  monitor the  development  of the  response  in 
individual  mice  as  influenza  virus  infection  is  established  and  then  cleared 
before the establishment of memory. The fragment culture technique developed 
provided  an  excellent  way  to  collect  antibody  from  various  tissues  of  the 
mucosal  and  systemic  immune  systems.  It  proved  sufficient for  ELISA  based 
analysis  but  not  IEF.  More  recently,  B  cell  clonality  has  been  investigated  by 
PCR methods and  has concentrated on the detection of lymphoma.  Perhaps an 
alternative  route  of  investigation  to  take  would  be  the  development  of  PCR 
assays  designed  to  detect  the  unique  variations  in  the  Ig  heavy  regions  of 
specific antibodies as previously described  (Kusic et al., 2003,  Leal et al., 2003, 
Zompi et al., 2004).
102Chapter 4
Characterisation of the  Immune Response to Particle Mediated 
Immunotherapeutic Epidermal  Delivery of a DNA Vaccine
1034.1  Introduction
Influenza DNA vaccines have been extensively studied and constructs encoding 
the  surface  glycoproteins,  HA  and  NA,  internal  proteins  NP  and  M1  and  non 
structural  protein  NS1  have  all  been  assessed  for  their  ability  to  generate 
protective immune responses (Chen et al.,  1998, Robinson et al.,  1997, Ulmer et 
al.,  1993a).  Immunisation with plasmid DNA encoding influenza HA is capable of 
inducing  cell-mediated  and  humoral  immunity  and  protecting  mice  against 
intranasal  challenge  with  influenza  virus  (Ulmer  et  al.,  1994,  Webster  et  al., 
1994).  Furthermore,  induction  of  CTLs  and  protection  against  virus  challenge 
has  been  demonstrated  following  immunisation  with  plasmid  DNA  encoding 
influenza  NP  (Ulmer et al.,  1993b).  These  studies  have  primarily  been  carried 
out  by  introducing  the  DNA  by  intramuscular  injection,  and  research  into  gene 
gun  immunisation  or  particle  mediated  immunotherapeutic  delivery  (PMID)  of 
DNA has been limited and less productive (Chen et al., 2000).
The  aims  of  this  study  were  to  assess  particle  mediated  immunotherapeutic 
delivery  (PMID)  as  a  method  of  DNA  immunisation  by  comparing  the  immune 
response  generated  to  that  of  the  “gold  standard”  (infection  that  results  in 
protection from  reinfection) already characterised for influenza virus  infection of 
mice in chapter 4.  More specifically, there was interest to determine whether non 
mucosal  PMID  of  influenza  virus  NP  DNA  was  able  to  generate  a  mucosal 
response in the D-NALT.
1044.2 Results
4.2.1  Cartridge Preparation, Quality Control and Immunisation Regimen
Preparation of cartridges for PMID using the BioRad Helios research device was 
carried out as previously described (section 2.14) and cartridges were tested for 
a  uniform firing  pattern  by layering  one sheet of mylar over a  layer of parafilm. 
Mylar  was  suggested  by  PowderJect/Chiron  to  act  as  a  substitute  "skin-like" 
membrane  to  monitor  penetration  of  plasmid  coated  gold  beads  through  the 
Mylar  and  into  the  parafilm.  Figure  11a  shows  a  typical  mylar/parafilm 
membrane following  test firing  and  a  poor firing  pattern  is  seen  in  Figure  11b. 
Densitometry  was  carried  out  using  a  BioRad  Densitometer  to  ensure  even 
penetration of the gold  beads. A representative scan showing a consistent firing 
pattern  can  be  seen  in  Figure  11a.  This  is  reflected  in  the  similar  size  and 
intensity  of gold  colour of spots  observed  on  the  parafilm.  Most firing  patterns 
were  like that observed  in  Figure  11a.  If a  poor firing  pattern was observed the 
gene gun was primed with helium by firing a few “empty shots” and the cartridge 
batch was  retested.  If the firing  pattern  remained  poor the batch was failed and 
the cartridges were remade.
The plasmid used contained the whole influenza virus NP gene inserted into the 
pVac vector.  The  details  of the  pVac-NP vector are  shown  in  Figure  12a.  The 
plasmid  contains  a  cytomegalovirus  intermediate  early  promoter  to  enable 
transcription  of the  NP  gene,  an  origin  of  replication  for growth  in  E.Coli,  and 
ampicillin  resistance which was used for selection.  Results of a simple digest of 
the  plasmid  to show the  presence of the whole  NP gene in  pVac-NP at around 
1600 bps is shown in Figure 12b.
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Figure  11:  Freshly prepared DNA cartridges were test fired through mylar layered 
over  parafilm  a)  shows  a  typical  even  firing  pattern.  Gold  particles  that  travel 
through the mylar do so at an even  rate for each shot and this  is  reflected  in the 
even size and intensity of colour of the spots on the parafilm b) shows an uneven 
firing  pattern where one shot has almost failed to penetrate the mylar and others 
vary in their colour density and size.
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Figure  12:  a)  plasmid  map  of  pVac  containing  the  whole  influenza  virus 
A/PR/8/34  nucleoprotein  (NP)  gene,  a  promoter  and  ampicillin  resistance  for 
selection  b) shows a  simple digest of the  plasmid to confirm the whole NP gene, 
roughly 1600 bps, is present.
1074.2.2  PMID of Influenza Virus Nucleoprotein Induces a Negligible Humoral 
Response but a Long Lived CD8* T Cell Response
In  initial  experiments,  mice were  immunised with  empty vector (pVac) or pVac- 
NP and  at several time  points  post primary immunisation, various systemic and 
mucosal  tissues  were  removed  and  cell  suspensions  were  restimulated  with 
influenza  virus-specific  peptide  in  IFNy  ELISPOT  assays  to  enumerate  virus- 
specific CD8+  T cells.
In  the  pVac  immunised  animals,  a  low  level  (<100  spots/5  x  105 /cells)  of cells 
spontaneously  producing  IFNy  were  present  in  MesLN  and  inguinal  lymph 
nodes  (IngLN),  but were generally not detected  in other samples tested (Figure 
13a).  The spontaneous release of IFNy may reflect highly activated  populations 
of  cells  in  the  MesLN  and  IngLN.  When  the  NP  gene  was  included  in  the 
plasmid  used  for  immunisation  (Figure  13b),  there  was  a  dramatic  increase  in 
the  numbers  of  cells  producing  IFNy  in  response  to  in  vitro  restimulation  with 
influenza  virus-specific  peptide.  The  cellular  response  was  dominated  by  that 
observed  in the spleen,  peaking  14 days  post-primary immunisation. There was 
also a  significant response observed  in the  IngLN,  and  more surprisingly in the 
D-NALT and  MedLN.  There were a  low  number of virus-specific cells  recruited 
to  the  lungs  with  a  slower kinetics.  At 6  months  post  immunisation  the  results 
indicated  that  there  were  populations  of virus-specific  IFNy  secreting  memory 
lymphocytes  observed  predominantly  in  the  spleen  with  lower  numbers 
circulating  to  the  periphery that were  still  detectable  in  the  MedLN,  IngLN  and 
MesLN.
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Figure 13:  Influenza virus-specific CD8+  T cells responses are first detected in the 
spleen  and  IngLN  and  peak in  the  spleen  day  10  after PMID  immunisation.  Five 
C57BL/6  mice  per  timepoint  were  immunised  with  2  non  overlapping  doses  of 
approximately  0.5/yg  pVac  (a)  or  pVac-NP  (b)  DNA.  Tisses  were  pooled  from  5 
mice  per timpoint and  cell  suspension were  plated  out in triplicate.  Virus-specific 
IFNk  secreting  CD8+   T  cells  were  were  enumerated  by  ELISPOT.  Background 
activated  IFNy secreting  cells were  observed  in  the  IngLN  and  MesLN  following 
pVac  immunisation.  pVac-NP  immunisation  generated  a  dominant  response  in 
the  spleen,  IngLN  and  MesLN.  A significant  response was  also  observed  in  the 
respiratory  compartment.  Error  bars  indicate  the  standard  deviation  between 
replicates and this data  is representative of two experiments.
109Minimal  levels  of  influenza  virus-specific  immunoglobulin  were  detected 
following  analysis  of  serum  samples  collected  at  various  time  points  post 
immunisation.  Serum  was  tested  as  previously  described  (section  2.10)  on 
sucrose  purified  influenza  virus  coated  plates,  and  also  on  purified  NP  (a  gift 
from  Dr Wendy Barclay,  University of Reading)  coated  plates  but no difference 
in optical density was observed (data not shown).
4.2.3  The Response Induced by PMID was Protective Against Influenza Virus 
Challenge
A  study was  set  up  to  investigate  if any  protection  was  provided  by the  virus- 
specific immune responses elicited  by PMID immunisation of the influenza virus 
NP  plasmid.  In  this  experiment,  animals  were  immunised  with  either  pVac  or 
pVac-NP,  left  to  reach  a  memory  state  over  6  weeks,  and  subsequently 
challenged  with  an  intranasal  infection  of  influenza  virus  A/PR/8/34.  Various 
tissues were removed and  IFNy ELISPOT assays were carried out to enumerate 
virus-specific cells at various times post-challenge.
The numbers of IFNy secreting  cells isolated from immunised animals following 
challenge are shown  in  Figure  14.  Immunising  mice with empty vector 6 weeks 
prior  to  challenge  with  live  virus  effectively  results  in  a  primary  response  to 
influenza  virus,  dominated  by  infiltration  of virus-specific  cells  to  the  lungs.  In 
general,  these  results  are  consistent,  within  the  bounds  of experimental  error, 
with those  observed when  the  primary  immune  response was  characterised  by 
IFNy  ELISPOT.  When  animals  are  immunised  with  the  pVac-NP  plasmid  the 
response  is  dramatically  different.  There  is  an  overwhelmingly  stronger  and 
kinetically faster recruitment of virus specific IFNy secreting  CD8+  T cells to the 
lungs first observed at 5 days post challenge, which is much earlier than seen in
110a  primary response.  The  level of cellular influx at day 7  is at the same level as 
seen at the peak of a primary response (day 10). This rapid  recruitment of cells 
continues  before  peaking  at  day  14.  The  precise  level  of  the  peak  response 
could  not  be  quantitated  as  the  spots were  too  numerous  to  accurately count. 
The  recruitment of CD8+  cells was first  recorded  in the  MedLN  followed  by the 
lungs  and  spleen  before  finally  a  few  virus-specific T  cells  are  seen  in  the  D- 
NALT.
Following the discovery that there was a rapid  recruitment of virus specific IFNk 
secreting CD8+  cells to the lungs,  it was of interest to investigate whether PMID 
immunisation  of  pVac-NP  could  induce  any  protection  from  influenza  virus 
infection.  The  previous  challenge  experiment  was  therefore  repeated  but  only 
lungs were collected at various days post challenge to determine virus titres.
Specific pathogen free  10 day old embryonated hen eggs were provided by The 
Institute for Animal Health (Compton, Berks) as a medium in which to propagate 
influenza  infected  lung  homogenates  as  previously  described  (section  2.16). 
Briefly,  lung  homogenates were prepared and  10-fold  serial dilutions were used 
to  infect  the  allantoic  cavity  of  the  eggs  in  triplicate.  Eggs  were  incubated  at 
37°C for 48 hours. The presence of influenza virus was detected by utilising the 
ability  of  the  virus  to  agglutinate  chicken  red  blood  cells.  The  amount  of 
infectious virus  in  a  lung  homogenate was estimated  by measuring  the  highest 
dilution  of homogenate that could  still  infect an  embryonated  egg.  The smallest 
amount of virus capable of doing this, on 50% of occasions, is known as the egg 
infectious  dose  (EID50).  Virus  titre  in  EID50  was  calculated  as  previously 
described (Mahy,  1985).
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Figure  14:  Infection with  live influenza virus after PMID of pVac-NP results in the 
rapid  infiltration  of virus-specific  CD8+   T  cells  into  the  lung.  Five  C57BL/6  mice 
per  timepoint  were  immunised  with  2  non  overlapping  doses  of  approximately 
0.5//g  pVac  (a)  or  pVac-NP  (b)  DNA  before  subsequent  intranasal  challenge  6 
weeks later with 500 EID50 influenza A/PR/8/34 virus. Tissues were pooled from 5 
mice per timpoint and cell suspensions were plated out in triplicate Virus-specific 
IFNy  secreting  CD8+   T  cells  were  were  enumerated  by  ELISPOT.  pVac 
immunisation  followed  by  challenge  (a)  resulted  in  a  primary  response  to 
influenza.  pVac-NP priming followed by challenge (b) was dominated by  a strong 
and  kinetically fast recruitment of virus specific IFNy secreting  cells to the lungs. 
Error  bars  indicate  the  standard  deviation  between  replicates  and  this  data  is 
representative of two experiments.
1 1 2Priming animals with pVac-NP was observed to induce a level of protection that 
can effectively control viral growth in the lungs and  reduce the viral load  (Figure 
15). At both days 5 and 8 post challenge, the average virus titre in the lungs was 
2 logs lower in the animals primed with pVac-NP.  By day 8 post challenge, 3 out 
of 5 of the animals had completely cleared the virus.
Interesting results showing that PMID immunisation of pVac-NP DNA provided a 
level of protection from influenza virus infection. This correlated with a significant 
and rapid influx of IFNy secreting CD8+  T cells into the lungs and was consistent 
with  the  hypothesis that  rapid  recruitment of influenza  virus-specific CD8+  cells 
to  the  lungs  could  contribute  to  control  of  viral  replication.  In  an  attempt  to 
determine the role of CD8+  T cells  in vaccine induced  protection from influenza 
virus infection,  CD8+  T cells were depleted in vivo by intra peritoneal injection of 
anti-CD8  monoclonal  antibody  at  days  -3,  0  and  every  2  days  post  influenza 
virus challenge throughout the sample time points.
In  this  experiment,  mice  were  immunised  with  pVac  or  pVac-NP  and  either 
depleted of their CD8+  T cells or left with them intact, before intranasal challenge 
with  influenza  virus.  Lungs were  removed  at days  5  and  8  post challenge and 
assessed for virus titre. Monoclonal antibody injection led to depletions of 99.5% 
of splenic CD8+  T cells.
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Figure  15:  PMID  of  pVac-NP  reduces  virus  titre  in  the  lungs  of  influenza  virus 
challenged  mice.  Five  C57BL/6  mice  per  group  were  immunised  with  2  non 
overlapping  doses  of  approximately  0.5/vg  pVac  or  pVac-NP  DNA  before 
subsequent  intranasal  challenge  6  weeks  later  with  500  EID50  influenza 
A/PR/8/34  virus.  Lungs  were  removed  and  virus  titrations  were  carried  out.  At 
both  days  5  and  8  post  challenge,  mice  primed  with  pVac-NP  showed  a  2  log 
reduction  in  virus  titre.  By day eight,  3  out  of 5  mice  primed  with  pVac-NP  had 
cleared  the  virus  completely.  Lung  virus  titres  were  analysed  using  the  Mann 
Whitney test and NP immunisation is shown to significantly reduce viral growth in 
the  lungs  upon  challenge.  This  data  is  representative  of  one  experiment,  with 
lung homogenates used to infect eggs in triplicate.
114The  lung  viral  titres  recorded  from  the  CD8+   T-cell  depletion  experiment  are 
shown  in  Figure  16.  It  can  be  seen  that  at  day  5  post  challenge  (Figure16a) 
there is no effect of depleting the CD8+  T cells. This result would be expected as 
the  ELISPOT  data  indicated  that the  CD8+   T  cells  are  few  in  number and  are 
only just beginning to arrive in the lungs by day 5  (Figure  14b).  By 8 days post­
challenge  (Figure  16b)  it  can  be  seen  that  2  out  of 3  animals  immunised  with 
pVac-NP  before the  challenge,  have  already  cleared  the virus from their lungs 
and  this  has  perhaps  given  a  false  suggestion  that depleting  the  CD8+  T cells 
has  no  effect  on  virus  titre.  The  data  generated  from  animals  who  were 
vaccinated with empty vector shows that depleting CD8+  T cells has the effect of 
increading  virus  titre  by  one  log.  However,  it  is  difficult  to  make  any  firm 
conclusions from  this  study,  as,  owing  to time  constraints  this  experiment was 
unable  to  be  repeated.  In  retrospect,  it  would  have  been  informative  to 
determine  the  virus  titres  at  day  7  after  the  challenge,  before  the  pVac-NP 
immunised animals have had a chance to clear the virus.
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Figure  16:  CD8  depletion  of mice  immunised  with  pVac-NP  did  not significantly 
affect virus clearance. Three C57BL/6 mice per group were immunised with 2 non 
overlapping  doses  of  approximately  0.5jjq  pVac  or  pVac-NP  DNA  before 
subsequent  intranasal  challenge  6  weeks  later  with  500  EID50  influenza 
A/PR/8/34  virus.  Mice  were  either  depleted  in  vivo  of  their  CD8+   cells  by 
monoclonal  antibody,  or  left  with  them  intact.  Lungs  were  removed  and  virus 
titrations were carried out. At day 5 post challenge,  CD8+  cell depletion  had  little 
effect on  lung virus titre.  By day eight,  2 out of 3 mice  in the groups primed with 
pVac-NP had cleared the virus and a conclusive interpretation of the results could 
not  be  made.  The  significance  of  viral  load  was  analysed  using  analysis  of 
variance followed  by Tukey’s test.  This data  is representative of one experiment, 
with lung homogenates used to infect eggs in triplicate.
1164.3 Discussion
An  important  discovery  in  the  field  of  DNA  vaccination  showed  that  the 
administration  of  plasmid  vectors  expressing  human  influenza  virus  protein 
resulted  in  protection  in  mice  from  disease  following  live  influenza  virus 
challenge  (Fynan  et  al.,  1993,  Ulmer  et  al.,  1993b).  Intranasal,  intramuscular 
and intravenous administration of plasmid DNA all resulted in protection to some 
extent  but immunisation  by gene  gun  generated  by far the  best results with as 
little  as  0.4//g  of DNA capable  of inducing  95%  protection.  In  mice  it has  been 
shown  that approximately  100 fold  less  DNA is  required  to  be administered  by 
PMID  to  obtain  a  comparable  response  to  that  induced  by  needle  injection 
(Fynan  et  al.,  1993).  DNA  vaccines  offer  many  advantages  over conventional 
immunisation  approaches:  they are  simple  to  make  and  deliver,  they can  elicit 
both  humoral  and  cellular  responses,  and  intracellular  expression  of  native 
antigens imitates the route of viral pathogens. There is also the added  bonus of 
being  able  to  deliver  multiple  antigens/co-stimulatory  molecules  by  combining 
several plasmids in one immunisation.
This study focused on assessing the response generated by PMID immunisation 
of  influenza  NP  DNA with  the  view of  comparing  this  to  the  natural  protective 
response generated  by intranasal influenza virus infection in mice. The aim was 
to  elucidate  information  regarding  the  efficacy  of  PMID  with  regard  to  the 
generation of mucosal and/or protective immune responses.
ELISPOT  was  used  to  quantitate  the  number  of  NP-specific  IFNk  producing 
CD8+   T  cells  induced  by  a  single  PMID  immunisation  (comprising  two  non 
overlapping  doses  of  approximately  0.5//g  of  DNA).  The  dominant  cellular 
response  is  observed  in  the  spleen  and  peaked  at  day  10  post  immunisation.
117There was also a substantial  response in the draining  lymph  nodes of the skin, 
the  IngLN.  An  early  response  was  also  observed  in  the  MesLN,  this  was 
expected  as  a  result  of  the  immunisation  method.  Most  interestingly,  a  virus- 
specific cellular response was observed  in the respiratory compartment, namely 
the  MedLN  and  more  surprisingly the  D-NALT.  We  believe  that this  is the first 
report of gene gun immunisation generating an antigen specific response in the 
D-NALT.  Six  months  post  immunisation,  the  memory  response  generated  can 
be  detected  in the  spleen,  IngLN,  MesLN  and  more  surprisingly in  the  MedLN. 
Figure  13a  shows  the  response  observed  when  animals  were  immunised  with 
an  empty  plasmid  vector.  There  is  a  background  response  observed  most 
significantly  in  the  MesLN,  this  is  however not surprising  considering  the  insult 
on  the gut  by the  immunisation  method  and  its  potential  to cause  inflammation 
and  subsequently activate  lymphocytes.  It is  however not observed  six months 
later when a significant memory response is observed (Figure 13).
Memory cells  located  primarily at the sites of potential  infection  have the ability 
to  respond  quickly  when  exposed  to  a  pathogen.  Thus,  according  to  their 
location,  populations  of  memory  T  cells  make  a  significant  contribution  to  the 
first line  of defense when  a  pathogen  is encountered  post vaccination.  CD8+  T 
cell  memory  can  remain  stable without  a  continuing  requirement for additional 
exposure  to  antigen  (Homann  et  al.,  2001,  Murali-Krishna  et  al.,  1999). 
Therefore, a brief exposure to antigen should  be sufficient to produce long-lived 
immunity.  It  has  also  been  shown  that  the  magnitude  of  the  peak  of effector 
CD8+   T  cell  responses  in  the  primary  immune  response  can  correlate  to  the 
extent of the long term memory induced  (Hou et al.,  1994). Together these data 
suggest that for a CD8+  T cell  inducing  DNA vaccine to be the most effective,  it 
should  induce  strong  antigenic  expression  which  results  in  a  significant
118expansion  of  CD8+   T  cells  and  leaves  an  expanded  population  of  residual 
memory T cells.
As  important  as  the  generation  of  CD8+   effector  and  memory  cells,  is  the 
requirement for CD4+  T cell  help for the generation and  maintenance of a good 
quality  memory  CD8+   T  cell  response  (Chan  et  al.,  2001).  These  authors 
showed that MHC class  II deficient mice were unable to mount a CTL response 
following  DNA vaccination.  It  has  been  subsequently  shown  that  CD8+   T  cells 
primed  in  the  absence  of CD4+   T  cell  help  may express  a  memory  phenotype 
but  are  devoid  of  memory function  (Bourgeois  et  al.,  2002).  These  data  have 
also  been  supported  in  the  influenza  model  where  CD8+   T  cell  memory  was 
found  to  be  impaired  in  CD4+   deficient  mice  (Belz  et  al.,  2002).  More  recently 
several  other studies  have  demonstrated  a  requirement for CD4+  T cell  help to 
establish  fully  functional  CD8+   T  cell  memory  (Janssen  et  al.,  2003,  Sun  & 
Bevan,  2003).  CD4+   T  cells  are  required  during  the  maintenance  phase  of 
memory development and  not  solely at the  original  CD8+   T  cells  programming 
phase (Sun et al., 2004). These data suggest that when designing and selecting 
novel  vaccine  candidates  it  would  be  an  advantage  if they  could  induce  both 
specific cytotoxic CD8+  T cell and CD4+  T helper cell responses.
Comparing the memory response generated  by PMID of NP DNA (Figure  13) to 
that  generated  by  natural  infection  (Figure  8),  it  would  appear  that  natural 
infection  has  generated  a  superior  memory  response.  Despite  the  ability  of 
PMID to generate a  primary response  in the  DNALT,  immunised  animals fail to 
maintain  a  memory  response  in  this  tissue.  A  stronger/longer-lasting  memory 
response was observed in the D-NALT following natural infection.
119Analysis of serum collected from  PMID immunised  animals showed that for this 
model antigen and  method  of immunisation there is a  limited ability to generate 
humoral  responses  following  a  single  immunisation.  This  result was  surprising 
as  there  are  several  reports  of  single  DNA  immunisations  generating  robust 
cellular and  humoral  immune  responses  (Justewicz  et al.,  1995,  Kwissa  et al., 
2000,  Lodmell  et  al.,  2002,  Lodmell  et  al.,  2003,  Tollefsen  et  al.,  2002).  The 
coating  antigen  for  the  ELISA  analysis  of  the  serum  was  sucrose  purified 
influenza virus A/PR/8/34 and  it was possible that there was a problem with the 
antibodies  in  the  serum  recognising  the  conformation  of the  NP  present in this 
preparation.  Dr  Wendy  Barclay  kindly  provided  some  purified  influenza  virus 
A/PR/8/34  NP which was also tested  as a coating antigen  but again  no specific 
antibodies  were  detected.  These  results  indicate  that  it  was  likely  that  a 
negligible humoral  response was generated to the single immunisation regimen 
adopted  for  these  studies.  A  report  investigating  the  immune  response  to 
influenza virus HA DNA following a single intramuscular administration indicated 
that a strong  IFNy secreting cellular response but a poor humoral response had 
been  induced.  Two  booster  immunisations  were  required  to  generate  a 
significant  virus-specific  IgG  response  in  the  serum  (Johnson  et  al.,  2000).  A 
subsequent study also  reported  that a  single  intramuscular immunisation  could 
not induce antibody production (Kasinrerk et al., 2002).
When  DNA vaccines for influenza virus were first studied,  a construct encoding 
NP  was  shown  to  generate  both  humoral  and  cellular  responses,  as  well  as 
protection  against  lethal  challenge.  And  it  was  suggested  that  protection  was 
CTL  mediated  (Ulmer  et  al.,  1993a).  Further  studies  of  DNA  immunisation 
against  influenza  virus  HA,  as  well  as  genes  encoding  internal  proteins,  and 
have analysed humoral as well as cellular immunity (Donnelly et al.,  1995,  Fu et 
al.,  1997,  Fynan  et  al.,  1993,  Kodihalli  et  al.,  1999).  In  conjunction,  a  study
120investigating  protection  following  intramuscular NP  DNA immunisation  reported 
that depletion  of CD8+   T cells  prior to  a  lethal  challenge,  completely abolished 
protection while depletion of CD4+  cells had a partial effect (Ulmer et al., 1998).
In  this  study,  characterisation  of the  immune  response  in  challenged  mice that 
had  been  prophylactically immunised  demonstrated  a significant influx of virus- 
specific  T  cells  into  the  lungs.  It  was  of  interest  to  investigate  whether  this 
recruitment of virus-specific cells to the  lungs afforded  any protection from viral 
replication.  It  was  observed  that  recruitment  of  effector  CD8+   T  cells  has  the 
effect of reducing viral  replication  in the  lungs to the extent that there  is a 2 log 
reduction  in  viral  titre  in  animals  primed  with  pVac-NP  before  intranasal 
influenza  virus  challenge.  Visually  there  were  no  obvious  signs  of  pathology 
observed  in  these  animals.  The  cellular  influx did  not  completely  abolish  viral 
replication  but resulted  in a  more rapid  clearance of the virus from the lungs.  In 
vivo  depletion  of  the  responding  CD8+   T  cells  was  inconclusive  and  requires 
further investigation  but appeared  to  have  minimal  effect on  viral  growth  in  the 
lungs. This data appears to conflict that of Ulmer et al. (1998). However, there is 
one major difference between the studies, and that is the dose of virus used for 
challenge.  This  study used  a  non-lethal  challenge whereas  Ulmer et al.  (1998) 
used  a  lethal  challenge  and  this  could  account for the  abrogation  of protection 
when  CD8+   T  cells  were  depleted.  The  immunisation  method  should  also  be 
taken into consideration. This study used PMID or gene gun delivery of NP DNA 
whereas  Ulmer et al.  (1998)  used  intramuscular injection of plasmid.  Gene gun 
immunisation is know to generate greater CD8+  T cell responses (Trimble et al., 
2003) which could also account for the differences seen between the studies.
To further complicate the discussion, a study focusing on the protection afforded 
by DNA vaccination  of internal  influenza virus  proteins was  recently carried  out
121(Epstein et al., 2000). The authors reported that intramuscular immunisation with 
plasmids  expressing  both  influenza  NP  and  matrix  protein  (M)  provided 
protection  from  a  lethal  challenge.  Depletion  studies  further  characterised  this 
response to be mediated by T cell immunity but CD8+  T cells were not essential. 
It was  observed  that  CD4+   or CD8+  T  cells  can  promote  survival  and  recovery 
from lethal influenza virus challenge in the absence of the other set.
Taken  together,  these  data  show  that  the  depletion  experiment  in  this  study 
should  be reinvestigated.  Perhaps with a lethal challenge and definitely with the 
depletion  of CD4+  and  CD8+  T cell  subsets  both  individually and  together.  This 
should aid in the clarification of reports published to date.
Many  of the  current  studies  on  DNA  vaccination  are  investigations  concerned 
with  generating  the  most  robust  immune  response  often  following  a  reliable 
“prime  boost”  regimen.  The  studies  reported  here  are  only  concerned  with 
characterisation  of the  mucosal  and  systemic response  to  a  single vaccination 
with  DNA.  Most  encouragingly  it  has  have  demonstrated  that epidermal  PMID 
delivery of a  plasmid  encoding  influenza  virus  NP  DNA can  induce  a  mucosal 
response in the D-NALT.
122Chapter 5
Phenotypic Analysis of Influenza Virus Specific CD8+ T Cells 
Distributed Throughout the Mucosal  Immune System
1235.1  Introduction
Lymphocyte  migration  from  the  blood  into  secondary  lymphoid  organs  is 
mandatory for maintaining  immune  surveillance  and  providing  efficient defense 
against  invading  pathogens.  The  major function  of CD8+   effector T  cells  is the 
killing  of other cells,  and direct contact with the target cell  is required for this to 
happen.  Target  cells  can  be  located  anywhere  in  the  body  and  thus  effector 
CD8+   T  cells  must  demonstrate  an  ability  to  migrate  throughout the  body  and 
effectively traffic to  sites  of  inflammation.  This  migration  is  partly  controlled  by 
tissue-selective  expression  of endothelial  adhesion  molecules that bind  ligands 
on the surface of circulating lymphocytes.
The aim of this study was to investigate the antiviral  CD8+  T cells generated  by 
mice following  experimental  influenza  virus  infection  or PMID  of influenza virus 
NP  DNA, with  respect to their expression  of adhesion  molecules. Virus-specific 
CD8+   T  lymphocytes  were  assessed  for  their  expression  of  the  common 
adhesion/activation  markers  CD44,  CD11a,  CD62L  and  CD69.  Subsequent  in 
vivo  transfer  studies  were  used  to  analyse  the  migratory  preferences  of 
activated  CD8+   splenocytes.  It  is  thought that the  analysis  of these  cells  could 
determine the  efficacy of PMID  immunisation  at stimulating  immune  responses 
that migrate to similar sites to those observed in a protective response and help 
elucidate more information regarding the common mucosal immune system.
5.2 Results
5.2.1  Phenotypic Analysis of Influenza-Specific Effector CD8* T Cells
Single  cell  suspensions  of  cells  isolated  from  various  mucosal  and  systemic
tissues were  prepared  and  stained  with  influenza virus-specific H-2Db  NP366-374
124tetramer as  previously described.  Cells were  subsequently counterstained  with 
anti-CD8  in  combination with either anti-CD44,  anti-CD11a,  anti-CD62L or anti- 
CD69  before  detection  of  immunofluorescence  was  carried  out  on  a 
FACSCalibur using CellQuest software (BD Biosciences, San Jose, CA).
Influenza virus-specific H-2Db NP366.374 tetramers were used as a tool to identify 
virus  specific  cells  generated  by  mice  following  intranasal  influenza  virus 
infection  or  PMID  immunization  using  an  influenza  NP  DNA  plasmid. 
Identification  of the  influenza  virus-specific cells  allowed  expression  levels  of a 
range of surface antigens implicated  in adhesion and  activation of leukocytes to 
be investigated.
CD44  is  a  cell  adhesion  receptor,  and  its  principal  ligand,  hyaluronic acid,  is a 
common  component  of  extracellular  matrices  (Lesley  et  al.,  1993).  In  the 
periphery,  the  level  of  expression  of  CD44  increases  upon  activation  of  B 
lymphocytes,  CD4+  T cells and CD8+  T cells (Budd et al.,  1987,  Hathcock et al., 
1993).  Memory cells can  be  recognised  by their CD44h l  phenotype (MacDonald 
et  al.,  1990).  CD11a  is  the  aL   chain  of  LFA-1  (CD11aCD18,  a^fi2  integrin)  a 
surface  glycoprotein  expressed  on  almost  all  leukocytes  (Larson  &  Springer,
1990)  and  is  involved  in  the  multistep  model  of  leukocyte  recruitment.  CD11a 
binds  to  its  ligands  ICAM-1  and  ICAM-2  mediating  the  firm  binding  of  rolling 
leukocytes to endothelium and  promoting  arrest and subsequent transmigration 
of leukocytes through the endothelial  layer and  into tissues  (von Andrian et al.,
1991). CD62L is a member of the selectin molecule family and is also known as 
L-selectin.  It is expressed on thymocytes and  peripheral  leukocytes,  including  B 
and T cells (Iwabuchi et al.,  1991).  CD62L is required for lymphocyte homing to 
peripheral  lymph  nodes  (Gallatin  et  al.,  1983)  and  its  expression,  along  with 
other  markers,  distinguishes  naive,  effector  and  memory  T  cells  (Sprent  &
125Tough,  1994).  CD69  (very early activation  marker)  is  closely  related to  NK cell 
activation  molecules  (Ziegler  et  al.,  1994a)  and  is  rapidly  induced  upon 
activation of lymphocytes (Ziegler et al.,  1994b).
The  characteristic  expression  patterns  of  the  surface  antigens  CD44,  CD11a, 
CD62L  and  CD69  on  CD8+   lymphocytes  isolated  from  naive  animals  were 
compared to that expressed  by cells  isolated from  influenza virus infected  mice 
and  the  results  are  shown  in  Figure  17.  It was  observed  that  CD8+CD44h l and 
CD8+CD11ah l  cells  (upper  right-hand  quadrants)  are  more  numerous  in  the 
spleens (and other tissues, data not shown) of mice infected with influenza virus. 
It was also observed that activated CD8+  T cells expressing low levels of CD62L 
(upper left-hand quadrant) were also more numerous in the spleens of influenza 
infected animals.  No difference in the level of expression of CD69 was observed 
between the mice.
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Figure  17:  Adhesion  molecule  expression  is  similar  in  both  naive  and  influenza 
virus activated lymphocytes. C57BL/6 lymphocyte gated staining of CD8 enriched 
(negative  selection)  splenic  lymphocytes which  are  either naive  or  10  days  post 
influenza  virus  infection.  The  characteristic  staining  patterns  of  CD44,  CD11a, 
CD62L and CD69 on total lymphocytes can be seen.
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Figure  18:  Shows the gating  strategy adopted for adhesion  molecule expression 
studies.  Cell  suspensions were first lymphocyte gated on a  Side Scatter (SSC or 
granularity)  v’s  Forward  scatter  (FSC  or  size)  plot  =  Region  R1.  Region  1   was 
then  assessed for expression  of CD8  and  tetramer =  Region  R2.  Region  2 was 
then applied to adhesion  molecule expression  (in this case CD44) on CD8+  cells 
(bottom  left  plot)  to  show  the  expression  levels  of  adhesion  molecule  on  CD8+  
tetramer lymphocytes (bottom right plot).
1 2 8At 10 days after the intranasal influenza virus infection of mice, the expression of 
the adhesion molecules on virus specific CD8+  splenocytes was observed to be 
upregulated  compared  with  the  expression  levels  observed  on  CD8+   T  cells 
isolated  from  naive  animals  (Figure  17).  It  is  likely  that  expression  of various 
surface antigens may vary during the course of an infection, so the phenotype of 
cells isolated at 7,  10,  14, 21  and  35 days post-infection were investigated. The 
flow  cytometry  gating  strategy  adopted  for  all  adhesion  molecule  analysis  is 
shown  in  Figure  18.  The adhesion  molecule expression  of splenic lymphocytes 
at  various  times  post-infection  (Figure  19)  gives  a  universal  picture  of  the 
phenotype  of  cells  found  in  all  the  tissues  investigated.  In  general,  all  of  the 
tissues  analysed,  namely:  lung,  spleen,  MedLN,  MesLN,  IngLN  and  D-NALT, 
expressed similar amounts and showed similar changes in expression of all the 
adhesion  molecules studied.  However,  there were  some differences, which will 
be  addressed,  but  due  to  the  large  volume  of  data  generated  only  relevant 
FACS plots will be shown.
At day 7, early in the infection, CD69 is expressed on almost all the splenocytes, 
and  was  also  seen  to  be  expressed  at  a  similar  level  on  the  majority  of 
lymphocytes found in the MedLN and in the lungs (data not shown). At this early 
timepoint  (day  7)  CD62L  expression  is  high,  indicating  the  relatively  naive 
phenotype of the virus-specific CD8+  lymphocytes at this stage of infection. The 
level  of CD11a  expression  in  the  spleen  appeared  to  slightly  increase  and  the 
other  tissues  examined  showed  a  similar  CD11a  phenotype.  The  number  of 
CD8+   tetramer* cells  showing  a  CD44h l  phenotype  varied  during  the  course  of 
infection.  Early  in  the  infection  at day  7,  CD44  expression  was  equally divided 
between  CD44'0  and  CD44hi.  As  the  infection  progressed,  the  CD8+  tetramer+  
lymphocytes become predominantly CD44h l before expression was slightly down 
regulated. This was also observed to be the case for the other tissues examined
129except  within  the  IngLN  where  the  majority  of  CD8+  tetramer+   cells  remained 
CD441 0 .  The  D-NALT also showed  some differences  in  staining,  but this will  be 
discussed in the next figure.
Figure 20 shows a snap shot of the adhesion molecule staining on cells isolated 
from various tissues at 14 days post influenza virus infection. This timepoint was 
chosen  because  it was the  best representative timepoint and  plots for all of the 
tissues could  be shown.  The  CD8+  tetramer+   D-NALT  population was observed 
to  have  an  intermediate  level  of CD44  expression  (Figure  20,  outlined  in  red). 
CD44  expression  in  the  D-NALT  was  observed  to  be  at  an  intermediate  level 
throughout the course of infection. Another significant result from this figure was 
the  observation  that  CD69  is  up  regulated  on  the  CD8+   tetramer+   lymphocytes 
isolated  from  the  MedLN  and  the  lungs  (also  indicated  in  red).  A  recent study 
has linked the expression of CD69, a marker of early activation, to the presence 
of  antigen.  Using  the  influenza  mouse  model,  peptide  stimulated  proliferating 
CD8+   (CFSElo w )  cells  were  found  to  rapidly  upregulate  CD69  (Lawrence  & 
Braciale,  2004).  The authors suggested  that undivided T cells and  T cells early 
in  their  proliferative  cycle  may  still  have  been  in  contact  with  antigen  in  the 
MedLN at day 5 of infection.
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Figure  19: C57BL/6 mice were intranasally infected with 500 EID50 influenza virus 
A/PR/8/34  and  tissues  were  collected  for  analysis  of  adhesion  molecule 
expression  on  influenza  virus-specific  H-2Db  NP366_ 374  tetramer  positive  cells. 
This  figure  is  a  representative  of the  adhesion  molecule  staining  on  all  tissues 
analysed  and  shows  splenocytes  at  various  time  points  following  intranasal 
influenza  virus  infection.  CD69  is  found  to  be  highly  expressed  early  in  the 
infection  (d7),  this  was  also found  to  be  the  case for lymphocytes  isolated  from 
the  MedLN  and  lungs (data not shown).  CD62L expression was also found to be 
high early in the  infection  indicating  the naive  phenotype of the cells.  Expression 
of CD44  was  found  to  remain  constant throughout the  course  of infection,  while 
CD11a  expression  was  observed  to  be  slightly  upregulated.  These  data  are 
representative of two experiments and tissue pooled from five mice per timepoint.
131132Figure 20: C57BL/6 mice were intranasally infected with 500 EID50 influenza virus 
A/PR/8/34  and  tissues  were  collected  for  analysis  of  adhesion  molecule 
expression  on  influenza  virus-specific  H-2Db  NP366_ 374  tetramer  positive  cells. 
This figure  shows the adhesion  molecule staining on all tissues analysed  at day 
14  post  influenza  virus  infection  when  the  D-NALT  populations  were  adequate 
enough  to  analyse.  Lymphocytes  isolated  from  the  D-NALT  at  this  and  every 
timepoint showed  a characteristic CD44in term ed iate phenotype.  CD69 expression  in 
the  lungs and  MedLN  is found  to be  high  suggesting that these  cells  are  still  in 
direct contact with antigen. These data are representative of two experiments and 
tissue pooled from five mice per timepoint.CD44
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133At various  timepoints following  PMID  immunisation  of influenza virus  NP  DNA, 
there  appears to  be  no distinct difference  in  expression  of adhesion  molecules 
by  CD8+   tetramer+   lymphocytes  isolated  from  the  spleen.  Splenocytes  were 
isolated at the same timepoints following immunisation as had been selected for 
investigation  of  surface  antigen  expression  following  experimental  influenza 
virus infection (Figure 21). Amongst the other tissues examined, the lymph node 
draining  the  site  of  immunisation,  the  IngLN,  showed  an  increasing  level  of 
CD69  expression,  at times  greater than  7  days.  A similar  result was  observed 
following  intranasal  influenza virus infection  in the MedLN, which is the draining 
lymph  node  for  the  lung.  The  CD69  expression  on  the  CD8+   tetramer+  
lymphocytes  isolated  from  the  IngLN  was  found  to  be  similar  to,  but  not  as 
extensive  as,  that  observed  on  MedLN  and  lung  lymphocytes  induced  by 
intranasal influenza virus infection.  CD44 and CD11a expression were observed 
to be predominantly high, while CD62L expression was primarily low.
A snap shot of the adhesion molecule expression across all of the tissues tested 
at  10  days  post  PMID  immunisation  of  mice  with  influenza  virus  NP  DNA  is 
shown  in  Figure  22.  This  time  point  was  chosen  because  it  was  the  best 
representative  timepoint  and  plots  for  all  of  the  tissues  were  available. 
Highlighted with  red  boxes are the most interesting  plots from this cross section 
of adhesion molecule expression. Again it was observed that the CD8+  tetramer+  
lymphocytes  isolated  from  the  D-NALT  have  an  intermediate  level  of  CD44 
expression, similar to that observed following intranasal influenza virus infection. 
CD69h l CD8+  tetramer+  lymphocytes were observed  in the  IngLN, which  may be 
expected  as these  are the draining  lymph  nodes of area  of the skin which was 
the site of immunisation.
134One  final  observation  was  the  response  seen  in  the  lungs.  Following  the 
discovery  that  two  gene  gun  immunisations  one  week  apart  has  the  effect  of 
boosting  the  specific  CD8+   response  (personal  communication  with  Dr  Fiona 
Cook) this technique was used to boost the numbers of tetramer positive cells in 
tissues  like  the  D-NALT where  very few cells  can  be  isolated.  Previously,  with 
ELISPOT data (Figure  13), when only one immunisation was given, there was a 
very  limited  response  observed  in  the  lungs.  Unfortunately  due  to  time 
constraints,  ELISPOT  characterisation  of  the  cellular  response  to  gene  gun 
immunisation with two immunisations could  not be investigated after this double 
immunisation regimen had been used.
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Figure  21:  C57BL/6  mice  were  immunised  twice,  one  week  apart  by  PMID  of 
influenza virus  NP  DNA.  Each  immunisation  comprised  2 non-overlapping  doses 
of  approximately  0.5/jg  DNA.  Tissues  were  collected  for  analysis  of  adhesion 
molecule  staining  of  virus-specific  H-2Db  NP366_ 374  tetramer  positive  cells.  This 
figure  is  a  representative  of  the  adhesion  molecule  staining  on  all  tissues 
analysed  and  shows  splenocytes  at  various  time  points  following  PMID 
immunisation.  No  major  difference  in  adhesion  molecule  expression  was 
observed up to day 35 post immunisation except that of CD69 which was found to 
be  upregulated  over  the  timecourse  in  the  spleen  and  more  markedly  in  the 
IngLN. These data are representative of two experiments and tissue  pooled from 
five mice per timepoint.137Figure  22:  C57BL/6  mice  were  immunised  twice,  one  week  apart  by  PMID  of 
influenza virus  NP  DNA.  Each  immunisation comprised 2 non-overlapping doses 
of  approximately  0.5/vg  DNA  each.  Tissues  were  collected  for  analysis  of 
adhesion  molecule  staining  of  virus-specific  H-2Db  N P ^ ^   tetramer  positive 
cells. This figure shows the adhesion molecule staining on all tissues analysed at 
day  10  post  PMID  immunisation  when  the  D-NALT  populations  were  adequate 
enough  to  analyse.  Lymphocytes  isolated  from  the  D-NALT  at  this  and  every 
timepoint showed  a  characteristic CD44in term ed iate phenotype.  CD69 expression  in 
the IngLN is found to be high suggesting that these cells are still in direct contact 
with antigen. These data are representative of two experiments and tissue pooled 
from five mice per timepoint.CD8
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138The  expression  of  CD44  in  the  various  tissues  examined  following  both 
intranasal  influenza  infection  and  PMID  immunisation of influenza  NP  DNA can 
be seen in Figure 23. The results indicate that the level of expression of CD44 in 
each  of  the  tissues  examined  is  similar  regardless  of whether  the  cells  were 
activated  as  a  result  of  immunisation  or experimental  infection.  This  was  also 
found to be the case for the other adhesion molecules examined.
The level of expression of CD44 on lymphocytes isolated from the lungs and the 
D-NALT  on  naive,  influenza  virus  activated  and  tetramer  positive  CD8+  
lymphocytes  can  be  seen  in  Figure  24.  In  the  D-NALT  it  was  observed  that 
although  CD8+   expression  was  upregulated  upon  activation,  CD44  expression 
remained  intermediate  or low,  and  CD8+  tetramer+   lymphocytes were observed 
to  have  a  CD44  intermediate  phenotype.  CD44  staining  on  naive  lung 
lymphocytes  also  identifies  CD8+CD44l0   and  CD8+CD44in term ed iate  populations. 
Upon  activation,  CD44  was  dramatically  upregulated,  however there  is  still  an 
obvious  cD44m term ed iate  population,  which  has  a  lower  level  of CD8  expression. 
When  the  activated  CD8+  T cells were  examined  for the  presence of influenza 
virus-specific H-2Db  NP366-374 tetramer bound to surface T cell  receptors,  it was 
observed  that that the  majority of the  cells were  CD44hl,  but some displayed  a 
CD44'n term ed iate  phenotype  with  a  similar  level  of  expression  of  CD44  that  was 
observed in D-NALT populations.
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Figure 23:  a comparison of the CD44  staining of tetramer positive cells at day 14 
following  activation  by either intranasal  influenza virus A/PR/8/34 infection or two 
PMID  immunisations, one week apart,  comprising two  non-overlapping doses of 
0.5pg  influenza  NP  DNA.  The  levels  of  expression  of  CD44,  and  the  other 
adhesion  molecules (data not shown) were observed to be similar irrespective of 
whether cells had  been activated by immunisation or experimental infection.
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Figure  24:  Shows  the  similarity  in  expression  of CD44  between  naive  lung  and 
D-NALT  lymphocytes and  how they were  both  observed to  have a  population  of 
CD44  intermediate  expressing  lymphocytes.  It  can  be  seen  that  CD44  is  not 
upregulated  in  the  D-NALT  following  activation  by  intranasal  influenza  virus 
infection.  Tetramer  positive  lung  lymphocytes  were  found  to  be  predominantly 
CD44h i while the tetramer positive  D-NALT population was observed to have and 
intermediate level of CD44 expression.
1415.2.2 Virus Specific Lymphocytes Generated by PMID Immunisation Home 
Preferentially to Respiratory Mucosal Sites.
The homing  properties of naive and effector CD8+  T lymphocytes from C57BL/6 
Ly5.1  mice were investigated  in an adoptive transfer model.  Effector CD8+  cells 
were  generated  either  by  intranasal  infection  with  influenza  virus  or  by  PMID 
immunisation of influenza virus NP DNA.  Splenic CD8+  T cells were transferred 
intravenously  into  naive  recipient  C57BL/6  Ly5.2  mice,  and  two  days  post 
transfer, tetramer staining was used to locate effector CD8+  T cells.
Experiments were designed to follow effector cells generated  in  C57BL/6  Ly5.1 
mice  once  they were  transferred  into  naive  C57BL/6  Ly5.2  recipients.  Initially, 
naive  splenic  CD8+   lymphocytes  were  transferred  as  a  control  to observe their 
homing  properties.  Figure  25  shows  the  tissues  in  which  naive  CD8+   T 
lymphocytes are found to migrate to 48 hours following intravenous transfer. Cell 
suspensions of C57BL/6  Ly5.2 tissues were  prepared  and  stained for CD8 and 
Ly5.1  to locate the transferred cells.  Naive CD8+   lymphocytes were observed to 
be  circulating  in  the  blood  and  throughout  the  peripheral  lymph  nodes.  They 
were also found in the lungs,  liver and  spleen.  Most significantly,  no naive CD8+  
lymphocytes were detected  in the  D-NALT where only background staining was 
observed.
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Figure 25: Total  naive  CD8+  T lymphocytes were  MoFlo sorted from the spleens 
of  20  C57BL/6  Ly5.1+  mice  and  transferred  intravenously  into  naive  C57BL/6 
Ly5.2+   recipients.  48  hours  post transfer,  the  location  of naive  splenic  C57BL/6 
Ly5.1+   CD8+lymphocytes was  assessed  by flow cytometry.  Region  R2  indicates 
the  Ly5.1+   CD8+   transferred  cells  which  were  predominantly  found  in  the 
peripheral  lymph  nodes,  spleen  and  circulating  in  the  blood.  Only  background 
staining  was observed  in the  D-NALT. The  percentage of total  cells that is  R2  is 
shown on each plot. These data are representative of one experiment.
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143In  the  next  experiment,  naive  splenic  CD8+   T  cells  were  replaced  with  total 
splenic  CD8+   T  cells  isolated  12  days  post  intranasal  influenza  virus  infection. 
The  location  of the  cells  transferred  from  the  influenza  virus  infected  mice  is 
shown  in  Figure 26. Transferred  populations of total CD8 cells were found  in all 
tissues including  the  lungs and  D-NALT (Figure 26a). This figure clearly shows 
the trafficking of total CD8+  T cells (region R2) activated by influenza virus to the 
D-NALT, which should be compared to the D-NALT plot in Figure 25, where only 
background  staining was observed when naive cells were transferred.  For each 
tissue, region 2 was further analysed for the presence of influenza virus-specific 
H-2Db  NP366-374  tetramer  bound  to  surface  T  cell  receptors.  Figure  26b  shows 
the tetramer staining of CD8+Ly5.1+  lymphocytes found  in the various tissues.  It 
can  be  seen  that the  influenza  virus-specific  CD8+   cells  preferentially traffic to 
the lungs and  D-NALT. They were also detected in the spleen and liver, while in 
contrast to the  results for transfer of cells from  naive  animals  very few,  if any, 
were observed to be circulating in the blood or to traffic to the lymph nodes.
Finally,  the  transfer was  repeated  with  total  CD8+   splenic T cells  isolated  from 
mice following  PMID  immunisation of NP  DNA (Figure 27).  Similar results were 
observed to those following the transfer of cells activated by intranasal influenza 
virus  infection.  Again,  it  can  be  seen  that  activation  leads  to  the  trafficking  of 
CD8+Ly5.1+   transferred  cells  to  the  D-NALT  (Figure  27a).  PMID  activation 
appears  to favour migration  to the  D-NALT where  19%  of the transferred  cells 
were found to be tetramer positive.
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Figure 26:  Total  CD8+  T lymphocytes were  MoFlo sorted from the spleens of 20 
C57BL/6  Ly5.1 +   mice  that  had  been  infected  with  500  EID50  influenza  virus 
A/PR8/34 virus  12 days  previously. The cells were transferred  intravenously  into 
naive  C57BL/6  Ly5.2+   recipients.  48  hours  post transfer,  the  location  of splenic 
Ly5.1+  CD8+  lymphocytes was assessed by flow cytometry a) splenic Ly5.1+  CD8+  
lymphocytes  (R2)  in  the  lungs  and  D-NALT  demonstrates  the  trafficking  of 
activated CD8+  T cells to the D-NALT b) indicates the presence of influenza virus- 
specific  H-2Db  NP366.374 tetramer bound to surface T cell  receptors  of region  R2 
lymphocytes.  Ly5.1+CD8+Tetramer  transferred  cells  were  predominantly 
observed  in  the  lungs  and  D-NALT,  but to  some  extent  in  the  liver and  spleen. 
Unlike naive T cells, very little if any trafficking was observed to the lymph nodes. 
The  percentage of total  Ly5.1+CD8+  cells found  in  each tissue that was tetramer 
positive is shown on each plot. These data are representative of one experiment.
145CD8
a)
Lungs
[25m «2L£16_Lungsj
DNALT
| 2SmarRL.01S  DNALT |
,dSm‘r
FL1-H FL1-H
Ly5.1
Tetramer
b)
Liver Spleen Inguinal LN
1 0 *
0% 1.83% 1 0 *
0% 1.09%
1.83 1.09 1 0 * 1 0 *
I x.‘*
E 3   1 0 = 3
1 0 1 m 1 0 1
Q% 9817% 9% ■ m .  9891%
irf  iff  id  irf
FL3-H
Mesenteric LN
i t f   «?  10  11?  ii?
FL3-H
0% 0.09%
0.09
9% A  '  9991%
Mediastinal LN
[jS S ^o jT jM ^
a   io :
0% 0.08%
0.08
Q   - t   9992%
id   iff  1   d   « f
FL3-H
Blood
[» w r io i4_l w « sc*J
Lungs DNALT
[»W *U115J»1ALT]
10 0% 0.12%
0.12
10* 0% 0.48%
0.48
10s 10J
i   -o=
F
L
2
-
H
101 A
10
0% 9 K   99.88% 0% S   99.52%
1U
1 1 ?   1 1 ? irf  ii?  id 1#  It? ii?  id  irf
0% 655%
6.55
5
"
.
.
*
*
93.45%
19.23%
19.23
" j \   80.77%
1 #   1 1 ?   1 0   1 1 ?   1 1 ?  
FL344
1 1 ?  1  d 10   11?  11? 
FL3+I
-►   CD8
Figure 27: Total CD8+  T lymphocytes were MoFlo sorted from the spleens of 20 
C57BL/6  Ly5.1+mice  immunised  twice,  one week apart with  2  non  overlapping 
doses of 0.5jjq influenza virus NP DNA, and transferred intravenously into naive 
C57BL/6  Ly5.2+  recipients. 48 hours post transfer, the location of splenic Ly5.1 +  
CD8+   lymphocytes  was  assessed  by  flow  cytometry  a)  splenic  Ly5.1+   CD8+  
lymphocytes  (R2)  in  the  lungs  and  D-NALT  demonstrates  the  trafficking  of 
activated CD8+  T cells to the D-NALT b) indicates the presence of influenza virus- 
specific H-2Db NP366.3 7 4  tetramer bound to surface T cell receptors of region R2 
lymphocytes.  Ly5.1+ CD8+ Tetramer  transferred  cells  were  predominantly 
observed  in  the lungs and  D-NALT,  but to some extent in the  liver and spleen. 
Unlike naive T cells, very little if any trafficking was observed to the lymph nodes. 
The percentage of total Ly5.1+CD8+  cells found in each tissue that was tetramer 
positive is shown on each plot. These data are representative of one experiment.
1465.3 Discussion
In the first part of this study it has been shown that with the exception of the D- 
NALT,  regardless of the tissue examined,  CD8+  tetramer+  cells induced  by both 
influenza  virus  infection  and  PMID  immunisation  of  NP  DNA,  have  a  common 
CD44h lCD11ah ,CD62L'° activated  phenotype.  CD69 expression was found to be 
high in the lungs and  MedLN following influenza virus infection and in the IngLN 
following  PMID  of  influenza  virus  NP  DNA.  The  D-NALT  did  not  appear  to 
upregulate CD44 expression, and  CD8+  tetramer+  lymphocytes found  here after 
infection  or  immunisation  displayed  an  intermediate  level  of CD44  expression, 
similar to that found on a population in naive lung lymphocytes.
CD44  was  originally  linked  to  lymphocyte  homing  by  Butcher  and  colleagues 
(Jalkanen et al.,  1987). CD44 is induced on effector and memory T lymphocytes 
and  metastastic tumours and  binds  hyaluronic acid  on  the  surface  of activated 
endothelial  cells.  It  has  also  been  shown  that  CD44  can  act  in  a  selectin-like 
manner,  mediating  transient  attachment  of  cells  that  are  flowing  over  an 
endothelial  surface  (DeGrendele  et al.,  1996).  A study  by the  same group  has 
also  shown  a  relationship  between  CD44  and  VLA-4  (very  late  antigen-4,  an 
integrin)  that  binds  vascular  cell  adhesion  molecule-1  (VCAM-1) 
(Siegelman  et al.,  2000).  There  is  however no  explanation  for this  relationship 
from  which  other  integrins,  like  LFA-1,  are  excluded.  It  was  also  shown  that 
absence  of  the  cytoplasmic  domain  of  CD44  abrogates  this  association  with 
VLA-4  and  resultant  firm  adhesion.  Furthermore,  CD44  can  be 
immunoprecipitated with VLA-4  but not LFA-1  and this association  requires the 
cytoplasmic domain of CD44. CD44 lacking the cytoplasmic domain is unable to 
associate with VLA-4 to produce firm adhesion both in vitro and in vivo (Nandi et 
al., 2004).
147These  data  suggest  that  the  combination  of  CD44/hyaluronic  acid  and  VLA- 
4A/CAM-1  act  together  to  aid  entry  of  effector  T  lymphocytes  into  sites  of 
inflammation  and  may  suggest  that  earlier  results  showing  that  VLA-4  can 
directly  mediate  tethering  and  rolling  (Alon  et  al.,  1995)  may  have  to  be 
reconsidered.  It  could  be  possible  that  the  studies  demonstrating  VLA-4 
tethering  to  activated  endothelial  cells  could  be  as  a  result  of  its  close 
association with CD44.
Several  studies  have  shown  CD44  to  act  as  a  pro-inflammatory  receptor  in  a 
variety  of  murine  models  including  colitis,  arthritis  and  hypersensitivity 
responses  (Camp  et  al.,  1993,  Mikecz  et  al.,  1995,  Wittig  et  al.,  2000).  More 
recently,  CD44  has  also  been  reported  to  play  a  role  in  coordinating  allergic 
airway inflammation.  Monoclonal  antibodies were  shown to  neutralise or cause 
shedding  of CD44,  thus  blocking  hyaluronic acid  binding  and  reducing  allergic 
respiratory inflammation  by preventing  lymphocyte and  eosinophil accumulation 
in  the  lung  (Katoh  et  al.,  2003).  By  contrast,  results  from  another  study  have 
demonstrated a protective anti-inflammatory role for CD44 in the lung  (Teder et 
al.,  2002).  Here,  CD44'/_   mice  developed  inflammation  following  non-infectious 
lung  injury which could  be partially reversed following  reconstitution with CD44+  
cells.  However,  using  monoclonal antibodies,  Katoh et al.  did  not deplete CD44 
expressing alveolar macrophages which are likely to be critical in the resolution 
of lung inflammation, and this may explain the differences seen.
One  final  study  on  CD44  worth  mentioning  was  carried  out  in  a  model  of 
Mycobacterium  bovis  infection  which  examined  the  expression  of  CD44  on 
activated  bovine T cells.  This study showed  that CD44 expression on  bovine T 
cells,  obtained from the lungs of infected  cattle, was down  regulated  compared 
to  that  of  naive  control  animals  (Waters  et  al.,  2003).  In  a  mouse  model  of
148rheumatoid  arthiritis,  stimulation  of  CD44  by  binding  to fragmented  hyaluronic 
acid  was  shown  to  upregulate  Fas  expression,  enhancing  Fas-mediated 
apoptosis of CD44 expressing synovial cells (Fujii et al., 2001). With this finding 
the  authors  suggest  that  there  could  be  selective  reduction  of  CD44h i  cells 
mediated by apoptosis.
Taking  this  information  into  consideration,  it would  be  interesting  to  look at the 
expression  of the  integrin VLA-4  on  CD8+   tetramer+   lymphocytes found  in 
the  D-NALT following  both  infection  and  immunisation  and  to compare  it to the 
other tissues  examined.  If CD44  does  have  a  close  relationship to VLA-4 then 
this may be reflected in the level of VLA-4 expression in the D-NALT.
Considering  the  reports  of  CD44  as  a  pro-inflammatory  receptor,  the 
intermediate  level of CD44 expression  on CD8+  tetramer+  lymphocytes found  in 
the  D-NALT  may  be  explained  by  the  observation  that  the  D-NALT  is  a  site 
where  little  inflammation  is  observed,  and  viral  clearance  is  delayed  in 
comparison to the lung following  intranasal  influenza virus  infection  (Dr S.  Hou, 
unpublished  data).  A  reduced  level  of CD44  expression  on  NALT  lymphocytes 
could perhaps be a characteristic that aids in the control of and the accumulation 
of  inflammatory  cells  as  was  observed  by Teder  et al.  The  D-NALT  may  also 
contain  a  unique  environment  which  requires  the  downregulation  of  CD44  to 
maintain these cells or allow higher throughput of cells through the tissue.
A  recent  study  investigating  the  phenotype  of  activated  virus-specific  CD8+   T 
cells  following  influenza  virus  infection  examined  the  expression  of  LFA-1  o- 
chain (CD11a) and VLA-4 (CD49d).  Purified naive CD8+  T cells were used in an 
adoptive transfer experiment where naive T cells were transferred intravenously 
before  an  influenza  virus  challenge  (Lawrence  &  Braciale,  2004).  The  authors
149report  low  levels  of  expression  of  both  markers  on  the  naive  undivided 
transferred  cells  which  was  dramatically  upregulated  when  the  cells  were 
activated  by  viral  infection.  A  similar  result  was  observed  in  this  study  with 
CD11a  expression,  however,  CD49d  expression  was  not  assessed.  As 
previously  discussed,  these  integrins  are  known  to  be  important  for  the 
interaction of activated T cells with endothelium at sites of inflammation and they 
have  been  directly implicated  in the  recruitment of T cells to the  lungs (Feng et 
al., 2000, Thatte et al., 2003, Wolber et al.,  1998).
Attempts  were  made  to  phenotype  influenza  virus-specific  CD8+   T  cells  with 
regard  to  their  expression  of  the  integrin  (LPAM-1).  This  was  however 
unsuccessful due to technical difficulties.  Prolmmune, the commercial source for 
multimer stocks,  stopped  production  of tetramer.  Some of the  new  Prolmmune 
Pentamer  was  tested  but  results  were  disappointing  as  pentamer  positive 
populations  were  very  dim  and  it  proved  hard  to  isolate  positive  populations, 
especially  when  there  were  very  few  virus  specific  CD8+   T  cells  in  the  cell 
suspension.
CD69 upregulation on T cells is linked to TCR engagement by antigen (Cosulich 
et  al.,  1987,  Ziegler  et  al.,  1994a).  When  antigenic  stimulation  is  withdrawn, 
CD69  expression  subsequently  declines  (Testi  et  al.,  1994).  A  study  by 
Lawrence  and  Braciale  (2004)  used  the  influenza  mouse  model  and  linked 
CD69 expression with proliferating cells (CFSEl0 W ) in the  MedLN at 5 days post­
infection. This was assumed to result from continued  antigenic stimulation. This 
is  understandable  at  an  early  timepoint  post  infection,  but  at  day  14  (and 
beyond) the data generated as part of this thesis shows CD69h l cells present in 
the  lungs  and  MedLN.  It  is  likely  that  virus  is  cleared  by  this  timepoint
150(Eichelberger et al.  (1991) and  Figure  15) therefore CD69 expression  is likely to 
be as a result of continued cellular activation at these sites.
Following  the  phenotypic  analysis  of  CD8+   tetramer+   cells  found  following 
infection and  immunisation, this study moved to characterise these cells further 
by  investigating  their  homing  properties.  It  was  hoped  that  this  would  reveal 
whether  the  immune  response  generated  by  PMID  immunisation  of  NP  DNA 
was  a  good  as  that  induced  by  experimental  infection.  Using  an  adoptive 
transfer  model,  the  characteristic  homing  pattern  of  naive  CD8+   T  cells  was 
compared  to the  antigen  specific  effector  CD8+   T  cells  generated  by  influenza 
virus  infection  or  immunisation.  As  expected,  naive  T  cells  were  found  to  be 
predominantly circulating  through  the  blood  and  lymph  nodes.  Upon  activation 
however,  the  homing  properties of T cells was dramatically altered. Activated T 
cells  showed  preferential  localisation  to  non  lymphoid  tissues,  which  has 
previously been  shown to occur independently of the  infectious agent,  infection 
route  and  tissue  of origin  (Masopust  et al.,  2001,  Masopust et al.,  2004).  This 
study  has  subsequently  shown  the  previously  undocumented  preferential 
migration of antigen specific effector CD8+  T cells to the D-NALT.
In  an  early experiment  in  the field  of lymphocyte  homing  studies,  Gowans  and 
Knight  (1964)  transferred  thoracic  duct  lymphocytes  intravenously  into  naive 
recipients and  detected donor lymphocytes  in the  recipient thoracic duct lymph. 
This  experiment  demonstrated  that  lymphocytes  continuously  recirculate 
between  the  blood  and  lymph.  The  authors  also  demonstrated  that  small 
lymphocytes  cross  high  endothelial  venules  to  enter  lymph  nodes.  Small 
lymphocytes  (which  would  be  primarily  made  up  of  naive  T  cells  but  would 
contain some circulating memory cells) were detected  in the lymph nodes, white 
pulp  of the  spleen  and  PP.  The  number of small  lymphocytes  detected  in  the
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lymphocytes  may  not  enter  non-lymphoid  tissues.  Experiments  have 
demonstrated that naive lymphocytes rarely enter non-lymphoid tissue. This has 
been  shown  using  in  vivo  migration  studies  and  adoptive  transfer of traceable 
naive  CD8+   T  cells,  which  did  not  enter  the  intestinal  lamina  propria  or 
epithelium  unless  activated  (Kim  et al.,  1997).  This  study demonstrated  limited 
trafficking  of naive  lymphocytes to non-lymphoid tissues  including  the  lung  and 
liver (Figure 25). This observation is supported by data reported by Westermann 
and colleagues who recorded limited trafficking of naive T cells through the skin 
and liver (Westermann & Pabst,  1996).
When  naive T cells encounter antigen  in  a  lymph  node,  their homing  pattern  is 
dramatically  changed.  Primary  infection  with  a  variety  of  viruses  has  been 
associated  with  the  appearance  of  activated  antigen-specific  CD8+   T  cells  in 
non-lymphoid  tissues.  For example,  following  infection  with  LCMV  or  influenza 
virus,  antigen-specific  CD8+   T  cells  have  been  detected  in  bone  marrow 
(Marshall et al., 2001, Slifka et al.,  1997). Analysis of primary immune responses 
to infection with  influenza virus  (Flynn et al.,  1998) or Sendai virus  (Usherwood 
et al.,  1999a) has shown substantial numbers of antigen specific CD8+  T cells in 
the lung, which are likely to have migrated to that site after primary activation in 
the  draining  lymph  node  (Lawrence  &  Braciale,  2004).  Belz  et al.  (1998)  have 
also  shown  the  presence  of antigen-specific CD8+   T  cells  in  the  liver following 
influenza  virus  infection  (Belz  et  al.,  1998)  which  was  not  investigated  in  this 
study, but data does show the preference of activated CD8+  T cells to migrate to 
the liver. This is of interest considering that productive infection of influenza virus 
is restricted to lung epithelial cells (Eichelberger et al.,  1991b). The liver has also 
recently  been  shown  to  be  a  site  of  specific  CD8+   T  cells  following  DNA 
vaccination  with  plasmid  expressing  hepatitis  B  surface  antigen  (Dikopoulos  et
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effector  CD8+   T  cells,  induced  both  by  viral  and  bacterial  infection,  is  to  non­
lymphoid tissues (Masopust et al., 2004). Together, these data demonstrate that 
activated  T  cells  migrate  to  sites  of  infection  and  traffic  to  other,  potentially 
uninfected tissues.
Data  recorded  in  this  study  demonstrates  that  influenza  virus  activated  and 
PMID activated virus specific CD8+  T cells, are effectively identical with regard to 
expression of the adhesion molecules examined.  However, those cells activated 
by  PMID  immunisation  of influenza virus  NP  DNA appear to have a  preference 
to migrate to the  D-NALT,  the mechanism of which  remains to be elucidated.  It 
is  possible  that  the  preferential  migration  of  activated  T  cells  to  the  D-NALT 
could  be  specific to  DNA immunisation  using  a  ballistic device and  it would  be 
interesting  to  repeat  the  transfer  study  with  CD8+   T  cells  activated  by 
intramuscular DNA immunisation to investigate this further.
The  homing  of  effector/activated  CD8+   T  cells  to  the  D-NALT  and  lungs 
observed with the adoptive transfers from influenza virus infected spleens is not 
surprising  considering  that  these  cells  are  perhaps  homing  to the  sites  of first 
stimulation/activation.  However, the homing of effector/activated  CD8+  T cells to 
the same tissues after PMID implies that these tissues are perhaps sites where 
effector/memory  T  cells  actively  home  to,  perhaps  in  their  role  of  immune 
surveillance.
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DiscussionThe  main  aim  of  this  study  was  to  characterise  the  mucosal  and  systemic 
immune  responses  in  a  murine  model  of experimental  influenza  virus  infection 
and  to  compare  the  results  with  the  immune  responses  elicited  following 
vaccination.  Influenza virus infection can generate sterilising immunity and it was 
hoped that by defining the immune responses that contribute to this protection, a 
useful  comparison  for  the  assessment  of  potential  efficacy  of  a  DNA  vaccine 
candidate  could  be  made.  It  was  also  of  interest  to  assess  whether  DNA 
vaccination by PMID could elicit a mucosal immune response.
The initial study was designed to characterise the humoral and cellular immune 
responses  generated  by  experimental  intranasal  influenza  virus  infection  of 
mice.  ELISA data showed that potential correlates of protection were a dominant 
virus-specific  Ig  response  in  the  MedLN,  spleen  and  to  some  extent the  lungs 
and  D-NALT.  Characterisation of the cellular response showed that a dominant 
virus-specific CD8+   IFNy secreting  cellular response in the lungs correlated with 
protection.  Recent  studies  on  the  induction  of  immune  responses  following 
influenza virus infection have shown that the response is initiated  in the MedLN 
and  the  virus-specific  effector  CD8+   T  cells  generated  there  go  on  to  seed 
populations  in  the  lung  and  spleen  (Lawrence  &  Braciale,  2004).  If  a  novel 
vaccine is to mimic influenza virus infection,  it is likely that initiation of a cellular 
immune response in the MedLN is likely to contribute to protective efficacy.
Surprisingly,  virus-specific CD8+   IFNy secreting  cells were also observed  in the 
MesLN.  This  leads  to  the  question  of  whether  activated  virus-specific 
lymphocytes  traffic  to  all  tissues  during  and/or after  infection.  Such  a  strategy 
could  be justified  by the immune system to ensure that an  invading  pathogen is 
completely eliminated.  After experimental  intranasal  influenza  virus  infection  of 
mice,  virus  replication  is  known  to  be  restricted  primarily  to  the  respiratory
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al.,  1997).  It is therefore likely that a wide dispersal of activated lymphocytes is a 
characteristic of all effector cells and  not simply restricted to what was observed 
in  the  murine  influenza virus  infection  model.  The widespread  dissemination  of 
antigen-specific  CD8+   T  cells  would  be  expected  to  have  important 
consequences  for  protection  from  secondary  infection,  and  therefore  it  would 
appear  advantageous  for  primary  and  memory  CD8+   T  cells  to  undergo  this 
widespread dispersal following any infection.
Following  the  clearance  of  infection,  the  immune  response  was  observed  to 
establish  memory populations which were found to be circulating  in the spleen, 
MesLN,  MedLN  and  the  D-NALT.  As  previously  discussed  it  seems  likely that 
the memory population identified in the D-NALT would have an effector memory 
phenotype.  These cells are resident in a  prime  location for contact with antigen 
and  activation  upon secondary infection, and this would  be a desirable immune 
response for a vaccine to generate.
It was  hoped  that  IEF  analysis  of fragment  cultures  would  elucidate  additional 
information  regarding the humoral immune response with  regard to the clonality 
and  migration  of response  generated.  It is  suggested  that this type  of analysis 
should  elucidate  information  regarding  the  ideal  strength  and  anatomical 
location  of  an  AFC  response  that  would  be  desirable  to  be  induced  by 
vaccination.  Unfortunately,  time  constraints  required  that  the  investigation 
moved away from this type of analysis. A novel method for analysis of the serum 
humoral response following infection was however developed.
Following  a  detailed  characterisation  of  the  immune  response  mediated  by 
influenza  virus  infection,  this  study  went  on  to  characterise  the  response
156generated  by  vaccination  of  influenza  virus  NP  DNA  using  a  ballistic  device. 
Initially, one immunisation of two non-overlapping doses of DNA (approximately 
0.5jjg  each)  was  administered  and  the  virus-specific  immune  response 
characterised  by  IFNy  ELISPOT  assay.  Unfortunately  the  single  immunisation 
regimen  that was  adopted  in  these  initial  studies  did  not appear to stimulate a 
detectable serum or mucosal virus or NP-specific antibody response.  ELISPOT 
data  showed  a  predominance  of  the  virus-specific  cellular  response  to  be 
located  in  the  spleen  14  days  post  immunisation.  A  significant  response  was 
also observed in the lymph nodes draining the immunisation site (IngLN) as well 
as  the  MesLN  and  more  surprisingly the  D-NALT.  It  is  believed  that this  is the 
first report of a mucosal  response initiated  in the D-NALT by a single gene gun 
immunisation  of  plasmid  to  an  abdominal  site.  The  response  generated  was 
similar  in  size  and  kinetics  when  compared  to  that  induced  by  influenza  virus 
infection.  There was however one striking difference in the responses observed 
in the  D-NALT, and that was the ability of influenza virus infection to generate a 
memory population observed six months post infection.  It is likely that this could 
be  an  important correlate  of protection  from further infection.  Ideally any  novel 
vaccine  candidates  should  induce  a  similar  memory  population  that  would  be 
expected to correlate with longevity of vaccine efficacy.
The  generation  of  a  memory  response  at  potential  sites  of  infection  is  a  very 
desirable  characteristic which  may  aid  in  the  rapid  mobilisation  of a  protective 
immune  response following  secondary encounter with  antigen.  The  generation 
of  a  robust  memory  response  has  been  linked  to  the  magnitude  of the  initial 
primary  response  in  an  infection  (Hou  et  al.,  1994).  It  would  appear  that  the 
generation  of  a  substantial  primary  response  is  reflected  in  an  enhanced 
memory  established  thereafter.  Recently,  research  in  the  field  of  DNA 
vaccinology  has  focused  on  improving  gene  expression  in  the  hope  of
157enhancing antigen expression and  generating a correspondingly higher primary 
response  and  increased  development  of  a  memory  cell  population.  Codon 
optimisation  is  a  technique  recently adopted  to  enhance  protein  expression  by 
increasing  the  translational  efficiency  of  a  gene.  Many  pathogens  have  a 
different  codon  bias  compared  to  mammals.  This  bias  can  result  in  low 
expression  levels of pathogen’s genes  in transfected  mammalian  cells and  this 
may correlate with low immunogenicity of some potential  DNA vaccines.  In such 
cases, it can be beneficial to synthesise genes containing the natural amino acid 
sequences  but  using  the  mammalian  preferred  codons  for  the  amino  acids. 
Several studies on codon optimisation  have  been carried out on the expression 
of  human  immunodeficiency  virus  (HIV)  and  human  papillomavirus  (HPV) 
proteins  and  have  shown  enhanced  expression  of,  and  improved  immune 
response to target antigen (Casimiro et al., 2002, Cid-Arregui et al., 2003, Liu et 
al.,  2004,  Mossadegh et al.,  2004,  Ramakrishna et al.,  2004). Another common 
method  of enhancing  the  primary immune  response to  DNA vaccination  is that 
of  the  use  of  genetic  adjuvants.  This  involves  the  use  of  genes  encoding 
cytokines,  growth  factors  or  co-stimulatory  molecules  which  are  included  with 
the gene of interest in the same plasmid, or administered on a separate plasmid 
premixed with the intended immunising plasmid (Chattergoon et al., 2004, Eo et 
al., 2001b, Miyahira et al., 2003, Moore et al., 2002).
When  PMID was assessed for production of a humoral  immune response it was 
concluded  that  a  single  immunisation  was  insufficient  to  generate  an  antibody 
response.  There  are  a  few  reports  that  have  demonstrated  that  a  single  DNA 
immunisation  is  inadequate  for the  generation  of a  humoral  immune  response 
and it often takes several immunisations or a prime boost regimen to generate a 
significant antibody response  (Johnson et al.,  2000,  Kasinrerk et al., 2002).  It is 
likely that this could also be the case in this study. Unfortunately time constraints
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was never assumed that a single immunisation would be sufficient to mimic the 
natural  response  generated  by  influenza  virus  infection  and  obviously  this  is 
another major difference between experimental viral infection and  immunisation 
that  would  have  to  be  addressed  should  this  technique  and  plasmid  be 
considered for further studies.
When  efforts  concentrated  on characterising the response following  DNA prime 
and  influenza  virus  challenge,  it was  initially observed  that the  majority  of the 
influenza  virus-specific  CD8+   IFNy  secreting  cells  produced  were  rapidly 
recruited to the lungs. As a result of enumerating the titre of virus in the lungs at 
this  stage  following  challenge,  it  was  discovered  that  the  cell  infiltration 
correlated with  reduced  viral  replication.  Viral titres were observed to be 2 logs 
lower compared with titres recovered from lungs of control mice immunised with 
empty  vector  before  subsequent  influenza  virus  challenge.  Mice  primed  with 
pVac-NP  were  observed  to  clear  the  virus  faster  from  their  lungs  and  it  was 
hypothesised  that the  reduction  in  viral  replication  was  as  a  result of the  IFNy 
being  produced  in the lungs. To clarify this observation, attempts were made to 
deplete  (in  vivo)  the  IFNy secreting  cells  that were thought to  contribute to the 
reduction  in  lung  viral  titre.  Unfortunately,  at  the  timepoint  chosen  to  analyse 
lung  homogenates for virus titre,  some of the mice  had  cleared  virus from their 
lungs and  no firm conclusions could  be made regarding the effects of depletion 
of CD8+  T cells.
An  alternative  approach  to  depleting  CD8+   T  cells  in  vivo  using  monoclonal 
antibody would be to investigate influenza virus infection in mice with a disrupted 
/?2-microglobulin  (£2-M) gene. jff2-M'7 ' mice  lack  MHC class  I  restricted  CD8+  T 
cells, and  in the influenza mouse model they have been shown to have a higher
159mortality  rate  to  infection.  Functional  CD8+   T  cells  are  necessary  for  survival 
when the virulent influenza virus A/PR/8/34 is used to challenge mice (Bender et 
al.,  1992). /?2-M_ /' mice would be an ideal strain to investigate the role of CD8+  T 
cells following  PMID of influenza virus NP DNA and subsequent viral challenge. 
Adoptive transfer of CD8+  T cells from /?2-M+/+ mice would show the central role 
that CD8+  T cells play in influenza virus infection.
Although  protection  was  observed  following  PMID  of influenza  NP  DNA,  there 
was still a  residual  level of influenza virus replication in the lungs.  Perhaps if an 
increased  humoral  response  had  been  stimulated  following  the  initial  DNA 
immunisation  it  would  enhance  efficacy  by  neutralising  virus  particles.  This 
would  require  further  characterisation  of  the  immunisation  regimen,  and 
assessment of the best method to obtain a strong antibody response.  It could be 
possible  that  two  or three  immunisations  could  generate  a  humoral  response. 
Alternatively,  a  prime  boost  regimen,  using  DNA  in  combination  with  either 
protein or with a recombinant viral vector expressing influenza virus NP could be 
a  method  to  consider.  Prime  boost  combinations  have  been  shown  to 
dramatically enhance protective immune responses generated in several mouse 
and  primate  models  (McShane,  2002,  Santra  et  al.,  2004,  Tritel  et  al.,  2003, 
Wang  et  al.,  2004).  However,  systemic  prime-boost  regimens  do  not  always 
generate  good  immunity  at  mucosal  sites.  Recently  it  has  been  shown  that 
mucosal  prime-boosting  immunisations can  successfully generate  mucosal and 
systemic responses (Eo et al.,  2001a,  Gherardi et al.,  2004,  Goonetilleke et al., 
2003,  Makitalo et al.,  2004).  Perhaps a  mucosal  prime-boost regimen would  be 
the  optimal  method  to  use  in  the  further  development  of this  study.  A  recent 
study has described  M cell targeted immunisation using a reovirus protein which 
binds to the surface of M cells in the NALT (Wu et al.,  2001). When conjugated 
to DNA, this protein was found to induce prolonged mucosal  IgA production andan enhanced  cellular CTL response.  There is also evidence that DNA plasmids 
can be engineered to enhance their capacity to elicit humoral responses but this 
may compromise their ability to generate good cellular responses e.g. the use of 
secretory signals can enhance release of a protein and generate better humoral 
responses  while  maintenance  of  an  intracellular  antigen  correlates  with  good 
Class  I  presentation  and  induction  of  cellular  responses  (Dr  Fiona  Cook, 
personal communication).
The final  objective of this  study was to characterise the  influenza virus-specific 
effector  CD8+   T  cells  further,  with  respect  to  their  anatomical  location, 
expression of homing molecules and migratory preferences. Following intranasal 
influenza virus infection CD8+  tetramer+  cells were assessed for their expression 
of CD44, CD11a, CD62L and CD69. Throughout the tissues examined over a 35 
day  period  following  infection,  the  activated  virus-specific  CD8+   T  cells  were 
found  to  have  similar expression  levels  of these  molecules over time and were 
predominantly  of the  CD44h lCD11ah lCD62Ll0   phenotype.  Lymphocytes  isolated 
from  the  lungs  and  draining  lymph  nodes  (MedLN)  were  also  found  to  be 
CD69hl.  The  presence  of  CD69  on  T  cells  is  usually  considered  to  reflect 
triggering  via  the  TCR  (Cosulich  et  al.,  1987,  Ziegler et  al.,  1994b)  and  in  the 
influenza model, stimulation with antigen (Lawrence & Braciale, 2004). However, 
at  day  35  post  infection,  these  cells  were  still  CD69hl,  at  a  time  when  PCR 
studies  have  shown  that  the  influenza  virus  genome  in  no  longer  present. 
Influenza virus genome has not been detected  more than  14 days post infection 
(Eichelberger et al.,  1991b) and analysis of APC distribution following respiratory 
virus  infection  has shown that APCs are not observed after day 9  post infection 
(Usherwood et al.,  1999b).
161During  influenza  virus  infection,  there  is  a  massive  clonal  expansion  in  the 
number of virus-specific CD8+  T cells (Tripp et al.,  1995), but most of the cellular 
progeny  are  destined  to  die  by  Fas-mediated  mechanisms  as  the  infection  is 
resolved  (Topham et al.,  1997).  Despite the  high  rate of apoptosis,  some virus- 
specific  CD8+   T  cells  survive  and  continue  to  be  retained  in  the  lung.  Is  it 
possible  that  the  persistent  high  expression  of  CD69  is  a  characteristic  of 
terminally  differentiated  CD8+   T  cells  destined  for  apoptosis?  A  recent 
publication  has  shown  that that the  majority of CD8+  T cells  isolated from  non­
lymphoid  tissues  during  acute  and  memory  responses  to  influenza  virus 
infection  express  the  intergrin  (VLA-1).  Additionally,  on  lung  CD8+
lymphocytes,  VLA-1  expression  was  found  to  correlate  to  resistance  from  the 
apoptosis that follows recovery from influenza virus infection  (Ray et al., 2004). 
Perhaps further analysis of CD69 expressing virus-specific lung lymphocytes for 
coexpression  of  VLA-1  could  explain  the  continued  expression  of  the  CD69 
activation antigen in the absence of influenza virus.
When  the  virus-specific  CD8+   T  cells  generated  following  PMID  immunisation 
were  analysed,  they  were  found  to  have  a  similar  CD44h lCD11ah lCD62Ll0  
phenotype.  Lymphocytes  isolated  from  the  IngLN,  which  drain  the  site  of 
immunisation  (the skin), were found to have a similar CD69h l phenotype as was 
observed  in  the  lungs  and  MedLN  following  influenza  virus  infection.  This 
extended  expression  of  CD69  could  perhaps  be  explained  in  this  case  by the 
continued  presence of antigen.  It is  possible that NP gene expression  could  be 
maintained  longer  than  influenza  virus  can  be  detected  in  the  lungs  following 
experimental  infection.  One of the original DNA vaccination studies reported the 
expression  of  protein,  from  a  plasmid  injected  intramuscularly,  to  continue  for 
greater  than  1   year  (Wolff  et  al.,  1992)  which  could  explain  and  extended 
expression of CD69.
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and  PMID  immunisation  of  DNA  both  induced  virus-specific effector  cells  that 
have  a  similar phenotype with  regard  to their expression  of CD44,  CD11a and 
CD62L.  Only  considering  these  adhesion  molecules  it  seems  that  DNA 
immunisation  has  generated  a  similar  primary  response  compared  to  that 
generated  by  experimental  infection.  However,  expression  of  several  other 
adhesion  molecules  could  be  examined  as  potential  candidates  whose 
expression  may  correlate with  immune  protection.  This  study  briefly  described 
the problems of pentamer staining and subsequent analysis of the expression of 
the  a  S i  integrin  on  the  lymphocytes  analysed.  One  of the  initial  aims  was  to 
characterise  the  expression  of  this  a4  integrin  on  the  D-NALT  cells,  as 
expression  of  this  antigen  has  been  associated  with  mucosal  homing  of 
lymphocytes (Hamann et al.,  1994).  It would  have been interesting to see if the 
a4  integrin  was  also  expressed  by  lymphocytes  isolated  from  the  D-NALT and 
whether we  could  establish  a  similarity  between  lymphocytes  found  in  the  gut 
following  influenza  virus  infection  and  those  located  in  the  D-NALT.  Are  these 
cell  populations derived  from the same  population of activated  effector cells, or 
do the D-NALT cells represent a specialised population? Taking into account the 
intermediate expression of CD44 on the lymphocytes  isolated from the D-NALT 
recorded  following  both  influenza  virus  infection  and  PMID  immunisation  of 
DNA, it suggests that these cells are specialised in some way characterised by a 
unique level of CD44 expression.
Further analysis of activated virus-specific cells involved a study of their homing 
characteristics. Total CD8+  T cells were isolated from the spleens of mice either 
intranasally  infected  with  influenza  virus  or immunised  by  PMID  with  NP  DNA, 
before  the  transfer  of  these  cells  into  naive  recipients  to  characterise  their 
homing preferences.  In both instances, the cells were observed to home to non­
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observed  that  virus-specific  cells  had  a  preference  to  home  to  the  respiratory 
mucosal tissues.
Studies  have been carried  out to investigate  lymphocyte  homing to the ONALT 
or the inductive site of the NALT (Csencsits et al.,  1999, Csencsits et al., 2002). 
Within  the  ONALT,  it  has  been  shown  that all  HEVs  express  peripheral  lymph 
node  addressin  (PNAd).  Anti  -   L-selectin  (CD62L)  monoclonal  antibody  has 
been  shown  to  prevent  >90%  of  naive  lymphocyte  binding  to  ONALT  HEVs, 
whereas anti-MAdCAM (which blocks almost all naive lymphocyte binding to PP 
HEVs)  minimally blocks binding.  This suggests a greater role  in the ONALT for 
L-selectin  -   PNAd  interactions,  rather  than  a^p7  -   MAdCAM-1  interactions 
associated  with  the  gut  mucosa.  It  has  been  shown  that  aS i  -   MAdCAM-1 
interactions  do  not  play  a  major  role  in  lymphocyte  homing  to  the  lung  or 
pulmonary tissues  (Abitorabi et al.,  1996,  Picker et al.,  1994),  but do provide a 
mechanism  for  protective  immunity  against  gut  pathogens  (Williams  et  al., 
1998).  It is therefore accepted that the aS i -  MAdCAM-1  interaction is regarded 
as intestinal rather than mucosal.
This study focussed  on the effector site of the  NALT, the  DNALT.  It is possible 
that  homing  to  the  DNALT  is  controlled  in  a  similar  manner  as  to  that  of the 
ONALT but this has still to be elucidated.
The  techniques  of  IEF  and  flow  cytometry were  used  to  characterise  anti-viral 
lymphocytes following  influenza virus  infection and vaccination  in the hope that 
information  regarding  their  location  and  phenotype  could  establish  information 
about their trafficking  by virture of the CMIS.  IEF failed to generate the required 
clonal  information due to a  lack of sensitivity and time constraints. The analysis
164of influenza virus-specific CD8+  T cells however, showed  no major difference in 
the  phenotype  of  cells  isolated  from  various  tissues  of  the  immune  system 
following  either influenza  virus  infection  or  PMID  of NP  DNA.  This  result could 
indicate  the  circulation  of  virus-specific  lymphocytes  throughout  the  immune 
system via the CMIS.  However,  it would  be unfeasible to assess the expression 
levels  of  all  adhesion  molecules  involved  in  lymphocyte  homing,  so  no  firm 
conclusions  can  be  made.  The  homing  characteristics  of splenic  CD8+   T  cells 
were  assessed  following  intranasal  influenza  virus  infection  and  PMID  of  NP 
DNA.  From this data,  it would appear that recently activated virus-specific CD8+  
T cells are free to traffic to the effector sites of the  respiratory immune system, 
regardless of the method of their activation.
From  all  of  the  data  generated  in  this  study  the  most  important  correlates  of 
protection that an influenza vaccine should induce are:
•  A virus-specific neutralising antibody response
•  A virus-specific IFNy secreting CD8+  T cell response in the lungs
•  A memory virus-specific cellular response in the D-NALT
•  Activated virus-specific T cells with a CD44h ,CD11ah lCD62L'° phenotype
Analysis of PMID as a  method of DNA vaccination  has shown that it is capable 
of inducing  a  mucosal  virus-specific  response  in  the  D-NALT,  and  that  it is  an 
effective  method for inducing  protection  using the NP gene as a model antigen. 
However,  no  evidence  was  obtained  to  show  that  the  method  can  induce  a 
memory  T  cell  population  in  the  D-NALT  and  in  comparison  with  the 
experimental  infection,  a substantial  cellular response was  not observed  in the 
lungs following a single immunisation.  More importantly there was no stimulation 
of an  antigen-specific antibody  response.  By chance  however,  a  response was
165observed  in the  lung following two immunisations administered  one week apart 
(the  immunisation  regimen adopted for the transfer studies) supporting the idea 
that  a  prime  boost  regimen  dramatically  enhances  an  immune  response.  This 
regimen  of  immunisation  could  also  potentially  induce  an  antibody  response, 
however  this  was  not  assessed  in  this  study.  A  single  PMID  immunisation 
appears to be an efficient method of influenza virus  NP immunisation that could 
be adapted to generate a better vaccine. The response that it failed to generate 
in  the  lungs  was  resolved  by  giving  two  immunisations  and  it  is  possible  that 
codon  optimisation  could  increase  gene  transcription  ultimately  increasing  the 
primary immune response and subsequent establishment of memory.
Future Directions
Several  interesting  results  have  been  generated  in  this  study  and  reviewing 
recent  literature  has  prompted  further  questions  that  would  have  been 
interesting to address had time allowed. To offer a more complete set of data,  I 
would  initially  envisage  this  study  continuing  by  revisiting  the  CD8+   depletion 
experiment  following  DNA  prime  and  influenza  virus  challenge.  It  would  be 
crucial  to  analyse  lung  homogenates  at  an  earlier  timepoint  post  challenge, 
before the NP vaccinated  individuals clear the virus.  It would also be interesting 
to analyse the effect of CD4+  T cell depletion, and the combination of CD4+  and 
CD8+  T cell depletion.  Secondly,  it would  be interesting to compare the  homing 
of activated  virus  specific  cells  induced  by  intramuscular  DNA  immunisation  to 
establish whether the method of PMID immunisation generates cells that have a 
preference  to  home  to  the  D-NALT  or  whether  it  is  a  characteristic  of  DNA 
immunisation in general.
166Thinking  of  a  more  long  term  analysis,  I  would  finally  suggest  the  following 
routes of investigation:
•  Phenotypic  analysis  of  virus-specific  cells  induced  by  influenza  virus 
infection  and  PMID  immunisation  with  regard  to their expression  of the 
integrins  <7i/?i  (implied  in  immune  protection  from  influenza  virus 
infection),  a $ i  (with  its link to CD44 expression) and  a4 07 (for its role in 
mucosal homing).
•  Analysis  of two  PMID  immunisations  of  DNA  one  week  apart  and  their 
ability to enhance both humoral and cellular immune responses.
•  And  finally,  the  effects  of  a  prime  boost  regimen,  perhaps  including  a 
recombinant virus expressing  influenza virus  NP as  a  mucosal  prime or 
boost.
167Chapter 7
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